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Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy, characterized by the 
uncontrolled proliferation and differentiation arrest of myeloid progenitors. Chemotherapy has been 
the front-line treatment for decades and cure remains elusive for the majority of AML patients. 
Genome-wide CRISPR-Cas9 screens have previously identified KAT7 as an AML-specific cell-
essential gene and therefore may represent a potential novel therapeutic target for AML. Here, I show 
that KAT7 loss leads to a rapid and dramatic global reduction in both H3K14ac and H4K12ac in 
association with reduced proliferation, increased apoptosis or enhanced differentiation of AML cells 
driven by the translocation of Mixed-lineage leukemia (MLL) gene. Mice transplantation with KAT7 
knock-out AML cell line showed delayed disease progression and prolonged survival compared to 
those injected with the wild-type counterpart. The acetyltransferase activity of KAT7 is essential for 
MLL-fusion AML as the E508Q catalytic dead mutant is unable to sustain the leukemic programme. 
Using the auxin-inducible degron (AID) system to induce rapid KAT7 protein degradation, I showed 
that KAT7 is required for the recruitment of the MLL-fusion associated adaptor proteins such as 
BRD4 and AF4 to gene promoters, which are critical for the maintenance of the MLL-AF9 
transcriptional programme. Although not found to be mutated among cases of AML, KAT7 is a 
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Chapter 1: Introduction 
 
1.1 Acute myeloid leukaemia and disease pathogenesis 
 
Acute myeloid leukaemia (AML) is an aggressive hematopoietic malignancy, characterised by the 
differentiation arrest and uncontrolled proliferation of myeloid progenitor cells (Döhner et al., 2015). 
Leukaemic blast cells infiltrate the peripheral blood, bone marrow and accumulate in other organs in 
the body. AML is associated with a plethora of clinical symptoms, including leukocytosis, anaemia, 
thrombocytopenia, bleeding and increased risk of infections (De Kouchkovsky and Abdul-Hay, 2016). 
The etiology of AML is not fully established, but it has been known that incidents increase with age 
(Bhayat et al., 2009; Dores et al., 2012). Other associated risk factors include genetic disorders and 
chemical or radiation exposure (Deschler and Lübbert, 2006).  
 
The molecular pathogenesis have traditionally been studied using cytogenetic analysis, which 
elucidated many recurrent chromosomal structural abnormalities (Grimwade et al., 2015; Mrózek et 
al., 2004; Rowley, 2008). With next-generation sequencing technologies, recurrent gene mutations are 
increasingly apparent in AML and gene-gene interactions have been reported (Papaemmanuil et al., 
2016; The Cancer Genome Atlas Research Network, 2013). Notably, the genetic aberrations found in 
AML can be classified into different functional categories, including transcription factor fusions (e.g. 
PML-RARA, RUNX1-RUNX1T1), tumour suppressors (e.g. P53, WT1), DNA methylation (e.g. 
DNMT3A/B, TET1/2, IDH1/2), activated signalling (e.g. FLT3-ITD, KIT, KRAS/NRAS), chromatin 
modifiers (e.g. MLL-fusions, NUP98-NSD1), myeloid transcription factors (e.g. RUNX1, CEBPA), 
cohesin, spliceosome and NPM1 (The Cancer Genome Atlas Research Network, 2013). Beyond 
somatic mutations, dysregulated epigenetic mechanisms are thought to play a role in AML 
pathogenesis, as seen by the recurrent somatic mutations in genes encoding many epigenetic 
modifiers (Figueroa et al., 2010a; Rampal et al., 2014; Shih et al., 2015; The Cancer Genome Atlas 
Research Network, 2013). In addition, studies have reported alterations in genome-wide DNA 
methylation patterns in AML patients (Figueroa et al., 2010b; Li et al., 2016a; The Cancer Genome 
Atlas Research Network, 2013).  
 
Despite the relatively low number of mutations per patient compared to other cancer types, genetic 
and epigenetic heterogeneity has been identified in AML (Lawrence et al., 2013, 2014; Li et al., 2016b). 
This heterogeneity can be found between different patients as well as within a patient. A founding 
leukaemia clone, which is defined by a clone with the highest variant allele frequency, and at least one 
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sub-clone are commonly detected in individual patients (The Cancer Genome Atlas Research 
Network, 2013; Welch et al., 2012). Understanding the underlying mutational profiles of AML can 
have implications on the therapeutic choice for the same patients at different stages of the disease 
(Grimwade et al., 2015). 
 
1.2 Current and emerging treatments for AML 
 
The conventional care for AML has not advanced for more than three decades, whereby induction 
chemotherapy serves as the front-line treatment for many patients (Döhner et al., 2016).  
Anthracycline in combination with cytarabine are given to patients suitable for intense chemotherapy, 
which include those younger than 60 years of age or older but showing favourable- or intermediate-
risk cytogenetics (Döhner et al., 2015, 2016). Antracycline is an antibiotic produced by Streptomyces 
peucetius varcaesitue and thought to interact with nuclear components such as DNA and 
topoisomerase, causing DNA damages (Minotti, 2004; Rabbani et al., 2005). Cytarabine is a 
pyrimidine analogue and the mechanism of cytotoxicity is presumably due to the cumulative effect of 
DNA polymerase inhibition and competitive incorporation of the nucleoside analogue into DNA; the 
latter results in chain termination and subsequent block of DNA synthesis (Galmarini et al., 2001; 
Kufe et al., 1980; Major et al., 1981, 1982). Post-remission treatments, also known as consolidation 
therapy, include further chemotherapy and hematopoietic-cell transplantation. These treatments aim 
to eliminate any residual diseased cells and prevent relapse (De Kouchkovsky and Abdul-Hay, 2016). 
 
Although the majority of the patients younger than the age of 60 achieve complete remission after 
induction therapy, the response rates are less optimistic in older AML patients (Döhner et al., 2015; 
Lowenberg et al., 1999). Relapse and subsequent resistance to chemotherapy are major barriers to the 
long-term survival of AML patients. It is estimated that only about 30% of the patients are cured of the 
disease, whilst the majority of the patients experience relapse (Döhner et al., 2015, 2016; Liesveld, 
2012). This relapse of the disease is associated with the clonal evolution of leukaemic blasts within 
individual patients (Garson et al., 1989; Testa et al., 1979). A recent study using next generation 
sequencing has revealed the pattern of clonal evolution of AML cells that led to disease relapse (Ding 
et al., 2012). The authors found that during or after chemotherapy, primary AML clones acquired 
additional mutations and gave rise to relapse clones. They suggested that although essential for initial 
remission, chemotherapy could introduce relapse-specific mutations into founding AML clones or 
surviving sub-clones, which can undergo selection and clonal expansion.  
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The effort to increase treatment options for AML patients can be reflected by the numerous novel 
agents that are currently in different phases of development. New formulation of chemotherapies 
includes topoisomerase inhibitors (e.g. Vosaroxin), hypomethylating agents (e.g. Guadecitabine) and 
CPX-351. CPX-351 combines cytarabine and antracyclin daunorubicin in 5:1 molar ratio and is 
encapsulated in liposome (Döhner et al., 2015; Stein and Tallman, 2015). In addition, an antibody-
drug conjugate (ADC) was developed to deliver the conjugated drug specifically to CD33+ leukaemic 
cells and have shown myelosuppressive effects (Döhner et al., 2015; Stein and Tallman, 2015). Many 
molecular targeted inhibitors are also under evaluation in clinical trials. Agents that target recurrent 
mutations include inhibitors against FLT3 (e.g. Quizartinib, Crenolanib, Gilteritinib) (Döhner et al., 
2015; De Kouchkovsky and Abdul-Hay, 2016; Stein and Tallman, 2015), IDH1/2 (e.g. AG-221, AG-
120) (Döhner et al., 2015; Pollyea et al., 2014; Stein et al., 2014) and BCL2 (DiNardo et al., 2019; 
Kontro et al., 2015; Pollyea et al., 2018; Pullarkat and Newman, 2016). DNA methyltransferase 
(DNMT) inhibitors Azacitidine and Decitabine have been approved for clinical use (Wouters and 
Delwel, 2016). Other epigenetic modifier inhibitors in clinical trial include a histone lysine 
methyltransferase DOT1L inhibitor EPZ-5676, a histone lysine demethylase LSD1 inhibitor 
GSK2879552, histone deacetylase (HDAC) inhibitors Pracinostat, Vorinostat and Panobinostat, and 
Bromodomain (BET) inhibitor OTX-015 (Daigle et al., 2011; Döhner et al., 2015; Grimwade et al., 
2015; Stein and Tallman, 2015; Wouters and Delwel, 2016). Potential targets in preclinical 
development include histone lysine methyltransferase inhibitors against EZH2 (Girard et al., 2014; 
Knutson et al., 2012), MLL-Menin (Borkin et al., 2015; Grembecka et al., 2012) or MLL-LEDGF 
(Čermaková et al., 2014) interface, histone lysine acetyltransferase inhibitors against CREBBP (Gang 
et al., 2014) and EP300 (Gao et al., 2013b), as well as histone arginine methyltransferase PRMT 
inhibitors (Alinari et al., 2015; Chan-Penebre et al., 2015). Notably, the emergence of many epigenetic 
targeted therapies in AML reflects the involvement of epigenetics in the pathogenesis of AML.  
 
1.3 CRISPR-Cas9 as a powerful tool to identify vulnerabilities in AML 
 
Understanding of the genetic contribution to diseases has been enhanced by advances in targeted 
gene-editing technologies, such as the clustered regularly interspaced short palindromic (CRISPR)-
Cas (CRISPR-associated) system. Originally a defence mechanism found in bacteria and archaea 
(Horvath and Barrangou, 2010), the CRISPR-Cas system has been exploited in a wide range of 
organisms, including mammalian cells (Bassett et al., 2015; Chen et al., 2015; Hart et al., 2015; Matano 
et al., 2015; Sánchez-Rivera and Jacks, 2015; Shi et al., 2015). This system composes of Cas protein and 
CRISPR RNA (crRNA). The latter possesses nucleotide sequence complementary to target region(s) of 
the genomic DNA. Depending on the types of CRISPR system (I-III), the manner in which precursor 
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CRISPR RNA (pre-crRNA) is processed into mature crRNA and the associated effector Cas protein 
differ.  
 
Type II CRISPR-Cas9 system is one of the best characterised versions and most commonly used for 
genome engineering due to its simplicity in terms of the number of genes involved (Makarova et al., 
2015). While type I and III CRISPR-Cas systems utilise a large multimeric crRNA-Cas complex to 
achieve nuclease activity, the type II system requires a single Cas9 endonuclease with crRNA and 
trans-activating crRNA (tracrRNA) and cleave target DNA sequences (Makarova et al., 2011). In the 
engineered CRISPR-Cas9 system, crRNA and tracrRNA are fused together and the system requires 
single guide-RNA (gRNA) (Ran et al., 2013). The simplicity has accelerated its development as a 
molecular tool (Rath et al., 2015). Specificity towards a particular region of the genome relies on a 20-
nucleotide variable region at the 5’ end of the gRNAs (Koike-Yusa et al., 2014). Double stranded break 
(DSB) triggers DNA repair pathways such as non-homologous end joining (NHEJ) or homology-
directed repair (HDR). Exploiting the inaccurate repair of DNA by NHEJ, nucleotide insertion or 
deletion (indels) can lead to frameshift mutations that derives non-functional protein (Ran et al., 
2013; Rath et al., 2015; Sander and Joung, 2014). Compared to RNA interference (RNAi), which 
utilises small interfering RNA (siRNA) or short hairpin RNA (shRNA) to generate knock-down of 
target genes, CRISPR-Cas9 creates targeted gene knock-out using gRNA. Both technologies suffer 
disadvantages. RNAi often results in incomplete suppression of gene expression, whereas the use of 
CRISPR-Cas9 is restricted to target regions in the genome with protospacer adjacent motifs (PAM). 
The possibility of off-targets is common to both technologies (Koike-Yusa et al., 2014; Ran et al., 2013; 
Sander and Joung, 2014; Shalem et al., 2015). Nevertheless, CRISPR-Cas9 serves as an invaluable tool 
to address many biological questions. 
 
The ability to generate bi-allelic mutations at a targeted locus has sparked many questions in the field 
of cancer research (Chen et al., 2015; Hart et al., 2015; Sánchez-Rivera and Jacks, 2015; Shi et al., 
2015). In particular, genome-wide loss-of-function genetic screening allows the identification of 
recessive genes important in cancer. CRISPR-Cas9 screens have been performed in human AML cell 
lines (Erb et al., 2017; Tzelepis et al., 2016; Wang et al., 2017). This method elucidated essential genes 
that drive leukaemic cells. Utilising AML cell lines with different genotypes informed genotype-
specific essentiality. In the CRISPR screen performed by Tzelepis et al., they identified 492 AML-
specific essential genes across 5 AML cell lines (MOLM-13, MV4-11, HL-60, OCI-AML2 and OCI-
AML3), 227 of which are druggable, defined as proteins with enzymatic activity which can potentially 
be targeted (Tzelepis et al., 2016; Wagner et al., 2016). Potential novel therapeutic targets within these 
large datasets may be teased out to ameliorate the current treatment landscape of AML.  
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It has been proposed that targeting leukaemia-specific mutations or dependencies is one of the 
successful examples to achieve higher cure rates in patients (Liesveld, 2012). Given that cure remains 
elusive for the majority of the AML population and the conventional treatment regimens for AML is 
non-specific, toxic and unsuitable for high-risk patients, this thesis aims to identify novel and 
promising druggable candidates by understanding the mechanism of their essentiality. Genome-wide 
CRISPR-Cas9 dropout screens revealed KAT7 as a novel AML-specific vulnerability that could 
potentially be exploited therapeutically (Tzelepis et al., 2016).  
 
1.4 KAT7 protein complexes and histone tail specificity 
 
KAT7, also known as MYST2 or HBO1, is a histone lysine acetyltransferase (HATs/KATs) belonging 
in the MYST family proteins (Avvakumov and Côté, 2007; Sheikh and Akhtar, 2018; Voss and 
Thomas, 2009) . The defining and common feature of MYST family protein is the highly conserved 
MYST catalytic domain, containing an acetyl-CoA binding motif and a C2HC-zinc finger motif 
(Avvakumov and Côté, 2007; Voss and Thomas, 2009). Other members of the MYST family include 
KAT5 (TIP60), KAT6A (also called MOZ or MYST3) and KAT6B (MORF or MYST4). Possessing 
only the zinc finger, serine-rich and MYST domains, KAT7 relies on forming multi-subunit 
complexes with scaffold protein JADE or BRPF, along with Esa1 associated factor 6 (EAF6) and 
inhibitor of growth protein 4/5 (ING4/5) for chromatin binding (Figure 1). ING4/5, JADE and BRPF 
subunits all possess the plant hormone domain (PHD), which is a recognition motif that binds to 
histone modifications on the N-terminal tail of histone H3 (Avvakumov et al., 2012; Lalonde et al., 
2013; Musselman et al., 2012; Saksouk et al., 2009).  
 
Figure 1 Protein complexes of KAT7 
KAT7 is found in complexes containing ING4/5, EAF6 and JADE1/2/3 or BRPF1/2/3. A) KAT7-JADE 
complex facilitates histone H4 acetylation on lysine residues 5, 8 and 12. B) KAT7-BRPF complex has 













ING4/5 consist of one PHD domain while both JADE and BRPF each possess two PHD domains. 
KAT7 complex is localized to H3K4me3 enriched region of the chromatin through the PHD domain 
of ING4/5 (Lalonde et al., 2013; Saksouk et al., 2009). However, the histone tail specificity of KAT7 is 
determined by the scaffold protein in the complex— KAT7-BRPF and KAT7-JADE complex has an 
affinity to histone 3 tails (H3K14ac, H3K23ac) (Feng et al., 2016; Kueh et al., 2011; Lalonde et al., 
2013; Mishima et al., 2011) and histone 4 tails (H4K5ac, H4K8ac, H4K12ac) (Doyon et al., 2006; 
Iizuka et al., 2009) respectively.  
 
All paralogues of JADE and BPPF proteins have multiple shared properties. Firstly, the two PHD 
domains are linked by zinc knuckle and are known as the PZP domain that is essential for chromatin 
binding (Avvakumov et al., 2012; Lalonde et al., 2013). Secondly, flanking the PZP domains are 
domain I and domain II where the former interacts with KAT7 and the latter binds ING4/5 and 
EAF6. It is hypothesized that the PZP domain of the scaffold protein drives the acetylation of lysine 
residues on H3 tail, however, the N-terminal region (EPcA-related N-terminal domain) just before the 
domain I in JADE protein is crucial for the histone H4 tail specificity and lysine acetylation on H4 
tails (Lalonde et al., 2013).  
 




KAT7 is involved in the initiation of DNA replication by regulating the assembly/formation of the 
pre-replication complex (pre-RC) (Doyon et al., 2006; Iizuka et al., 2006; Miotto and Struhl, 2008, 
2010, 2011). In G1 phase of the cell cycle, KAT7 is recruited to the replication origins by direct 
binding with Cdt1 and serving as a co-activator of Cdt1, consequently affect the licensing activity of 
Cdt1 (Miotto and Struhl, 2008). The Cdt1-dependent recruitment of KAT7 leads to global histone 4 
acetylation at the origin, which is positively correlated with the loading of minichromosome 
maintenance (MCM) protein complex required for the firing of replication origins (Miotto and 
Struhl, 2010). Potential involvement of non-histone acetylation by KAT7 in controlling this process 
has been speculated due to in vitro evidence of KAT7 acetylating subunits of the pre-RC such as Orc2, 
Geminin, Mcm2 and Cdc6 (Iizuka et al., 2006). Furthermore, KAT7 has also been reported to play a 
role in the S phase of the cell cycle for DNA synthesis (Doyon et al., 2006). Together, these evidences 
illustrate the catalytic-dependent activity of KAT7 in regulating the cell cycle.  
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1.5.2 Transcription and regulation of gene expression 
 
KAT7 has been implicated in transcription control in various cellular contexts, in part, via its histone 
acetylation function. Occupancy of KAT7 at the 5’ region of genes positively correlated with gene 
expression in RKO colon carcinoma cell lines, with enrichment of KAT7 found both upstream and 
downstream of TSS (Avvakumov et al., 2012). In addition to promoter binding, KAT7 is localized 
at/to gene bodies. Tetrameric KAT7 complex (KAT7-JADE-ING4/5-EAF6) localizes to H3K4me3-
enriched chromatin region to acetylate lysine residues on histone tails, whilst in dimeric form, KAT7-
JADE has affinity to H3K36me3, a modification that marks active coding regions of the gene (Barth 
and Imhof, 2010; Wu and Snyder, 2008), in order to deposit H4 acetylations across the gene body 
(Saksouk et al., 2009). This suggests that KAT7 plays a role not only in the initiation stage but also in 
the elongation of transcription. Furthermore, intragenic region (also known as intronic region) 
H3K14ac and pan-H4 acetylations by KAT7 is implicated in regulating the transcription of 
endothelial genes such as VEGFR-2 transcription in human and zebrafish endothelial cells (Yan et al., 
2018). 
 
Several studies suggested that KAT7 could modulate the transcriptional programme through 
functions other than histone acetylations. In particular, multiple studies have associated KAT7 as co-
factors of hormones receptors (Georgiakaki et al., 2006; Iizuka et al., 2013; IIZUKA et al., 2017; 
Sharma et al., 2000). Intrinsic E3 ligase activity of the MYST domain of KAT7 has been linked to the 
ubiquitination of estrogen receptor (ER) which destabilizes the ER for proteasomal degradation  
(Iizuka et al., 2013; IIZUKA et al., 2017). In another study, Sharma et al., identified interactions 
between KAT7 and androgen receptor (AR) both in vitro and in vivo (CV-1 monkey kidney cell line). 
Binding of KAT7 to AR represses AR-mediated transcription and this is thought to be mediated via 
the N-terminal region of KAT7 (Sharma et al., 2000). In contrast to the findings of Iizuka et al., 
Sharma et al, did not detect inhibitory effect of KAT7 on ER-dependent transcription. KAT7 is a co-
activator of various other nuclear hormone receptor, including progesterone receptor to modulate its 
transcriptional activity (Georgiakaki et al., 2006). Importantly, KAT7 may regulate transcription by 
physical interaction with nuclear factors and/or via its non-histone acetylation function. Depending 
on the context, KAT7 may promote or suppress gene expression.  
 
1.5.3 Physiological roles of KAT7 
 
Loss of KAT7 has severe consequences in development— mice embryos lacking KAT7 do not develop 
beyond mouse embryonic day 10.5 (E10.5) and is arrested at the 10-somite stage due to growth 
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retardation and down regulation of genes essential for embryonic patterning (Kueh et al., 2011). 
Importantly, KAT7 is responsible for global H3K14ac in mouse embryos and primary embryonic 
fibroblasts and the KAT7 mutant of these cell types were able to proliferation normally and showed 
no defects on DNA replication in vitro, suggesting KAT7 is dispensable for general DNA replication, 
cell cycle and proliferation (Kueh et al., 2011). KAT7 is also required to maintain global H3K14ac in 
fetal livers and for the expression erythroid regulator genes in erythropoiesis (Mishima et al., 2011). 
Together, these studies imply the critical role of KAT7 as a transcription regulator for important 
developmental genes.  
 
1.6 KAT7 in cancer and diseases 
 
The role of KAT7 in cancer is not well explored. A study has found the concentration of KAT7 
protein in cancer cell lines are more abundant compared to normal cells (Iizuka et al., 2009). Among 
primary cancers, tissues from testis, breast, ovary and bladder tumours have high KAT7 protein levels 
(Chen et al., 2017; Iizuka et al., 2009). Knock-down of KAT7 has anti-tumour effects in bladder cancer 
cells, via the Wnt/B-catenin signalling pathway, and has been proposed as a potential therapeutic 
target in the treatment of this carcinogenesis (Chen et al., 2017).  Although KAT7 is also normally 
highly expressed in testis (Iizuka et al., 2009; Sharma et al., 2000), it possesses putative tumour 
suppressive roles in hormone receptor driven tumours such as prostate and breast cancers (Iizuka et 
al., 2013; IIZUKA et al., 2017; Sharma et al., 2000). Depending on the context, HATs can serve as an 
oncogene or tumour suppressors. In AML, HATs of the MYST family are frequent targets of 
chromosomal translocations (Sheikh and Akhtar, 2018). While KAT6A and KAT6B are known targets 
of chromosomal translocations that drive AML (Borrow et al., 1996; Carapeti et al., 1998; Esteyries et 




This thesis aims to validate dropout hits from the genome-wide AML CRISPR-Cas9 screens and 
further elucidate the molecular mechanism of essentiality of the most promising candidate. In 
particular, to decipher the potential role of KAT7 in the pathogenesis of AML, by addressing the 
following broad objectives: 
• Investigate the phenotypic consequences of KAT7 knock-out in various AML cell lines. 
• Characterize the molecular functions of KAT7 in cellular models of AML. 
• Understand the mechanism of action of KAT7 in vulnerable AML subtypes. 
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Chapter 2: Materials and methods 
 
2.1 Cell culture 
 
All Cas9-expressing cell lines, with the exception of Nomo-1, were kindly provided by the Vassiliou 
group. Cas9-expressing MOLM-13, MV4-11, OCI-AML2 and OCI-AML3 were generated in the study 
performed by Tzelepis et al. Cas9-expressing THP-1 and K562 cell lines were generated in a separate 
study in Vassiliou’s group. Nomo-1 cell line was derived from Mathew Garnett. Generation of Cas9 
expressing Nomo-1 is described below.  
 
MOLM-13, MV4-11, THP-1, HL-60 and K562 were cultured in RPMI 1640 medium (52400-25, Life 
Technologies) supplemented with 10% fetal bovine serum (10270-106, Life Technologies). OCI-
AML2 and OCI-AML3 were cultured in MEM-a (BE12-169-F, Lonza) with 20% fetal bovine serum 
(10270-106, Life Technologies) and 1% GlutaMax (35050-038, Life Technologies). Nomo-1 was 
cultured in RPMI 1640 supplemented with 10% FBS, 1% penicillin/streptomycin (15070063, Life 
Technologies), 1% sodium pyruvate (11360039, Life Technologies), 1% glucose (Sigma).  To maintain 
Cas9 expression, blasticidin (R210-01, Invitrogen) was added to MOLM-13, MV4-11, THP-1, Nomo-
1, HL-60, OCI-AML2 and OCI-AML3 at 10 µg/ml, and K562 at 15 µg/ml. 293 FT cells were cultured 
in DMEM (21969-035, Life Technologies) supplemented with 10% fetal bovine serum (10270-106, 
Life Technologies) and 1% GlutaMax (35050-038, Life Technologies). All cell lines were incubated at 7 
°C with 5% CO2. The oncogenic mutations and patient profile of cell lines used in this study are 
indicated in Table 2.1.   
 
Table 2.1 Cell lines used in this study and the oncogenic  






OCI-AML3 NRAS, NPM1, BAX, DMNT3A
HL-60 NRAS, TP53, CDKN2A




2.2 gRNA design and cloning of gRNA into expression vector   
 
The two best-performing gRNAs (unpublished data) from the genome-wide CRISPR-library used in 
the initial screens (Tzelepis et al., 2016) were selected for the initial validation of candidate genes. For 
KAT7 and SIK3, additional 4-5 gRNAs were designed using WTSI Genome Editing (WGE) 
(http://www.sanger.ac.uk/htgt/wge/). Only gRNAs that target the exon of all putative transcripts and 
have no less than 3 nucleotide off-target mismatches in the sequence were selected. All gRNAs were 
cloned into the Bbsl site of pKLV2-U6gRNA5(insert)-PGKpuro2ABFP-W (Figure 2.1D) (Koike-Yusa 
et al., 2014).  
 
2.3 Virus production and transduction 
 
Lentivirus was produced by transfecting 293 FT cells in one well of 6-well plates. 0.9 µg lentivirus 
vector, 0.9 µg psPax2 packaging vector (12260, Addgene), 0.2 µg pMG2.G (12259, Addgene) and 2 µl 
of PLUS reagent (15338100, Invitrogen) were added to 500 µl Opti-MEM (51985026, Invitrogen) and 
mixed by vortex. The mixture was incubated for 5 min at room temperature. 6 µl of Lipofectamine 
LTX (15338100, Invitrogen) were then added to the mixture, vortexed and further incubated for 30 
min at room temperature. The transfection mixture was added to each well and incubated for 6-8 h at 
37 °C with 5% CO2 and then replaced with DMEM (21969, Invitrogen) supplemented with 10% fetal 
bovine serum (10270-106, Life Technologies) and 1% GlutaMax (35050-038, Life Technologies). Viral 
supernatant was collected on day 2, filtered with 0.45µm surfactant-free cellulose acetate (SFCA) 
syringe filter (190-2545, Nalgene) and stored at -80 °C.   
 
AML and CML cell lines were transduced by adding lentivirus and 8 µg/ml polybrene (Millipore) to 
3.0 x 104 cells per well of 96-well plate (for proliferation assay) or 1 x 106 cells per well of 6-well plate 
and incubated for 22 h at 37 °C.  Viral supernatant was then replaced with culture media and cells 
were passaged. BFP-positive cells were sorted on day 3 post-transduction and used for subsequent 
functional assay (see below).  
 
2.4 Generating Cas9 expressing Nomo-1 cell line and blasticidin selection 
 
Cas9 construct is integrated into the genome by lentivirus transduction. The Cas9 expression vector is 
illustrated in Figure 2.1A and previously reported by Tzelepis et al. The concentration required for 
blasticidin selection was determined by a “kill curve” assay, which is the minimum concentration of 
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blasticidin to kill all wild-type cells. Concentration tested: 1, 5, 10, 15, 30 µg/mL. Blasticidin 
concentration >10 µg/mL killed all Nomo-1 cells. 
 
Figure 2.1 Cas9, Cas9 reporter and gRNA constructs 
A) The Cas9 construct used to generate the Cas9 expressing cell lines used in this study. The Cas9 gene 
and blasticidin resistant (Bsd) genes are expressed under the EF1-alpha promoter. B-C) Cas9 reporter 
construct to assess the Cas9 activity of cells. Gene encoding fluorescence proteins are expressed with the 
PGK promoter and gRNA are expressed under the U6 promoter. B) BFP and GFP expression with gRNA 
targeting GFP (gGFP). C) mCherry and BFP expression with gRNA targeting BFP (gBFP). D) gRNA 
scaffold construct with gRNA insert at the BbsI restriction site, expressed under the U6 promoter. 






2.5 Cell sorting and FACS analyses  
 
Cell sorting was performed using Mo-Flo XDP or BD INFLUX under containment-level 2 (CL2) 
condition. FACS analyses for functional assays were performed using BD LSRFortessa. All raw files 
were analysed using FlowJo.  
 
2.6 Sub-cloning and characterisation of Cas9-expressing AML cells 
 
Single cells of MOLM-13, MV4-11, THP-1, HL-60, OCI-AML2, OCI-AML3 and MOLM-13luciferase 
were sorted into individual wells of 96-well plate and cultured for 2-3 weeks until colonies were 
observed. Growing colonies were transferred to 24-well then 12-well plates, further expanded. Cas9 
activity was examined using the Cas9 reporter construct pKLV2-U6gRNA (target GFP)-PGK-BFP-
T2A-GFP (Figure 2.1B) (Tzelepis et al., 2016). As the presence of luciferase protein in MOLM-
13luciferase give rise to autofluorescence that interferes with the GFP channel, we opted to use a variant 
reporter whereby GFP is replaced by BFP and BFP is replaced with mCherry: pKLV2-U6gRNA (target 
BFP)-PGK-mCherry-BFP-mCherry (Figure 2.1C) (Tzelepis et al., 2016) to assess the Cas9 activity of 
this cell line.  
 




The validation of each candidate gene was performed in triplicates in 96-well plates. The relative 
percentage of BFP-positive and BFP-negative cells was determined for each well every 2 days between 
day 4 and 12 post-transduction by FACS. Culture media were refreshed every two days. Cells were 
fixed in 4% Paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for 10 min and resuspended 




2.3 x 105 cells were harvested to stain for CD11b (17-0118, eBioscience) or CD13 (17-0138, 
eBioscience). APC-conjugated mouse IgG1 k isotype control (17-4714, eBioscience) was used to 
detect non-specific binding. Cells were washed once in PBS and once in staining buffer (2% fetal 
bovine serum in PBS), followed by resuspension in anti-human CD11b or CD13 antibody solution 
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(1.15 µl antibody per 100 µl staining buffer per test) for 30 min on ice in the dark. After incubation, 




2.3 x 105 cells were analysed using Annexin V Apoptosis Detection Kit APC (88-8007, eBioscience). 
Cells were washed once with PBS and once in 1X binding buffer.  10X binding buffer (88-8007, 
eBioscience) was diluted by adding 1 mL 10X binding buffer with 9 mL dH2O.  Cell pellets were 
resuspended in 100 µL annexin V binding buffer (1.15 µL Annexin V-APC per 100 µL 1X binding 
buffer) and incubated in dark for 15 min in room temperature. Next, cells were washed in 1X binding 
buffer and resuspended in 200 µL of the same buffer. 1.15 µL of PI solution (88-8007, eBioscience) 
was added immediately before flow cytometry analysis. Samples are kept on ice following staining.  
 
2.7.4 Cell cycle 
 
2.3 x 105 cells were washed twice with PBS and fixed in ice-cold 70% ethanol for at least 24 h at 4 °C. 
Fixed cells were washed once in PBS and resuspended in Propidium Iodide (PI) staining solution 
[Triton X-100 (0.1% v/v), RNase A (50 µg/ml) and PI (25 µg/ml)] overnight at 4 °C. DNA content was 
analysed by flow cytometry. 
 
2.8 Cloning and generation of gRNA-resistant wild-type, G485A and E508Q 
mutant KAT7 cell lines  
 
KAT7 cDNA (wild-type and G485A) that is resistant to gKAT7 (5) and gKAT7 (A10) targeting was 
cloned into a separate lentiviral plasmid backbone (EF1a-GFP-2A). Briefly, the plasmid was linearized 
by BsrGI (NEB) and Not1 (NEB). KAT7 cDNA, in the form of gBlock, is subsequently cloned by 
Gibson assembly according to the manufacturer’s guidelines. The resulting plasmid pKLV-
EF1aGFP2AKAT7-W, expressing wild-type KAT7 was used to generate E508Q transgene. The KAT7- 
plasmid was double digested sequentially by BsaBI (NEB) followed by SrfI (NEB) to remove the 
specific segment in the MYST region of the wild-type KAT7 sequence. Sequential digestion was used 
as the optimal temperature for enzymatic activity differs for these two restriction enzymes. The 
volume of enzyme added is typically <10% of reaction volume where reaction volume is up to 50 µL. 
 
The plasmid is first digested by BsaBI in following mixture and conditions: 
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0.5 µg Plasmid DNA 2.5 µL 
BsaBI  2.5 µL 60 °C for 90 min 
CutSmart 37.5 µL 80 °C for 20 min 
dH2O 47.5 µL Store at 4° C 
 47.5 µL 
 





Linearized DNA was extracted by first running the digested DNA in 1% agarose gel (Figure 2.2) and 
using the QIAquick Gel Extraction kit (28704, Qiagen), following manufacturer’s protocol. The image 
of the gel (Figure 2.2) shows the linearized DNA and the circular DNA where the latter appears to be 
smaller in length. This is because circular DNA migrates more rapidly than the linearized plasmid of 
the same mass. Furthermore, a faint band of 600 bp can be seen and this corresponds to the other 
digested product that is smaller in length. Both of these confirms that the plasmid DNA has been 
digested.  
 
Next, we used the Gibson assembly to ligate the linearized vector with E508Q gBlock. Gibson 
assembly was performed following the manufacturer’s protocol (E2611, NEB). The plasmid was 
amplified by transforming NEB 5-alpha Competent E. coli (C2987H/I, NEB) and plated on ampicillin 
agar plates to select for plasmids, conferring ampicillin resistant, that are successful ligated. The next 
day, colonies were picked and grown in 2xTY media + 50 µg/mL ampicillin. The plasmids were 
purified from E. coli using Miniprep Kit (27104, Qiagen). Cloning was confirmed by Sanger 
sequencing. The transgene was introduced to MOLM-13 cells via lentiviral transduction.  
BsaBI digested DNA 47.5 µL 
SrfI 2.5 µL 
 50 µL 
37 °C for 2 h 




Figure 2.2 Double digestion of plasmid backbone for the integration of E508Q mutant sequence 
The plasmid pKLV-EF1aGFP2AKAT7-W was digested with BsaBI and SrfI to linearize the plasmid 
backbone and for the cloning of the sequence corresponding to the E508Q mutation by Gibson assembly. 
The thick bands in lane 3 and 4 are the linearized plasmid DNA (pDNA). The blue arrow indicates a 
faint band at ~600bp, corresponding to the digested product. Note that the undigested pDNA in lane 6 
migrate faster along the agarose gel, compared to the linearized pDNA.  
 
2.9 Sanger Sequencing  
 
LIGHTRun tube NightXpress service was used for capillary sequencing to identify successful cloning. 
Samples were prepared as follows: 5 µL of purified plasmid DNA at a concentrate of 80-100 ng/µL 
mixed with 5 µL of 5 µM primer.  
 
2.10 Western blot 
 
The total number of cells was quantified by TC20 cell counter (Bio-Rad). Cells were harvested by 
centrifugation and washed twice in PBS. Cell pellets were then resuspended in NuPAGE LDS sample 
buffer (NP0007, ThermoFisher), NuPAGE sample reducing agent (NP0009, ThermoFisher) and water 
at a concentration of 1 x 106 cells/ 100 µL. Samples were heated at 95 °C for 5 min and vortexed at 
room temperature for 10 min. An equal volume of samples was loaded into each well of Bis-Tris gels 
and electrophoresis were run at 150 V for 60 min in 1X MOPS SDS running buffer (NP0001, 









activated by suspending in 100% methanol for 2 min and washed in water before suspending in 1X 
transfer buffer (NP0006-1, ThermoFisher). Gel to membrane transfer was performed in ice-cold 1X 
transfer buffer at 90-110 V for 1.5 h or until good separation. Membrane was block with 5% milk 
(170-6406, Bio-Rad) or BSA (A9647, Sigma) in 0.1% TBS-T (1X TBS buffer (28358, ThermoScientific) 
with 0.1% Tween 20 (P9416, Sigma)) for at least 30 min. Primary antibodies were incubated at 4 °C 
over-night with rolling or shaking. Membranes were washed 3 times in 0.1% TBS-T for 10 min each 
the following day. The secondary antibody was blocked in 5% milk or BSA at room temperature for 1 
h with rolling or shaking. Lastly, membranes were washed 3 times in 0.1% TBS-T for 10 min each. 
Enhanced chemiluminescent (ECL) (RPN3244, Amersham) or SuperSignal Pico PLUS (34577, 
ThermoScientific) was used as the substrate for the detection of horseradish peroxidase (HRP) on 
immunoblots. 
 
All antibodies used for western blots are listed in Table 2.5.  
 
2.11 In vivo mouse work 
 
MOLM-13 luciferase-expressing cells were transduced with lentivirus for gRNA-mediated knock-out 
of KAT7 using gKAT7 (A10) or empty control. BFP-positive cells were sorted at day post-
transduction. 5 x 105 cells were injected via the tail vein of immunocompromised NSGW41 male mice 
(derived by breeding NSG and KITW41 animal to homozygosity, i.e. KitW41/W41, Prkdc-/-, and Il2rg-
/- or Il2rg+/Y) on day 3 post-transduction. 5 mice were injected in each treatment group. 
Bioluminescence was done by injection of 2 mg/mL of D-luciferin (BioVision) per mouse. Mice 
quantification of bioluminescence was performed using IVIS Spectrum In Vivo Imaging 
System (PerkinElmer), with Living Image version 4.3.1 software (PerkinElmer) according to the 
manufacturer’s instructions. Log-rank (Mantel-Cox) test was performed to measure statistical 
significance.          
 
2.12 Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
 
For each sample, 500 ng RNA was made up to a volume of 11.875 µL in nuclease-free water. Then, 0.5 
µL random primers (C1181, Promega) and 1 µL dNTP (U1511, Promega) were added to each RNA 
sample. Next, the samples were incubated at 65 °C for 5 min then immediately snap cool on ice for 5 
min. After RNA and primers were denatured, RNA was reverse transcribed to cDNA by adding 4 µL 
5x first-strand buffer (Invitrogen, 18064-071), 2 µL 0.1M DTT (18064-071, Invitrogen), 0.5 µL RNase 
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out (10777-019, Invitrogen) and 0.125 µL Superscript II (Invitrogen, 18064-071) to each sample. 
Then, the mixture was placed in PCR machine with the following cycles: 25 °C for 10 min (primer 
annealing), 42 °C for 50 min (extension) and 70 °C for 15 min (inactivation of enzyme). The cDNA 
was subsequently diluted 1 in 30 times by adding 5 µL of cDNA to 145 µL nuclease-free water to a 
total volume of 150 µL. Next, to perform quantitative-PCR, 5 µL diluted cDNA is added with 0.6 µL 5 
µM forward primer, 0.6 µL 5 µM reverse primer, 1.3 µL nuclease-free water and 7.5 µL 2X SensiMix 
SYBR Low-ROX kit (QT625-05). qPCR cycles are performed using qPCR machine (Mx3005P, 
Agilent) as follows: 95 °C for 10 min followed by 40 cycles of 95 °C for 30 s; 60 °C for 30 s; 72 °C for 
30 s. Primers used for RT-PCR are listed in Table 2.3. Expression fold change is calculated as follows: 
2-DDCT, where DDCT = Dknock-out (target gene- GAPDH) - Dempty (target gene- GAPDH).  
 
2.13 Optimization of qPCR primers 
 
RT-PCR primers were designed using PrimerBank (https://pga.mgh.harvard.edu/primerbank/). 
ChIP-qPCR primers were designed using Primer-BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). All qPCR primers are tested for specificity prior 
to use for RT-qPCR or ChIP-qPCR. The presence of a single peak in the dissociation curve indicates 
that only one PCR product is present. More than one peak in the dissociation curve is likely due to 
more than one target has been amplified. Primers with more than one peak are discarded and 
redesigned. Only primers that give rise to one PCR product were used.   
 
2.14 Optimization for ChIP-seq 
 
For ChIP-seq purposes, DNA fragments are required to be 100-700 base-pair (bp). This is dependent 
on various factors, including the cell line, cell number and concentration, sonicator equipment model, 
cross-linker(s) used and the duration of cross-linking. Double cross-linking whereby a protein-
protein linker such as disuccinimidyl glutarate (DSG) or ethylene glycol bis(succinimidyl succinate) 
(EGS) are used in addition to formaldehyde (FA), which links protein-DNA, typically requires longer 
cycles. We fixed the cell number per condition to be 20 x 106 cells using 1% FA (ThermoFisher, 
28908).  
 
To determine the number of sonication cycles required to obtain 100-700 bp DNA fragments for 
MOLM-13, MV4-11 and OCI-AML3 cross-linked with the above conditions for 5 and 10 min, we 
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assayed various cycles ranging from 5-25 cycles. For collection at each sonication cycle, 50 µL of 
samples were extracted from the 2 mL suspension.  
 
For 5 min cross-linked MOLM-13, the desired DNA-fragment is achieved between 8-14 sonication 
cycles (Figure 2.3A) and 8-17 cycles for 10 min cross-linked (Figure 2.3B). Therefore, we chose to use 
10 cycles for both 5 min and 10 min cross-linked MOLM-13, under the condition of 20 x 106 cells per 
2mL and cross-linking with 1% FA.  
 
MV4-11 cross-linked for 5 min requires 8-11 cycles while 10 min require 11 cycles (Figure 2.4A). Note 
that, not enough DNA was loaded to the lane 8 (8 cycles, 10 min) and lane 10 (14 cycles, 10 min). 
Given the data available, we chose to use 10 cycles and 11 cycles for 5 min and 10 min cross-linked 
MV4-11, respectively.  
 
OCI-AML3 cross-linked for 5 min requires 8-14 cycles while 10 min require 11-14 cycles (Figure 
2.4B). Lane 4 (11 cycles, 5 min) and lane 8 (8 cycles, 10 min) were not loaded with sufficient DNA. 
However, we are still able to identify the optimal cycles. We opted for 11 cycles for both 5 min and 10 
min cross-linked OCI-AML3.  
 
Summary of optimal cycles for MOLM-13, MV4-11 and OCI-AML3 for 5 min and 10 min cross-







Additionally, we used the bioanalyzer (5067-4626, Agilent) to analysed the DNA fragment length of 
sonicated samples for 10 min cross-linked input samples of MOLM-13 and OCI-AML3. Although the 
sonication was not entirely efficient, as seen with a peak between 500-1000 bp in both cell lines, the 
majority of the DNA is within the target range (Figure 2.5).  
 
To reverse cross-link the protein-DNA linkage and retain the DNA, the following was added to 10 µL 
of samples and incubated at 65 °C for 2 h 
 
 
 5 minutes 10 minutes 
MOLM-13 10 10 
MV4-11 10 11 
OCI-AML3 11 11 
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Nuclease free H2O 74 µL 
5 M NaCl 4 µL 
20 mg/mL Proteinase K 8 µL 
10 mg/mL RNase A 4 µL 
 90 µL 
 
De-crosslinked DNA was then purified by QIAquick PCR purification Kit (Qiagen, 28104). 10 µL 
purified DNA was added with 2 µL 10X gel-loading buffer (Invitrogen, 10816015) and loaded into 
wells of 1.5%-2% agarose gel with a 100 bp DNA ladder (N3231, NEB). 
 
Figure 2.3 DNA fragments after sonication of cross-linked MOLM-13 
MOLM-13 cells crosslinked with 1% formaldehyde for A) 5 min or B) 10 min and sonicated for various 
cycles to determine the number of cycles required to achieve the optimal 100-700 bp DNA fragments.  
 

















Figure 2.4 DNA fragments after sonication of cross-linked MV4-11 and OCI-AML3 
A) MV4-11 and B) OCI-AML3 crosslinked with 1% formaldehyde for 5 min or 10 min and sonicated for 




Cycle # 5 8 11 14
5 min






Cycle # 5 8 11 14
5 min










Figure 2.5 Analysis of input DNA fragments after the sonication of cross-linked MOLM-13 and OCI-
AML3 by bioanalyzer 
Cells were cross-linked with 1% formaldehyde for 10 min and sonicated for 10 and 11 cycles for MOLM-
13 and OCI-AML3, respectively. Two distinct peaks are evident in both cell lines— one between 35-500 
bp and the other between 500-1000 bp. Majority of the DNA fragments are within the 35-500 bp. These 
samples were submitted as input for ChIP-seq.  
 
 
2.15 Validation of antibodies used in ChIP-seq 
 
The success of ChIP-seq is dependent on the ability of the selected antibody to immunoprecipitated 
the target protein. We analysed two different KAT7 antibodies—monoclonal (58418, Cell Signalling) 
and polyclonal (ab70183, Abcam) for ChIP, followed by western blot analysis of the lysate. In 
addition, we also tested monoclonal and polyclonal H3K14ac antibodies (C15210005, C15410310 
respectively, Diagenode) and H4K12ac antibody (07-595, EMD Millipore) Briefly, ChIP (see below) 
was performed until the washing step, after which, the supernatant was removed by centrifugation 
and the magnetic beads was retained using a magnetic rack. The beads (along with saved input) were 
then resuspended in SDS sample buffer, reducing agent as with standard western blot described above, 
and heated at 95 °C for 5 min followed by shaking at room temperature for 10 min. Samples were 
centrifuged to collect the liquid to the bottom of the Eppendorf tube and the magnet beads were 
removed from the sample using a magnetic rack, the supernatant is transferred into a new Eppendorf 
tube. Samples were stored in -80 °C until the loading on to the gel.  
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A band from the ChIP with polyclonal KAT7 antibody (pAb KAT7), indicated by the yellow arrow, 
corresponds to the expected molecular weight of KAT7, reflecting successful immunoprecipitation of 
KAT7 protein (Figure 2.6). No band was observed for input, IgG control, immunoprecipitation with 
pAb H4K12ac antibodies, mAb and pAb H3K14ac antibodies (Figure 2.6). Insufficient loading could 
explain the lack of bands observed in the input lane. Absence of positive immunoprecipitation using 
the antibodies targeting the histone marks may be due to very little samples loaded, low quality of the 
antibodies or low abundance of the histone marks. 
 
Figure 2.6 Immunoblot of ChIP using KAT7, H3K14ac and H4K12ac antibodies in MOLM-13 
Chromatin immunoprecipitation using monoclonal (mAb) and polyclonal (pAb) antibodies of KAT7 
and IgG (5 µg antibody per ChIP) and other KAT7-mediated histone lysine acetylation targets (2 µg 
antibody per ChIP). 20 x 106 MOLM-13 cells were cross-linked with 1% formaldehyde for 10 min and 5 
min for KAT7 and histone ChIP, respectively. The bands at approximately 60 kDa are signals from the 
heavy chain of the antibodies used in the ChIP. The arrow indicates the successful pull-down of KAT7 
protein using polyclonal KAT7 antibody.  
 
2.16 ChIP-Seq sample preparation 
 
AML cells were cross-linked in 1% FA at room temperature for 5 min (histones ChIP) or 10 min 
(non-histone ChIP) and subsequently clenched with 0.125 M Glycine (Sigma) at room temperature 
for 5 min. Cross-linked cells were washed twice with ice-cold PBS before sequential lysis with LB1 (50 
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mM Hepes, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100), LB2 (10 
mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA), LB3 (10 mM Tris-HCl, 100 mM NaCl, 1 
mM EDTA, 0.5 mM EGTA, 0.1% Na-Deoxycholate, 0.5% N-lauroylsarcosine) on ice for 10 min each.  
Lysed samples were sonicated for 10 cycles (MOLM-13) or 11 cycles (MV4-11 and OCI-AML3) using 
Bioruptor Pico instrument (Diagenode) for 10 min cross-linked cells and 10 cycles (MOLM-13, MV4-
11) for 5 min cross-linked cells. Each cycle is 30 s ON/ 30 s OFF. Triton-X (Sigma) was added to the 
sonicated samples to a final concentration of 1% before centrifugation at 20000x g at 4 °C for 10 min. 
10% of samples were kept as input. Lysates were incubated with antibody (Table 2.5) at 4 °C 
overnight, with rotation. Dynabeads Protein A/G (ThermoFisher) was added the next day and 
incubated at 4 °C for 4h, with rotation. ChIP samples were washed with RIPA wash buffer (50 mM 
HEPES, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-Deoxycholate) 3 times followed by wash 
with Annealing buffer (TE+ 50 mM NaCl). Elution Buffer (1% SDS, 50 mM Tris-HCl, 10 mM EDTA) 
was added to each ChIP samples and heated at 65 °C for 30 min. Beads were subsequently removed 
and samples were heated, at 14000 rpm, 65 °C overnight to reverse cross-linking whilst supplemented 
with 0.2 mg/mL RNase A (ThermoFisher, 10753721). 0.2 mg/mL Proteinase K (Life Technologies, 
25530049) was added the next day to digest proteins by shaking at 450 rpm at 65 °C for 4h. DNA was 
purified by the QIAquick PCR purification Kit (Qiagen, 28104). PBS and LB1, LB2, LB3 and RIPA 
wash buffers were all supplemented with Sodium Butyrate (Sigma, 303410), cOmplete EDTA-free 
protease inhibitor cocktail (Roche, 4693132001) and PMSF (Sigma. 93482) immediately before use. 




ChIP is performed as illustrated above with ChIP-seq. Input DNA is diluted 1 in 20 or 1 in 40, to 
obtain a concentration of <20 ng per 5 µL. KAPA SYBR Fast qPCR kit (KK4620) was used following 
the manufacturer’s protocol. Thermal profile on qPCR machine (Mx3005P, Agilent) are as follows: 1 
cycle of 95 °C for 3 min (enzyme activation); 40 cycles of 95 °C for 3 s (denaturing) and 60 °C for 20 s 
and 72 °C for 20 s (anneal and extend); 1 cycle of 95 °C for 1 min, 55 °C for 30 s, and 95 °C for 30 s 
(dissociation). Percentage Input is calculated as 100 x 2ΔCt, where ΔCt = Ct Normalized input – Ct ChIP; Ct 
Normalized input = Ct Input – log2 (input dilution factor); input dilution factor = fraction of input saved 




2.18 ChIP-seq processing 
 
Reads of ChIP-seq sample and input DNA were mapped to the human genome GRCh38 using BWA-
MEM version 0.7.17 (https://github.com/lh3/bwa) using default parameters. Duplicates were marked 
by Samtools mkdup (Li et al., 2009). Peaks (broad and narrow) were called by MACS2 version 1.4.1  
(Zhang et al., 2008) using input DNA as control with parameters --broad-cutoff 0.01 for broad peaks, 
and –q 0.01 for narrow peaks. Broad and narrow peaks were merged into a union set. Broad peaks that 
overlap with one or more narrow peaks were removed. Locations of peaks (promoter, exon, intron or 
intergenic) were computed by customized scripts using Ensembl transcript annotation of GRCh38 
version 91. Peaks were associated with promoter(s) if more than half of the peak length is located within 
±2 kb from the transcription start site. Promoter occupancies of a transcript were quantified as the 
highest MACS2 signal amongst all the peaks within the 2 kb window. If multiple isoforms exist, genic 
promoter occupancy was calculated as the highest signal amongst isoforms. 
 
The public dataset used in this study: Geo Expression Omnibus GSM1845161 and GSM1845133. 
 
2.19 RNA extraction and RNA-seq processing 
 
RNA was extracted from AML cells with RNeasy Plus Mini Kit (Qiagen) according to the 
manufacturer’s instructions. Sequencing was performed on Illumina HiSeq v4 platform with 75-bp 
paired-end sequencing.  
 
RNA-seq reads were mapped to the human genome assembly GRCh38 using STAR version 2.5.0c 
(Dobin et al., 2013). tolerating mismatch rate of 0.01 and allowing maximal intron lengths of 50 kb. 
Read counts were calculated by STAR --quantMode using Ensembl annotation of GRCh38 version 91 
and normalized as fragments per kilobase of gene length per million uniquely mapped reads (FPKM). 
Differential expression analysis was done by DESeq2 (Love et al., 2014) using paired sample design and 
significant genes were identified using adjusted p-values of 0.05 as the cut-off. 
 
2.20 Data availability 
 
The ChIP-seq and RNA-seq data have been deposited in the GEO database under accession numbers 
GSE133516. 
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2.21 Generation of Auxin Inducible Degron (AID) KAT7 protein degradation 
system and treatment with indole-3-acetic acid (IAA) 
 
MOLM-13 and MV4-11 cells were introduced with pKLV-EF1aGFP2AKAT7_linkermAID-W by 
lentivirus transduction. Transduced AML cells were subsequently sorted for GFP-expression to enrich 
for population with KAT7-AID integration. KAT7-AID transgene is resistant to modification by 
gRNA (5) and gRNA (A10). KAT7-AID cells were subsequently transduced with lentivirus expressing 
pKLV2-U6gKAT7(A10)-PGKpuro2ABFP-W, as with gRNA-mediated knock-out described above, to 
knock-out endogenous KAT7 and subsequently sorted for BFP-positive cells to enrich for knock-out 
population. GFP-BFP-double- positive cells were introduced with OsTIR1 F-box transgene via 
lentivirus transduction of pKLV-EF1a-mCherry-2A-OsTIR1-W. Cells with OsTIR1 transgene 
integration was enriched by sorting for the mCherry-positive cells. Indole-3-acetic acid (IAA) is the 
most common plant hormone of the auxin family. IAA (Sigma) was dissolved in water (W3500, 
Sigma) at a concentration of 500 mM and stored in -20 °C. MOLM-13 and MV4-11 AID cells were 
treated with 500 µM IAA for 24h at 37 °C, 5% CO2 for ChIP-qPCR experiments and 48 h at 37 °C, 5% 
CO2 for differentiation assay. 
 
2.23 IBET -151 treatment and viability assay 
 
IBET-151 was dissolved in ethanol at a concentration of 10 mM. All cells tested was treated with 1 
nM, 3 nM, 10 nM, 30 mM, 100 nM, 300 nM, 1 µM and 3 µM of IBET-151 (0.1% ethanol) for 3, 4 or 5 
days, in 96-well plate. Viability of cells was assayed at each time point using CellTiter-Glow 
Luminescent Cell Viability Assay (7572, Promega), following the manufacturer’s protocol. Briefly, 
both cells and reagent were equilibrated at room temperature for approximately 20 min. 100 µL 
reagent was added to each well and mixed by pipetting. Next, the plates were shaken for 2 min and left 
at room temperature for 10 min. Luminescent was assayed using the Infinite F200 Pro plate reader. 
 
2.24 Statistical analysis 
 
Student’s t tests (two-tailed) were used for statistical testing unless stated otherwise. Mean was 
calculated from at least three replicates, as indicated in each figure, and the error bars represent the 
standard deviation. Student’s T-test (two-tailed) statistical testing was used unless indicated 
otherwise. P value of ≤0.05 were considered statistically significant. 
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Table 2.2 List of gRNAs used in this study 















KAT2A (1) GGATGAGATAAACCGACTGC 
SIK3 (1) GATCTCGTAGTAGCCGATAC 
SIK3 (2) GGATCTCGTAGTAGCCGATA 
SIK3 (3) GACGAGATCGACCGCACCAT 
SIK3 (4) GTCGTAGTAGCCGATACGGG 
SIK3 (5) GCGGCTGGTGAGCATACCCG 
SIK3 (6) GCTTGAGTACCGGTGGACCT 
KAT7 (1) GGTGACTCGAGCAGATCGTC 
KAT7 (2) GGGTGACTCGAGCAGATCGT 
KAT7 (3) GCTTTAACAGGACACCTTAC 
KAT7 (4) GATCGAAGCTGTCTCTCCGT 




Table 2.3 Sequences of primers used for RT-qPCR 
 
Primer sequence (5'-3') 
Gene Forward  Reverse 
HOXA11 TGCCAAGTTGTACTTACTACGTC GTTGGAGGAGTAGGAGTATGTCA 
HOXA10 CTCGCCCATAGACCTGTGG GTTCTGCGCGAAAGAGCAC 
HOXA9 TACGTGGACTCGTTCCTGCT CGTCGCCTTGGACTGGAAG 
HOXA7 TCGTATTATGTGAACGCGCTT CAAGAAGTCGGCTCGGCATT 
HOXA5 AACTCATTTTGCGGTCGCTAT TCCCTGAATTGCTCGCTCAC 
MEIS1 GGGCATGGATGGAGTAGGC GGGTACTGATGCGAGTGCAG 
PBX3 ATTACAGAGCCAAATTGACCCAG TCTCGGAGAAGGTTCATCACAT 
GAPDH GGAGCGAGATCCCTCCAAAAT GGCTGTTGTCATACTTCTCATGG 
BCL2 GGTGGGGTCATGTGTGTGG CGGTTCAGGTACTCAGTCATCC 
c-Myc GGCTCCTGGCAAAAGGTCA CTGCGTAGTTGTGCTGATGT 
CDK6 GCTGACCAGCAGTACGAATG GCACACATCAAACAACCTGACC 
JMJD1C CAGGTCTCGTGCCAATCAAAA GCTGTTGCTGGTGTGTATTCT 
SENP6 TCCTGTAAGGTTAAGTCGGCT AGATAGAGGAGGAGTAGGCTGAT 
 
 
Table 2.4 Sequences of primers used for ChIP-qPCR 
 
Primer sequence (5'-3') 
Gene Forward  Reverse 
control GGCTCCTGTAACCAACCACTACC CCTCTGGGCTGGCTTCATTC 
SENP6 TGCCTTTGTATAGGCCCGTC ACGCCGCCTCCTTCTTAATC 
PBX3 CAGATGGGTCCGCCTTGTTC TGAACCGTGGGAAGTCAACA 
PBX3 (intron) AGTCAGAACCTCTCCGTGGT CCTCTGAGAAACCGGAGTCG 
MEIS1 TTCCCCAAGTTAGCTGAGCG AGGATCCGGTGGAGGAGAAA 
MEIS1 (intron) CTTCAGAGAACGATGCGGGT AAGTCTAGCAACTGGGTGGC 
JMJD1C TGAAACAAAACCCAACGCGG GGAGGGAGACGGAGCAGTA 
CDK6 TACTCTGGCGCTTTGTTGTG CGCTGTAGGTAGCAGAGGT 
BCL2 GAGGAGGGCTCTTTCTTTCTTC GCCTGTCCTCTTACTTCATTCTC 
BCL2 (enhancer) GAGCCCTCAACCTTGTGATAG AAGGTAGCCCTGACCATAGA 
HOXA9 ATGCTTGTGGTTCTCCTC CAGTTG CCGCCGCTCTCATTCTCAGC 
HOXA10 CGCAACCACCCCAGCCAG TTGTCCGCCGAGTCGTAGAGG 
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Application Type  Host 
KAT7  Abcam ab70183 ChIP pAb rabbit 
MLL1 Bethyl Lab A300-086A ChIP pAb rabbit 
BRD4 Bethyl Lab A301-985A ChIP pAb rabbit 
AF9 Bethyl Lab A300-597A ChIP pAb rabbit 
AF4 Abcam ab31812 ChIP pAb rabbit 
RNA Pol II S5 Abcam ab5131 ChIP pAb rabbit 
H4K5ac Abcam ab51997 ChIP mAb rabbit 
H4K8ac Abcam ab15823 ChIP pAb rabbit 
H3K14ac Diagenode  C15210005 ChIP mAb rabbit 
IgG Cell Signalling 3900S ChIP mAb rabbit 
          
KAT7  Cell Signalling 58418 WB mAb rabbit 
H3K14ac Diagenode  C15410310 WB pAb rabbit 
H3K23ac Abcam ab61234 WB pAb rabbit 
H4K5ac Diagenode  C15410025 WB pAb rabbit 
H4K8ac Diagenode  C15410103 WB pAb rabbit 
H3K12ac Abcam ab177793 WB mAb rabbit 
H4K16ac Abcam ab109463 WB mAb rabbit 
H3K9ac Cell Signalling 9649 WB mAb rabbit 
H3K4me3 Diagenode  C15410003 WB pAb rabbit 










H3K27me3 Diagenode  C15410195 WB pAb rabbit 
Actin Sigma-Aldrich A2228 WB mAb mouse 
Anti-rabbit IgG, 
HRP- linked 









Chapter 3: Phenotypic validation of CRISPR-Cas9 AML-specific 
cell essential genes identify KAT7 as a potential novel therapeutic 




Functional genomic screens using CRISPR-Cas9 is a powerful tool for identifying a wealth of novel 
drug targets for diseases such as oncology due to the ease of generating targeted bi-allelic mutations 
(Chen et al., 2015; Hart et al., 2015; Sánchez-Rivera and Jacks, 2015; Shi et al., 2015). Large-scale 
screenings will often identify false-positive hits (Sharma and Petsalaki, 2018), therefore major efforts 
are needed to distinguish biologically or therapeutically meaningful candidates from the extensive 
output of viability-based negative-selection screens.  
 
Focusing on the dropouts generated from the AML CRISPR-Cas9 screens performed by Tzelepis et 
al., we aim to confirm and provide biological insights on promising genetic vulnerabilities in the hope 
to advance the current therapeutic landscape of AML. In this chapter, we perform downstream 
validation of a selection of genes which protein product encodes a catalytic activity, namely kinases 
and epigenetic modifiers, that have not previously been mechanistically studied from a therapeutic 
angle in the context of AML. In addition to proliferation which was the phenotypic readout of the 
AML CRISPR-Cas9 screens, we also assayed the effects of candidate gene knock-out on cellular and 
biological processes such as apoptosis, differentiation and cell cycle.  
 
3.2 Assessing the Cas9 activity of human AML cell lines 
 
Prior to the validation of candidate genes from the AML CRISPR-Cas9 screens (Tzelepis et al., 2016), 
we first assessed the Cas9 activity of the AML cell lines that were used in the dropout screens 
(MOLM-13, MV4-11, OCI-AML2, HL-60 and OCI-AML3) as well as additional leukemic cell lines 
(THP-1, Nomo-1 and K562). The reporter construct pKLV2-U6gRNA (target GFP)-PGK-BFP-T2A-
GFP (Tzelepis et al., 2016, refer to Chapter 2.6 for details), which expresses the BFP gene, GFP gene 
and gRNA targeting GFP (gGFP), was used. In the presence of active Cas9 proteins within the cell, the 
GFP gene sequence will be modified and consequently result in truncated or non-functional GFP 
protein, thereby lacking GFP expression. The proportion of active Cas9 cells within the population 
can, therefore, be assessed by calculating the proportion of BFP-positive population against the total 
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of all transduced cells (BFP-GFP-double-positive and BFP-single positive populations). Among the 
cell lines, K562 bulk population has the highest Cas9 activity (98.8%) and THP-1 has the lowest Cas9 
activity (35.7%) (Figure 3.1). The Cas9 activity of other cell lines ranged from 70-80% in the bulk 
population— MOLM-13 (70.7%), MV4-11 (85.8%), OCI-AML2 (78.2%), OCI-AML3 (71.8%), HL-60 
(87.2%) and Nomo-1 (82.5%) (Figure 3.1). The presence of Cas9-inactive cells within the cell 
population would predictively lead to lower gene editing efficiency, we therefore enriched for clones 
with high Cas9 activity by single-cell sub-cloning. After testing the Cas9 activity of individual clones, 
the clones with the highest Cas9 activity (>93%) were selected for use in validation and mechanistic 
studies (Figure 3.2). The importance of high Cas9 activity in functional studies is illustrated in Figure 
3.3, using a previously validated gene, KAT2A. Loss of KAT2A was reported to induce CD11b 
expression, a marker for myeloid differentiation (Tzelepis et al., 2016) and we showed that lower Cas9 
activity (pre-cloned population) results in no observable CD11b expression on day 4 post-
transduction, while an increase in CD11b is seen in MOLM-13 with higher Cas9 activity (post-cloned 
population) (Figure 3.3). 
 























Figure 3.1 Cas9 activity of AML and CML cell lines before single-cell cloning. 
The left panel shows mock (non-transduced, BFP-GFP double negative) population for gating purposes. 
The right panel shows reporter gRNA transduced population on day 3 post-transduction. The percentage 
of cells with active Cas9 activity is indicated and calculated by the proportion of BFP-positive population 
against the total of all transduced cells (BFP-GFP-double-positive and BFP-single positive population).  
 
 
Figure 3.2 Cas9 activity of AML and CML cell lines after single-cell cloning. 
MOLM-13, MV4-11, OCI-AML2, OCI-AML3 and THP-1 were transduced with lentivirus expressing 
the gGFP-BFP-GFP reporter construct and HL-60 and MOLM-13luciferase were transduced with lentivirus 
expressing the gBFP-mCherry-BFP construct (refer to Chapter 2.6 and Figure 2.1). Colonies with >93% 
Cas9 activity were selected for downstream experiments. 
  
THP-1 OCI-AML3 MOLM-13 OCI-AML2 MV4-11 
HL-60 MOLM-13luciferase 
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Figure 3.3 Cas9 activity and effect on functional phenotype 
A-B) MOLM-13 cells transduced with Cas9 reporter virus reveal a difference in Cas9 activity in old (pre-
cloned) and new clones (post-cloned). BFP and GFP double-positive reflects cells with inactive Cas9, 
whilst cells with BFP positive only are Cas9 active. A)  83.9% of cells have active Cas9 in old clone, B) 
98.3% Cas9 activity in new clone. C-D) gRNA-mediated knock-out of KAT2A induce different levels of 
CD11b expression in the old (C, blue histogram) and the new (D, orange histogram) MOLM-13 clones, 
compared to empty control (grey histogram).  
 
3.3 Validation of AML-specific druggable candidate genes from CRISPR-Cas9 
dropout screens  
 
In the AML CRISPR-Cas9 screens, 492 dropouts were AML-specific cell essential genes (not a 
dropout in HT-29 colon cancer line and HT-1080 fibrosarcoma line), 227 were “druggable” (Tzelepis 
et al., 2016).  The Drug Gene Interaction Database (DGIdb) define druggable genes as genes/proteins 
that have potential or known to interact with drugs (Cotto et al., 2018). Within the “druggable” 
categories, many targets are either implicated in cancer and/or inhibitors are in clinical trials such as 
DOT1L, MCL1 and BCL2 (Caenepeel et al., 2018; Hird and Tron, 2019; Klaus et al., 2014; Li et al., 
2019; Montero and Letai, 2018; Perini et al., 2018; Stein et al., 2018).  We selected histone modifiers 









candidates include four kinases (HIPK1, STK3, SIK3 and RSK1) and four epigenetic modifiers 
(KDM2A, KDM5B, KAT6A and KAT7). The 2 best performing gRNAs from the CRISPR-Cas9 screen 
performed by Tzelepis et al. (unpublished data) were used for validation in selected two cell lines, 
MOLM-13 and OCI-AML3. As all candidate genes, except for SIK3 and RSK1, were essential in 
MOLM-13 but not in OCI-AML3 according to the screen results, these 2 cell lines could serve to 
validate essentiality and non-essentiality of the selected candidates. 
 
 
Table 3.1 List of novel histone modifiers and kinases that are AML-specific cell-essential genes. 
Values indicated are the false discovery rate (FDR) of each gene in the respective cell lines (data derived 
from Tzelepis et al.). FDR <0.2 is considered significant cell-essential genes (highlighted in blue). 
Homeodomain interacting protein kinase 1 (HIPK1); Serine/threonine-protein kinase 3 (STK3); Salt 
inducible kinase 3 (SIK3); Ribosomal protein S6 kinase (RSK1), also known as RPS6KA1; lysine 
demethylase 2A (KDM2A); lysine demethylase 5B (KDM5B); lysine acetyltransferase 6A (KAT6A); 
lysine acetyltransferase 7 (KAT7). 
 
Knock-out of HIPK1 and STK3 showed a weak suppressive effect on the proliferation of MOLM-13 
(Figure 3.4A, C) and had no effect in OCI-AML3 (Figure 3.4B, D). KAT6A, SIK3 and RSK1 knock-out 
confirmed the screen results. Targeting SIK3 and KAT6A in MOLM-13 had a strong and moderate 
suppressive effect, respectively (Figure 3.4E, K) but weak and no effect on proliferation in OCI-AML3, 
respectively (Figure 3.4F, L). RSK1 showed a slight effect in both cell lines (Figure 3.4G-H). KDM2A 
showed weak phenotype in MOLM-13 (Figure 3.4I) and OCI-AML3 (Figure 3.4J). KDM5B knock-out 
did not affect the proliferation of MOLM-13 or OCI-AML3 (Figure 3.4M-N). KAT7 knock-out in 
OCI-AML3 showed a slight decrease in proliferation over a period of 12 days (Figure 3.4P); however, 
proliferation was strongly decreased in MOLM-13 (Figure 3.4O). In summary, both SIK3 and KAT7 
knock-out showed a prominent decrease in proliferation and therefore selected these two genes for   
further investigations.   
 
MOLM-13 MV4-11 HL-60 OCI-AML2 OCI-AML3 HT-1080 HT-29
HIPK1 0.08 1.00 1.00 1.00 1.00 1.00 1.00
STK3 0.15 1.00 1.00 0.87 1.00 0.95 1.00
SIK3 0.05 0.70 1.00 1.00 0.16 1.00 1.00
RSK1 0.01 1.00 0.02 0.00 0.00 1.00 1.00
KDM2A 0.09 0.65 0.60 0.26 0.69 1.00 1.00
KDM5B 0.15 0.49 1.00 0.53 0.22 1.00 1.00
KAT6A 0.15 0.07 0.78 0.04 0.42 1.00 1.00





























































































































































































































































































































































































































































The left and right panel depicts MOLM-13 and OCI-AML3 knock-outs respectively. Competition-based 
proliferation assay between transduced (BFP-positive) and non-transduced (BFP-negative) cells. Two 
gRNAs for each gene were selected from the CRISPR library and gRNA was delivered to AML cells by 
lentivirus transduction. The proportion of BFP-positive population is normalized to day 4. Each data 
point is the average of triplicates.  
 
3.4 Proliferation of KAT7 and SIK3 knock-out in various AML and CML cell lines  
 
As SIK3 and KAT7 knock-out showed the most drastic effect on proliferation in MOLM-13, we 
further tested the effect of these two genes in 3 additional AML cell lines (MV4-11, OCI-AML2 and 
THP-1) and a chronic myeloid leukaemia (CML) cell line (K562) by using the best performing gRNA 
among the one selected from the library—gSIK3 (A4) and gKAT7 (A10) (Figure 3.5). SIK3 knock-out 
showed a strong reduction in the proliferation in MOLM-13 and MV4-11 cells (Figure 3.5A, D), a 
moderate decrease in OCI-AML2 and THP-1 proliferation (Figure 3.5B, E) and no apparent effect in 
OCI-AML3 and K562 (Figure 3.5C, F). Knock-out of KAT7 strongly reduced the proliferation of 
MOLM-13, MV4-11, OCI-ALM2 and THP-1 cells (Figure 3.5A, B, D, E), whilst minimal effect was 
observed in OCI-AML3 and K652 (Figure 3.5C, F). According to the dropout screens (Tzelepis et al., 
2016), SIK3 was not essential in MV4-11 or OCI-AML2 but was found to be essential in the validation 
experiments. KAT7 knock-out was validated in all cell lines used in the screen and additionally found 
to be a vulnerability in THP-1. To address the potential off-target effects of the gRNAs chosen from 
the genome-wide library, we designed and tested additional gRNAs for KAT7 (gKAT7) and SIK3 
(gSIK3), in MOLM-13 and MV4-11 (Figure 3.6). Among the gKAT7, only gKAT7 (5) has a 
comparable effect on proliferation as gKAT7 (A10) which was derived from the CRISPR library 
(Figure 3.6A). gSIK3 (A4) from the genome-wide library, gSIK3 (1), gSIK3 (2), gSIK3 (3), and gSIK3 
(4) all have a similar effect on proliferation in MOLM-13 and MV4-11 (Figure 3.6B). For the purpose 
of further validation, we used gKAT7 (A10) and gSIK3 (A4) for downstream experiments. 
Furthermore, MOLM-13 was selected as the model cell line initially to investigate the cellular 
mechanism underlying the proliferation phenotype as it showed the strong anti-proliferative 




Figure 3.5 Proliferation of SIK3 and KAT7 knock-out in additional cell lines 
Competition-based proliferation assay between transduced (BFP-positive) and non-transduced (BFP-
negative) cells. Best performing gRNA for SIK3 and KAT7 was delivered by lentivirus. The proportion of 
BFP-positive population is normalized to day 4. Mean ± standard deviation, n=3. KAT7 knock-out 
showed a strong decrease in proliferation in A) MOLM-13, B) OCI-AML2, D) MV4-11, and E) THP-1 
whilst no effect on the proliferation of C) OCI-AML3 and F) K562. SIK3 knock-out has a strong 
reduction in the proliferative ability of A) MOLM-13 and D) MV4-11, moderate effect in B) OCI-AML2 


























































































































































Figure 3.6 Proliferation of MOLM-13 and MV4-11 with different gRNAs targeting KAT7 (gKAT7) 
and SIK3 (gSIK3). 
Competition-based proliferation assay between transduced (BFP-positive) and non-transduced (BFP-
negative) cells. A) gKAT7 B) gSIK3. The proportion of BFP-positive population is normalized to day 4. 








































































































































To understand the cellular processes underlying the proliferation phenotype observed in SIK3 and 
KAT7 knock-out, we asked whether apoptotic cell death was responsible for the decrease in 
proliferation of the AML cells (Figure 3.7). Knock-out of KAT7 in MOLM-13 results in a 13.7-times 
increase in Annexin V-positive cells compared to the empty negative control (p=0.03) on day 9 post- 
transduction (Figure 3.7A, C, E). This is four times more than the positive control, KAT2A knock-out 
(Figure 3.7A, D, E). On a smaller magnitude, SIK3 knock-out in MOLM-13 has a 1.8-fold increase in 
Annexin V-positive cells (Figure 3.7A, B, E) but this difference is not statistically significant (p=0.15). 
 
Figure 3.7 Apoptosis of SIK3 and KAT7 knock-out in AML cell lines 
MOLM-13 was transduced by lentivirus expressing gSIK3 (A4), gKAT7 (A10), gKAT2A (1) or empty 
control. BFP-positive (knock-out) cells were sorted on day 3 and levels of apoptosis measured on day 9.  
A-D) MOLM-13 transduced with gRNA targeting A) empty, B) SIK3, C) KAT7, and D) KAT2A and 
stained for Annexin V and Propidium Iodide (PI). E) Significant increase in Annexin V-positive cell 
population in KAT7 knock-out relative to empty day 7 post- transduction. Mean ± standard deviation, 
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3.5.2 Differentiation  
 
Previous studies found that the inhibition of KAT2A induces myeloid differentiation in AML 
(Tzelepis et al., 2016). We thus investigated whether knock-out of SIK3 or KAT7 induces 
differentiation in AML cells, by assessing the expression of two myeloid differentiation markers, 
CD11b and CD13, on day 5, 6 and 7 post-transduction. KAT2A knock-out was used as a positive 
control. Increase in CD11b expression, relative to the empty transduced cells, is detectable in KAT7 
knock-out and KAT2A knock-out but not in SIK3 knock-out MOLM-13 cells (Figure 3.8). CD11b 
levels in knock-out also increase by approximately 10% each day from day 5 to day 7 post-
transduction in KAT7 knock-out cells (Figure 3.8). A marginal increase in CD13 expression, 
compared to empty control, can be seen in all knock-out cells by day 7 (Figure 3.9), however, not as 
striking as CD11b. Further repeats showed that genetic ablation of KAT7 strongly induced CD11b 
expression in MOLM-13 and leads to 6 times more differentiated cells on day 7 (Figure 3.10B, G; 
p=0.003) than the empty control. This is 2 times higher than the positive control KAT2A knock-out 
(Figure 3.10C, G). CD13 expression increased by 2.6-fold in KAT7 knock-out, compared to the empty 
control (Figure 3.10E, H), but this increase was slightly weaker than KAT2A knock-out (Figure 3.10F, 
H). SIK3 knock-out did not show a drastic increase in CD11b or CD13 differentiation markers (Figure 




Figure 3.8 Time course CD11b differentiation assay in SIK3, KAT7 and KAT2A knock-out MOLM-
13 cells 
MOLM-13 was transduced by lentivirus expressing gSIK3 (A4), gKAT7 (A10), gKAT2A (1) or empty 
control. BFP-positive (knock-out) cells were sorted on day 3 post-transduction and assayed on day 5, 6 
and 7. CD11b expression in SIK3 knock-out (green), KAT7 knock-out (blue) and KAT2A knock-out 
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Figure 3.9 Time course CD13 differentiation assay in SIK3, KAT7 and KAT2A knock-out MOLM-13 
cells 
MOLM-13 was transduced by lentivirus expressing gSIK3 (A4), gKAT7 (A10), gKAT2A (1) or empty 
control. BFP-positive cells (knock-out) were sorted on day 3 post-transduction and assayed on day 5, 6 
and 7. CD13 expression in SIK3 knock-out (green), KAT7 knock-out (blue) and KAT2A knock-out (red), 
against empty (grey). 
Day 5 
Day 6 
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Figure 3.10 CD11b and CD13 cell surface marker expression of SIK3 and KAT7 knock-out in 
MOLM-13 
MOLM-13 was transduced by lentivirus expressing gSIK3 (A4), gKAT7 (A10), gKAT2A (1) or empty 
control. BFP-positive (knock-out) cells were sorted on day 3 and assayed on day 7. Mean ± standard 
deviation, n=2 (except KAT7-knock-out: CD11b, n=5; CD13, n=3). A-C) CD11b expression in knock-
out (coloured), against empty (grey), with 10% spontaneous differentiation in wild-type cells. D-F) CD13 
expression in knock-out (coloured), against empty (grey), with 10% spontaneous differentiation in wild-
type cells. G) Relative CD11b levels in wild-type and knock-out, with KAT7 showing statistical 
significance. H) Relative CD13 levels in wild-type and knock-out. Two-tailed t-test, *, P ≤ 0.05; **, P ≤ 
0.01; ***, P ≤ 0.001.  
 
3.5.3 Cell cycle  
 
An alternative explanation for the observed proliferative phenotype could be due to cell cycle arrest. 
In particular, we saw a strong decrease in proliferation in MOLM-13 upon the knock-out of SIK3, but 
apoptosis assays revealed non-significant increase cell death. This prompted us to look at the cell cycle 
status of the knock-outs. Using propidium iodide (PI) to stain DNA, we detected an increase in the 
number of cells in Sub G1, S and G2/M phases and a corresponding decrease in G1 phase of MOLM-
13 SIK3 knock-out compared to empty on day 8 post-transduction (Figure 3.11). However, this result 









































Sample Name CD11b+ :: Freq. of Parent
Puroselection_CD11b-APC_Empty_001.fcs 10.8 
Puroselection_CD11b-APC_KAT7 (A10)_003.fcs 67.2 
CD11b+
10.5



















Sample Name CD11b+ :: Freq. of Parent
Puroselection_CD11b-APC_Empty_001.fcs 10.8 













































Sample Name CD11b+ :: Freq. of Parent
Puroselection_CD11b-APC_Empty_001.fcs 10.8 
Puroselection_CD11b-APC_KAT2A_004.fcs 35.  CD13+
22.8



















Sample Name CD13+ :: Freq. of Parent
Puroselection_CD13-APC_Empty_005.fcs 10.3 
Puroselection_CD13-APC_SIK3 (A4)_006.fcs 22.8 
CD13+
27.6



















Sample Name CD13+ :: Freq. of Parent
Puroselection_CD13-APC_Empty_005.fcs 10.3 
Puroselection_CD13-APC_KAT7 (A10)_007.fcs 27.6 
CD13+
32.5





























Figure 3.11 Cell cycle analysis of SIK3 and KAT7 knock-out in MOLM-13 
MOLM-13 was transduced by lentivirus expressing gSIK3 (A4), gKAT7 (A10), gKAT2A (1) or empty 
control.  BFP-positive (knock-out) cells were sorted on day 3 and cells are stained with PI on day 8.  




3.6 KAT7 knock-out in additional AML cell lines 
 
The data thus far showed gRNA-mediated KAT7 knock-out and SIK3 knock-out induces prominent 
proliferation defects in multiple AML cell lines. KAT7 knock-out, in addition, showed increased 
apoptosis and CD11b expression in MOLM-13.  A slight increase in apoptosis was observed in 
MOLM-13 SIK3 knock-out whilst no changes in CD11b expression was observed. Due to these 
striking phenotypes as a result of genetic loss of KAT7, we thus chose to focus our efforts on 
understanding the mechanism of essentiality of KAT7 in AML. After selecting, designing and testing 
various gRNAs that target KAT7, we opted to use gKAT7 (A10) and gKAT7 (5) for further 
experiments as these two gRNAs resulted in the most rapid loss of proliferation across cells in which 
KAT7 is essential. 
 
3.6.1 Apoptosis  
 
Focusing on KAT7 as a vulnerability in AML, we investigated the effect of KAT7 knock-out in MV4-
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AML2 and THP-1 result in a significant increase in the proportion of Annexin V-positive cells on day 
9 post-transduction (Figure 3.12). There is no significant increase in apoptotic cells in OCI-AML3 
following the genetic ablation of KAT7 (Figure 3.12). These data are consistent with the proliferation 
phenotype described above in Chapter 3.3. Notably, levels of annexin-V in THP-1 knock-out 
compared to empty control was not as drastic as MOLM-13, MV4-11 and OCI-AML2. This could be 
due to the fact that THP-1 possess the p53 mutation (Sugimoto et al., 1992). Wild-type p53 is a 
positive regulator of apoptosis, among many other cellular processes (Aubrey et al., 2018). In the case 
of THP-1, the presence of p53 mutant may compromise the protein’s ability to induce maximal 
apoptosis under stress, such as coping with the loss of KAT7. This may suggest that KAT7-induced 
apoptosis is mediated through p53. Existing studies suggest that p53 negatively regulates KAT7 in 
Saos-2 osteosarcoma cells and mouse embryonic fibroblast, most likely through the binding of p53 
protein to the catalytic domain of KAT7 (Iizuka et al., 2008). The possibility of KAT7 in regulating 
p53 has been briefly explored in this study. Iizuka et al., compared the ability of KAT7 to acetylate 
histone or p53 as substrates and found KAT7 prefers histone substrates. p53 acetylation is only 
detectable in reactions without histones (Iizuka et al., 2008). To address whether the apoptosis 
associated with KAT7 loss is mediated through p53 in AML, more p53 mutation cell lines need to be 
assayed. Possibly through generating isogenic p53 mutant cell lines of MOLM-13 or inhibiting KAT7 
in other p53 mutated AML cell lines.   
 
 
Figure 3.12 Apoptosis of KAT7 knock-out in AML cell lines 
AML cells were introduced with gKAT7(A10) via lentivirus transduction and BFP-positive cells were 
sorted day 3 post-transduction and stained with Annexin-V-APC antibody on day 9 post-transduction. 
Mean ± S.D., n= 3 (biological replicates), two-tailed t-test (N.S. non-significant, P > 0.05; *, P ≤ 0.05; **, 

















































































































































































































Sample Name Subset Name Count
Puroselection_20170606_d7_MOLM13_empty_001.fcs BFP+ 9166 
Puroselection_20170606_d7_MOLM13_kat7_002.fcs BFP+ 7334 

















Sample Name Subset Name Count
Puroselection_20170606_d7_MOLM13_empty_001.fcs BFP+ 9166 
Puroselection_20170606_d7_MOLM13_kat7_002.fcs BFP+ 7334 

















Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170606_d7_OCIAML2_empty_009.fcs 10072 20.2 
Puroselection_20170606_d7_OCIAML2_kat7_010.fcs 9984 54.0 



















Sample Name Subset Name Count
MV411_d6_20180726_KAT7_A10_059.fcs BFP+ 10096 
MV411_d6_20180726_Empty_058.fcs BFP+ 11350 








































Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170606_d7_HL60_empty_011.fcs 7862 10.5 
Puroselection_20170606_d7_HL60_kat7_012.fcs 7523 13.4 
CD11b+
12.9










Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170607_d8_HL60_empty__009.fcs 7959 8.85 
Puroselection_20170607_d8_HL60_kat7_012.fcs 7170 12.9 
CD11b+
31.9










Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170612_d13_HL60_empty__009.fcs 7941 10.9 
Puroselection_20170612_d13_HL60_kat7_012.fcs 7039 31.9 
13.4



















Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170606_d7_HL60_empty_011.fcs 7862 10.5 
Puroselection_20170606_d7_HL60_kat7_012.fcs 7523 13.4 



















Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170606_d7_HL60_empty_011.fcs 7862 10.5 
Puroselection_20170606_d7_HL60_kat7_012.fcs 7523 13.4 





























3.6.2 Proliferation  
 
Next, we repeated the proliferation assay in the MOLM-13, MV4-11, THP-1, OCI-AML2, OCI-AML3 
with gKAT7 (A5) in addition to gKAT7 (A10) that was previously used in Figure 3.5. Furthermore, we 
utilized HL-60 and Nomo-1 to investigate the essentiality of KAT7 in other AML cell lines. The 
proliferation of HL-60 was not affected by the loss of KAT7 whereas Nomo-1 proliferation was 
compromised in KAT7 knock-out (Figure 3.13). Collectively, our findings so far suggest KAT7 may be 
essential for MLL-fusion positive AML, but not in MLL-fusion negative cell lines.  
 
 
Figure 3.13 Proliferation of KAT7 knock-out in AML cell lines 
The proliferation of KAT7 knock-out using two individual gKAT7 (5 and A10) or empty control in 
different AML cell lines. The relative percentage of BFP-positive (gKAT7-transduced) cells were assayed 
over time and all time points were normalized to day 4. Mean ± SD, n= 3 
 
 
In OCI-AML2, gKAT7 (5) transduced cells have a less pronounced effect on proliferation, compared 
to gKAT7 (A10) transduced cells of the same cell line. This may be due to the high transduction 
efficiency which resulted in ~80% transduced cells. Figure 3.14 illustrates a gRNA depletion 
simulation comparing the changes in proliferation of experiment starting with high transduction 
















































































































































































































Sample Name Subset Name Count
Puroselection_20170606_d7_MOLM13_empty_001.fcs BFP+ 9166 
Puroselection_20170606_d7_MOLM13_kat7_002.fcs BFP+ 7334 

















Sample Name Subset Name Count
Puroselection_20170606_d7_MOLM13_empty_001.fcs BFP+ 9166 
Puroselection_20170606_d7_MOLM13_kat7_002.fcs BFP+ 7334 

















Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170606_d7_OCIAML2_empty_009.fcs 10072 20.2 
Puroselection_20170606_d7_OCIAML2_kat7_010.fcs 9984 54.0 



















Sample Name Subset Name Count
MV411_d6_20180726_KAT7_A10_059.fcs BFP+ 10096 
MV411_d6_20180726_Empty_058.fcs BFP+ 11350 








































Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170606_d7_HL60_empty_011.fcs 7862 10.5 
Puroselection_20170606_d7_HL60_kat7_012.fcs 7523 13.4 
CD11b+
12.9










Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170607_d8_HL60_empty__009.fcs 7959 8.85 
Puroselection_20170607_d8_HL60_kat7_012.fcs 7170 12.9 
CD11b+
31.9










Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170612_d13_HL60_empty__009.fcs 7941 10.9 
Puroselection_20170612_d13_HL60_kat7_012.fcs 7039 31.9 
13.4



















Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170606_d7_HL60_empty_011.fcs 7862 10.5 
Puroselection_20170606_d7_HL60_kat7_012.fcs 7523 13.4 



















Sample Name Count CD11b+ :: Freq. of Parent
Puroselection_20170606_d7_HL60_empty_011.fcs 7862 10.5 
Puroselection_20170606_d7_HL60_kat7_012.fcs 7523 13.4 













































































































Fig. S1. KAT7 gRNA-mediated knock-out shows the strongest anti-proliferative compared to KAT6A and KAT2A.
A) gRNAs targeting various histone lysine acetyltransferase (HAT/KATs) in MOLM-13 and MV4-11. gRNA against 
KAT2A (gKAT2A) KAT6A (gKAT6A) and KAT7 (gKAT7). B) Proliferation of KAT7 knock-out using two individual gRNA 
or empty control in MLL-fusion AML cell lines. C) Proliferation of KAT7 knock-out using one individual gRNA or 













































































































































Fig. S1. KAT7 gRNA-mediated knock-out shows the strongest anti-proliferative compared to KAT6A and KAT2A.
A) gRNAs targeting various histone lysine acetyltransferase (HAT/KATs) in MOLM-13 and MV4-11. gRNA against 
KAT2A (gKAT2A) KAT6A (gKAT6A) and KAT7 (gKAT7). B) Proliferation of KAT7 knock-out using two individual gRNA 
or empty control in MLL-fusion AML cell lines. C) Proliferation of KAT7 knock-out using one individual gRNA or 




























































Assuming that non-transduced, BFP-negative cells double every 24 hours, whilst transduced, BFP-
positive, KAT7 knock-out cells conferring growth disadvantage duplicate 1.8 times every 24 hours. An 
initial 80% transduced cells (20% non-transduced) at time point 0 will give rise to 43.9% viable cells at 
day 19. On the contrary, starting with 30% transduced cells (70% non-transduced) will result in 18.2% 
proliferative cells at day 19. Although KAT7 is an essential gene in some AML cell lines, such as OCI-
AML2, the proliferation assay is based on the competition between BFP-positive and BFP-negative 
cells, therefore, the relative proportion of transduced and non-transduced cells can influence the 
dynamic of depletion. Keep transduction efficiency between cell lines and between gRNAs as similar 
as possible when making comparisons is ideal. Transduction efficiency is dependent on both virus 
titer as well as cell lines. Virus titer can vary between batches of virus production and titration for each 




Figure 3.14 Simulation of cell proliferation with different percentage of initial transduced cells 
Prediction of the cell proliferation dynamics of knock-out cells, conferring growth disadvantage, overtime 
with a high or low proportion of transduced cells on day 0. Given that the effect of knock-out is constant, 
high percentage of transduced cells (80% transduced at day 0) results in a slower depletion dynamic 


























80% transduced at d0
30% transduced at d0
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3.6.3 Differentiation  
 
Differentiation time-course experiment in Chapter 3.5.2 showed day 7 represents the time point in 
which significant levels of CD11b marker was observed (Figure 3.8), we therefore assayed the effect of 
KAT7 knock-out on CD11b expression using gKAT7 (A10) in various cell lines at this time point 
(Figure 3.15). Notably, an increase in CD11b was associated with the loss of KAT7 in MOLM-13 
(61%), OCI-AML2 (32%) and Nomo-1 (21.1%).  
  
 
Figure 3.15 CD11b expression of KAT7 knock-out in AML cell lines 
CD11b-APC staining in empty (grey) and KAT7 knock-out (red) cells on day 7 post-transduction in 
different AML cell lines. BFP-positive knock-out cells were sorted day 3 post-transduction.  
 
Initially, we observed 40% population of differentiated cells in MV4-11 on day 6 (Figure3.16A) and by 
day 7, the CD11b-positive population reduced to 22.8% (Figure3.16B), suggesting that MV4-11 
undergo apoptosis soon after signs of differentiation. However, this finding was not reproducible, 
therefore MV4-11 is unlikely to have increased CD11b expression following knock-out of KAT7. It is 
likely that following the loss of KAT7, MV4-11 induces apoptosis without differentiation. As we did 
not observe CD11b changes in THP-1 knock-out nor did we observe a drastic increase in apoptosis, 
we assessed CD14, another marker for myeloid differentiation, and day 7 showed 24.1% of 





Figure 3.16 Expression of myeloid differentiation marker in KAT7 knock-out MV4-11 and THP-1 
BFP-positive knock-out cells were sorted day 3 post-transduction. A and B) CD11b expressions in empty 
(grey) and KAT7 knock-out (red) MV4-11 cells on day 6 and day 7 post-transduction respectively.  C) 
CD13 expressions in empty (grey) and KAT7 knock-out (blue) THP-1 cells on day 7 post-transduction.  
 
3.7 In vivo effects of KAT7 loss 
 
To assess if KAT7 inactivation has effects in vivo, we injected KAT7 knock-out luciferase-expressing 
MOLM-13 cells into NSGW41 male mice (derived by breeding NSG and KITW41 animal to 
homozygosity, i.e. KitW41/W41, Prkdc-/-, and Il2rg-/- or Il2rg+/Y). This breed of mice was chosen based on 
several considerations. Firstly, previous experiments have demonstrated efficient and sustained 
engraftment of MOLM-13 cells into the bone marrow of NSGW41 mice. Kit signalling is required for 
the expansion of progenitor cells, as such human Kit-proficient cells populate the bone marrow, 
replacing the endogenous murine Kit-mutant hematopoietic cells (Waskow et al., 2014).  Secondly, the 
agouti coat of NSGW41 mice allows for better visualization of the bioluminescent signal, compared to 
dark-furred mice. Lastly, male mice were chosen as MOLM-13 was derived from a male AML patient. 
Mice transplanted with KAT7 knock-out MOLM-13 cells had significantly slower AML progression 
and increased survival compared to those injected with wild-type cells (Figure 3.17). Transplantation 
of KAT7 knock-out MOLM-13 cells eventually led to the development of abnormal masses at ectopic 
parts of the body, including under the skin and on the liver. This might be due to KAT7 knock-out cells 
undergoing differentiation, whereby the maturation of AML cells allows for “metastasis” in other organs. 










Figure 3.17 Disease progression and survival of mice injected with luciferase-expressing MOLM-13 
cells 
Luciferase expressing MOLM-13 with KAT7 knock-out or empty control cells were transplanted into 
NSGW41 male mice day 3 post-transduction. BFP-positive cells were sorted day 2 post-transduction. A) 
bioluminescent signal on day 8 and day 15 post-injection B) Kaplan-Meier survival plot (n=5 in each 
arm). Experiment and figures generated in collaboration with Etienne De Braekeleer. 
 
 
3.8 Expression of KAT7 in normal haematopoiesis  
 
To understand the expression of KAT7 in normal hematopoiesis, we utilized the BloodSpot platform 
(Bagger et al., 2019). Gene expression profiles of hematopoietic cells obtained from the bone marrow 
of healthy subjects showed that levels of KAT7 transcript fluctuate through hematopoietic 
differentiation (Bagger et al., 2019; Rapin et al., 2014). Notably, common myeloid progenitor (CMP) 
and megakaryocyte-erythroid progenitor (MEP) appear to have the highest expression of KAT7, 
compared to other hematopoietic cells in the myeloid lineage differentiation tree (Figure 3.18) (Bagger 
et al., 2019; Rapin et al., 2014), which may suggest that KAT7 is required to maintain the potency of 




























Figure 3.18 Expression of KAT7 in normal hematopoietic cells 
Transcripts (Log2 expression) of KAT7 in cells extracted from the bone marrow healthy patients (Bagger 
et al., 2019; Rapin et al., 2014). A) Myeloid hierarchical differentiation tree and expression of KAT7 in 
the corresponding stem and progenitor and myeloid cells. B) Jitter strip chart, corresponding to the cells 
depicted in the differentiation tree. Each dot represents one sample and the lines represent the median 
expression of each cell type. Hematopoietic stem cell (HSC); Multipotent progenitors (MPP); common 
myeloid progenitors (CMP); Granulocyte monocyte progenitors (GMP); megakaryocyte-erythroid 
progenitors (MEP); early promyelocyte (early_PM); late promyelocyte (late_PM); myelocyte (MY); 







3.9 KAT7 mutations and expression in other cancer types 
 
Among normal cell types, KAT7 is most highly expressed in testis (Iizuka and Stillman, 1999; Sharma 
et al., 2000). In the context of cancer, analysis of the The Cancer Genome Atlas (TCGA) dataset 
(genomics data of 37 cancer types) showed that testicular germ cell cancer (TGCT) represents the 
tumour type with the highest expression of KAT7 (Figure 3.19) (Deng et al., 2017), possibly correlated 
to the high expression in normal testis cells. We utilized the cBioPortal platform that facilitates the 
analysis and visualization of large-scale cancer genomics datasets to look for mutations in KAT7 
among AML patients. We assessed 3 AML genomic studies (TCGA Research Network, 2013; Tyner et 
al., 2018; Welch et al., 2016), which consist a total of 1008 AML patient samples (878 patients queried) 
and found no KAT7 alterations—mutations, amplification, deletion or fusion—among those profiled 
(Cerami et al., 2012; Gao et al., 2013a). The lack of KAT7 alterations found among AML patients 
could suggest that KAT7 is not an oncogene involved in AML initiation however, may play a critical 
role in maintaining leukemogenesis which could potentially be exploited therapeutically. Interestingly, 
we observed KAT7 mutations in other cancer types, most frequently in uterine corpus endometrial 
carcinoma (UCEC), whereby 7.89% of UCEC patients possess a mutation in this gene (Cerami et al., 
2012; Gao et al., 2013a; Grossman et al., 2016). 164 mutations were detected among all the TCGA 
datasets, 118 of which are mutations in the protein-coding region of KAT7 (Grossman et al., 2016). 
Missense mutations are the predominant alterations in KAT7 among the various cancer types, 
constituting 89.8% (106 of 118) of all KAT7 alterations documented (Figure 3.20) (Grossman et al., 
2016). There is no obvious mutational “hotspot” within the coding region of KAT7 and mutation sites 
appears to be distributed across the gene (Figure 3.20). It is unclear if these mutations are oncogenic 





Figure 3.19 KAT7 expression in 37 cancer types from The Cancer Genome Atlas (TCGA) 
Log2 transformed reads per kilobase million (RPKM) transcript levels of KAT7 obtained from 
FireBrowse (Deng et al., 2017). In the corresponding tumour types (red), as well as normal tissues (blue). 
Normal tissue samples missing in some cancer types (grey). Testicular germ cell tumour (TCGT); Uveal 
melanoma (UVM); brain lower grade glioma (LGG); glioma (GBMLGG); acute myeloid leukemia 
(LAML); glioblastoma multiforme (GBM); thyroid carcinoma (THCA); Pheochromocytoma and 
Paraganglioma (PCPG); skin cutaneous melanoma (SKCM); breast invasive carcinoma (BRCA); 
ovarian serous cystadenocarcinoma (OV); thymoma (THYM); esophageal carcinoma (ESCA); lung 
squamous cell carcinoma (LUSC); prostate adenocarcinoma (PRAD); kidney renal clear cell carcinoma 
(KIRC); stomach and esophageal carcinoma (STES); lung adenocarcinoma (LUAD); stomach 
adenocarcinoma (STAD); Pan-kidney cohort (KIPAN); uterine carcinosarcoma (UCS); mesothelioma 
(MESO); sarcoma (SARC); kidney renal papillary cell carcinoma (KIRP); rectum adenocarcinoma 
(READ); head and neck squamous cell carcinoma (HNSC); Cholangiocarcinoma (CHOL); colorectal 
adenocarcinoma (COADREAD); cervical and endocervical cancer (CESC); bladder urothelial carcinoma 
(BLCA); colon adenocarcinoma (COAD); pancreatic adenocarcinoma (PAAD); kidney chromophobe 
(KICH); lymphoid neoplasm diffuse large b-cell lymphoma (DLBC); adrenocortical carcinoma (ACC); 






Figure 3.20 Location and type of mutations in the protein-coding region of KAT7 found across The 
Cancer Genome Atlas (TCGA) dataset 
Image obtained from NCI GDC Data Portal (Grossman et al., 2016). Each circle represents a mutation. 
The position of each mutation is presented relative to the domains of KAT7 protein. The height (y-axis) 
of the circles indicates the frequency of the mutation within the TCGA dataset. Missense mutations 
(blue), frameshift mutations (red), stop gained mutations (purple) are indicated by the respective 






CRISPR-Cas9 dropout screens provide a wealth of novel therapeutic targets. Validation of genome-
wide CRISPR-screens is imperative due to false-positive and false-negative hits. Despite the 8 chosen 
novel druggable candidate genes are significant dropouts (<20% FDR) in the MOLM-13 cell line, only 
SIK3, KAT6A and KAT7 knock-outs show strong phenotypic consequence on cellular proliferation 
over the course of 14 days. Whilst KDM5B knock-out shows no effect in MOLM-13, HIPK1, STK3, 
RSK1 and KDM2A knock-outs induce a weak effect on the proliferative ability of MOLM-13 cells 
based on our validation. This may be partly explained by the difference in the duration of the 
experiment between validation (14 days) and screening (30 days). These genes may affect the fitness of 
MOLM-13 over a longer time-course. Although it is possible that the chosen gRNAs for each gene 
may not effectively modify the genetic target, thus result in functional protein, this scenario is less 
likely given our gRNA selection criteria were based on those that were depleted in the AML CRISPR-
Cas9 screen performed by Tzelepis et al. From our validation, we found SIK3 is additionally essential 
MYST Znf KAT7 protein domain 
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in MV4-11 and OCI-AML2 as this was not picked up from the screens. The output of KAT7 
validation is consistent with the screening output across all AML cell lines. Interestingly, KAT5 is also 
a member of the MYST family protein like KAT6A and KAT7 and is an AML-specific essential gene 
(Tzelepis et al. screening results reflect dropout in MOLM-13 and OCI-AML2 cell lines), but was not 
identified as a druggable gene in the DGIdb characterization.  
 
SIK3 knock-out has a strong defect in proliferation across multiple AML cell lines. However, this 
phenotype was not associated with a significant increase in apoptosis or differentiation. The 
proliferation may be associated with growth or cell cycle arrest. Recent studies have shown that the 
catalytic activity of SIK3 is important for the proliferation of MLL-fusion positive AML cells 
(Tarumoto et al., 2018). Tarumoto et al., went on to show that SIK3-dependent phosphorylation of 
HDAC4, prevents HDAC4-mediated inhibition of MLL-fusion target genes such as MEF2C. 
 
Genetic ablation of KAT7 induces anti-proliferation and pro-apoptotic phenotypes in various AML 
cell lines, particularly those habouring MLL-fusion mutations. Myeloid differentiation of various 
magnitude is further observed in KAT7 knock-out in the MLL-fusion positive AML cell lines MOLM-
13 (MLL-AF9), OCI-AML2 (MLL-AF6), THP-1 (MLL-AF9) and Nomo-1 (MLL-AF9) but not in 
MV4-11 (MLL-AF4). Before the knock-out cells eventually undergo cell death, cell lines that 
differentiate after KAT7 knock-out may temporarily restore the function of the transformed 
hematopoietic cell. Our validation revealed KAT7 is a genetic vulnerability in an MLL-AF4 positive 
AML cell line. MLL-AF4 translocation is commonly associated with acute B lymphoblastic leukaemia 
(B-ALL) (Ayton and Cleary, 2001; Meyer et al., 2013, 2018). KAT7 may also be essential for MLL-AF4 
positive B-ALL and whether KAT7 can be therapeutically exploited in this subtype of leukemia is an 
interesting avenue to explore. 
 
We have briefly investigated the effects of KAT7 loss in vivo, by transplanting KAT7-knock-out 
luciferase-expressing MOLM-13 cells into immunodeficient mice. Even though this experiment 
showed that mice harbouring MOLM-13 KAT7 knock-out have delayed disease progression and 
prolonged survival, the in vitro studies thus far suggests that differentiation may be initiated by the 
day of injection (day 3 post-transduction) and could affect the engraftment of AML cells at the bone 
marrow. Cells undergo differentiation soon after transduction (approximately 30% CD11b 
differentiated cells on day 5 post-transduction), and thus would likely to have changes in gene 
expression by day 3 post-transduction, thereby changing the properties of the cells. This could explain 
the ectopic engraftment of KAT7 knock-out MOLM-13 cells seen in the mice experiment. 
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An inducible KAT7-knock-out mouse model would be invaluable to comprehensively assess the loss 
of KAT7 in vivo, particularly in evaluating if the loss of KAT7 has detrimental effects. Furthermore, 
the lack of KAT7 inhibitor presently means that it is not yet possible to assess the wholistic effect of 
inhibiting KAT7 at an organismal level, including effects on normal haematopoiesis and other cell 
types. Development of small molecules or drugs against KAT7 will facilitate our understanding of 
whether targeting KAT7 results in minimal toxicity and possess AML-specific efficacy. Encouragingly, 
a recent genome-wide CRISPR-Cas9 study on haematopoiesis of human primary CD34+ human 
progenitor and stem cells (HPSCs) and T-cells (Ting et al., 2018) did not identify KAT7 as a 
significant player in the development of these cells, which suggests that inhibiting KAT7 may not have 
detrimental effects on the development of normal blood cells. Possible additional experiments using 
the CRISPR-Cas9 based gene-editing methods include knocking-out KAT7, by co-transfection of 
gRNA and Cas9, in CD34+ human cord blood cells and AML cells (MLL-fusion positive and MLL-













In the previous chapter, we validated KAT7 as an essential gene in AML following reports of it being a 
CRISPR-Cas9 dropout candidate (Tzelepis et al., 2016; Wang et al., 2017). Histone acetyltransferases 
can be found in many eukaryotic organisms, ranging from yeast to human. This class of enzyme 
controls cellular homeostasis and a plethora of biological processes through their function in 
catalysing the transfer of acetyl group from acetyl-CoA to e-lysine residues onto proteins, including 
histones proteins (Sheikh and Akhtar, 2018). Among many important functional roles of KAT7 is its 
ability to regulate gene expression (Avvakumov et al., 2012; Saksouk et al., 2009; Sheikh and Akhtar, 
2018; Yan et al., 2018).  
 
Information on KAT7 in the context of AML is scarce with only one study to date that has explored 
this topic. Sauer and colleagues reported that the expression of KAT7 is decreased in human AML 
blast cells compared to the non-malignant CD34+ progenitor cells. Furthermore, the overexpression 
of KAT7 negatively affects the proliferative ability of mouse hematopoietic stem cells and the knock-
down of KAT7 by shRNA boosted colony formation in THP-1 (AML cell line) and SEM (B-ALL cell 
line) (Sauer et al., 2015). The inconsistency between this study and our findings thus far prompted us 
to explore further into the molecular function of KAT7 in our cellular models of human AML.  
 
In this chapter, we characterize the changes in histone acetylation marks following KAT7 loss and 
explore whether the catalytic function of KAT7 is important for sustaining AML. We investigate the 
genome-wide binding profiles of KAT7 to identify its distribution across various functional elements 
of protein-encoding genes. We subsequently link KAT7 occupancy with gene expression data to 
narrow down the group of genes that are likely regulated by KAT7. Together, the aim is to enhance 
our understanding of the general molecular functions of KAT7 in AML cells.  
 
4.2 KAT7 protein and H3K14ac levels are depleted after gKAT7 mediated knock-
out 
 
In chapter 3, we concluded that introducing KAT7 gRNA resulted in proliferation, apoptosis and/or 
differentiation phenotypes in many AML cell lines. To determine if these phenotypes are attributed to 
on-target editing in the KAT7 gene by the selected gKAT7, we assess if KAT7 is knocked-out at a 
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protein level using gKAT7 (A10). Firstly, we wanted to establish the time point at which KAT7 
protein is depleted after transduction. We assessed day 3 and day 4 post-transduction in MOLM-13 
and THP-1 and found that KAT7 protein in gRNA transduced cells are reduced, compared to empty 
control, but still detectable at day 3 for both cell lines (Figure 4.1A). By day 4, KAT7 protein levels are 
abolished for both cell lines (Figure 4.1A). We further assess H3K14ac, a histone mark modified by 
KAT7 and strongly reduced with the loss of KAT7 in vivo (Kueh et al., 2011). Interestingly, global 
H3K14ac levels are depleted in knock-out cells compared to empty control at day 3 post-transduction, 
even in the presence of detectable levels of KAT7 protein (Figure 4.1A). Expectedly, levels of this 
histone mark are further reduced at day 4 (Figure 4.1A). These data, therefore, reveal that at day 4 for 
post-transduction, the global KAT7 protein level is abolished and the loss of KAT7-modified histone 
marks is rapid. Importantly, we detected the on-target effect by gKAT7 (A10) and day 4 is an 
appropriate time point for further analysis.  
 
 
4.3 KAT7 modified histone marks H3K14ac and H4K12ac are depleted in KAT7 
knock-out cells 
 
In vitro and in vivo studies have elucidated the histone lysine residues acetylated by KAT7, as 
mentioned in Chapter 1. Briefly, KAT7 protein complex has specificity for lysine residues on histone 3 
and histone 4 tails. On histone 3, lysine residues 14 and 23 are reported targets for KAT7-BRPF 
complex (Feng et al., 2016; Kueh et al., 2011; Lalonde et al., 2013; Mishima et al., 2011). On histone 4, 
KAT7-JADE complex acetylates lysine residues 5, 8 and 12 (Doyon et al., 2006; Iizuka et al., 2009). We 
hence investigate whether loss of KAT7 results in changes in the levels of these histone lysine 
acetylation, using MOLM-13 as the model cell line. Strikingly, we see a global loss in H3K14ac and 
H4K12ac acetylation marks in the knock-out, relative to the control, on day 4 after transduction 
(Figure 4.1B). Minor depletion of H4K8ac marks can be seen in the knock-out relative to the empty 
control (Figure 4.1B) and H3K23ac and H4K5ac appear to have no global change associated with the 
loss of KAT7 protein (Figure 4.1B). These data suggest that KAT7 is the main HAT responsible for 
global H3K14ac and H4K12ac levels in MOLM-13, whilst the levels of other known KAT7 histone 
targets may be compensated or acetylated by other HATs within the cell.  
 
Next, we investigated if levels of H3K14ac and H4K12ac are reduced in other AML cells, including cell 
lines which proliferation was unaffected by KAT7 knock-out. Indeed, across various AML cell lines, 
global depletion of H3K14ac and H4K12ac was observed, irrespective of whether KAT7 is an essential 
gene in that cell line (Figure 4.1C). Although we cannot attribute the loss of H3K14ac and H4K12ac 
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marks to the proliferation and apoptosis phenotype from these set of experiments, however, we can 
deduce that H3K14ac and H4K12ac are dispensable for general proliferation and apoptosis. This is 
because, despite the loss of KAT7 protein and the corresponding depletion of these two histone 
marks, OCI-AML3 and HL-60 can proliferate and not induce apoptosis. 
 
 
Figure 4.1 Changes in levels of KAT7 protein and KAT7-mediated histone lysine acetylation 
following gRNA-mediated knock-out of KAT7 
AML cell lines were transduced with lentivirus expressing empty (-) or gKAT7(A10) (+) and were sorted 
by flow cytometry for BFP-positive population on day 3 post-transduction. A) Time-course experiments 
in MOLM-13 and THP-1. Lysates were harvested on day 3 (D3) and day 4 (D4) post-transduction for 
immunoblot of KAT7 and H3K14ac. B) Immunoblots of all known KAT7 histone lysine acetylation 
targets on day 4 post-transduction in MOLM-13. C) Changes in global H3K14ac and H4K12ac levels in 
MLL-fusion positive (MOLM-13 and THP-1) and MLL-fusion negative (OCI-AML3 and HL-60) cell 
lines on day 4 post-transduction. 
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4.4 Changes in other histone modifications upon KAT7 loss 
 
To begin to address if the global level of gene expression is affected after KAT7 knock-out, we looked 
into various histone modifications in MOLM-13 on day 4 post-transduction. We first looked at 
histone modifications that are found on the promoter region actively transcribed genes such as 
trimethylation at H3K4 (H3K4me3) (Barth and Imhof, 2010; Liang et al., 2004; Zhang et al., 2015) and 
found that knock-out of KAT7 did not lead to changes in global H3K4me3 (Figure 4.2A). We next 
assessed H3K9ac, which is commonly found to be positively correlated with both gene expression and 
H3K14ac levels (Barth and Imhof, 2010; Karmodiya et al., 2012; Liang et al., 2004). As histone 3 lysine 
9 residue is not a known direct target for KAT7, it is therefore not surprising to observe no changes in 
the acetylation level with the loss of KAT7 protein (Figure 4.2A).  
 
H3K27ac, a histone modification that is also associated with the promoter region of active genes as 
well as with enhancers (Creyghton et al., 2010; Heintzman et al., 2009; Sheikh and Akhtar, 2018; 
Wang et al., 2008), decreases after KAT7 loss (Figure 4.2A). This is an interesting observation as it 
implies that the loss of H3K14ac and/or H4K12ac may result in reduced acetylation levels of 
neighbouring lysine residues. It could be that KAT7-mediated acetylation can act as docking sites for 
other HATs, such as p300 and CBP that writes H3K27ac (Bose et al., 2017; Jin et al., 2011; Sheikh and 
Akhtar, 2018; Tie et al., 2009). To probe into this further, we performed a time course experiment and 
observed that like H3K14ac, H3K27ac is gradually reduced but not abolished at day 5 post-
transduction in MOLM-13 cell line (Figure 4.2C). Furthermore, from day 3 after transduction in 
which we see the depletion of global H3K14ac levels, we do not observe as much decrease in H3K27ac, 
when comparing the knock-out with the empty control. This further implies that the loss of H3K27ac 
is a secondary event following loss of KAT7 protein and KAT7 modified acetylation marks. This 
change in global H3K27ac levels is not as pronounced in other AML cells such as THP-1 and OCI-
AML3 on day 4 post-transduction (Figure 4.2B), compared to MOLM-13 (Figure 4.2C), suggesting 
that the magnitude of change in H3K27ac levels may be cell-line specific.  
 
In addition, we also assessed levels of H3K27me3, a transcriptional repressive mark at promoters 
(Barth and Imhof, 2010; Calo and Wysocka, 2013; King et al., 2016; Wang et al., 2008) and saw no 
apparent change of this histone modification globally in MOLM-13 KAT7 knock-out cells on day 4 
post-transduction (Figure 4.2A). Similarly, the levels of H3K79me2, a mark that is only known to be 
methylated by DOT1L and is associated with the gene body of actively-transcribed genes (Barth and 
Imhof, 2010; Nguyen and Zhang, 2011; Steger et al., 2008; Wood et al., 2018), did not change in 
knock-out cells compared to empty control (Figure 4.2A). The turnover rates and half-life of 
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methylation marks are relatively slower and longer respectively, compared to histone acetylation and 
phosphorylation (Barth and Imhof, 2010), therefore assessing at a later time point might be more 
appropriate. Conversely, later time point changes are more likely to be secondary effects as opposed to 
acute, primary consequences. Collectively, these findings suggest that loss of acetylation marks, 





Figure 4.2 Levels of activating and inactivating histone marks after KAT7 knock-out 
AML cell lines were transduced with lentivirus expressing empty (-) or gKAT7(A10) (+) and cells were 
sorted by flow cytometry for BFP-positive population on day 2 or day 3 post-transduction. A) 
Immunoblot of activating histone marks H3K9ac, H3K27ac, H3K4me3 and H3K79me2; and 
inactivating histone marks H3K27me3 and H3K27ac of MOLM-13 lysates harvested on day 4 post-
transduction. B) Immunoblot of H3K27ac levels in THP-1 and OCI-AML3 on day 4 post-transduction. 
C) Time course experiment in MOLM-13. Lysates were harvested from day 2 to day 5 post-transduction 
for the immunoblot of H3K27ac.  
 
 
4.5 KAT7 catalytic activity 
 
We next investigated whether H3K14ac and H4K12ac are associated with the previously observed 
proliferation and differentiation phenotypes in cell lines in which KAT7 is an essential gene. To 
THP-1 OCI-AML3 MOLM-13 
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address this, we can ask if the catalytic activity of KAT7 is required for the phenotypes. Interestingly, 
among the gKAT7 used in the study, gRNAs that target the MYST catalytic domain –gKAT7 (A10) 
and (5)—resulted in the most drastic proliferative defect, compared to gRNAs that target the serine-
rich domain (gKAT7 (1) and (2)), zinc finger domain (gKAT7 (3)) or gRNA that does not target a 
protein domain (gKAT7 (4)) (Figure 4.3 and Figure 3.6A proliferation in chapter 3). gRNAs targeting 
of the non-catalytic domain may result in truncated but catalytic active protein product, whereas 
gRNAs that target the highly conserved MYST domain are likely to impair the catalytic function even 




Figure 4.3 Schematic of KAT7 protein and the targeting sites of the different gKAT7 
The various gKAT7 used in this study, targets different protein domains of KAT7. gKAT7 (1) and 
gKAT7 (2) targets DNA sequences corresponding to the Serine-rich domain (Ser) while gKAT7 (3) 
targets the Zinc finger domain (ZnF) of KAT7. Sequences modified by gKAT7 (4) do not correspond to a 
protein domain. gKAT7 (A10) and gKAT7 (5) target the MYST catalytic domain and display the most 
drastic proliferative defect.  
 
4.5.1 G485A catalytic active mutant 
 
We initially adopted the G485A MYST domain mutation of KAT7 that is widely referenced in the 
literature (Chen et al., 2013; Iizuka et al., 2008, 2009, 2013; Miotto and Struhl, 2010; Wong et al., 2010) 
to investigate the involvement of KAT7 catalytic activity in the observed phenotype, namely 
proliferation and differentiation, in MOLM-13. As KAT7 is an essential gene, we utilized a knock-in-
knock-out approach to first introduce the G485A mutant KAT7 transgene followed by knock-out of 
the endogenous KAT7. Importantly, the KAT7 transgene is resistant to gRNA-mediated modifications 
by gKAT7 (5 and A10), by altering the nucleotide sequences to create synonymous mutations in the 
gRNA targeted region of the KAT7 cDNA. Therefore, the endogenous KAT7 gene can be ablated 





gKAT7 (3) gKAT7 (4) gKAT7 (A10) gKAT7 (5)
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The KAT7 construct is designed to incorporate a selectable marker for the positive integration and 
expression of mutant KAT7. To achieve this, we link the GFP transgene to the KAT7 transgene using 
T2A sequence, where both genes are under the expression of EF1-alpha promoter (Figure 4.4A). GFP 
and KAT7 transgenes are transcribed and translated as one mRNA transcript. Once translated, the 
T2A peptide induces “self-cleavage”, generating two separate proteins (Ibrahimi et al., 2009; Kim et 
al., 2011)—GFP and mutant KAT7. The levels of GFP signal, therefore, reflects the integration of 
KAT7 transgene into the genome and the expression of KAT7 mutant protein. The targeted G485A 
mutation was confirmed at the plasmid level by Sanger Sequencing (Figure 4.4B). Using the same 
approach described above, we also generated wild-type KAT7 that is resistant to gKAT7 (5 and A10). 
The KAT7 transgene was subsequently introduced to MOLM-13 cells via lentivirus transduction. The 
resulting MOLM-13 cells express the transgene KAT7 (G485A or wild-type) and the endogenous 
KAT7, hereafter referred as G485A KAT7 and wild-type KAT7 MOLM-13.  
 
To assess the function of the G485A KAT7 mutant, we targeted the endogenous KAT7 by gRNA-
mediated knock-out so that the MOLM-13 cells only express the mutant KAT7. To our surprise, we 
found that G485A KAT7 mutant did not result in loss of H3K14ac (Figure 4.5A). This finding is 
inconsistent in two aspects. Firstly, previous reports of G485A implied that this mutation in KAT7 
results in abolished of catalytic activity (Chen et al., 2013; Iizuka et al., 2008, 2009, 2013; Miotto and 
Struhl, 2010; Wong et al., 2010). Secondly, based on our findings above and findings of previous in 
vivo studies which implied the loss of H3K14ac is associated with the loss of KAT7 protein (Kueh et 
al., 2011; Mishima et al., 2011), we would expect H3K14ac to be abolished or at least strongly reduced 
in a KAT7 catalytic dead mutant. A catalytic mutant of KAT7 would predictively phenocopy the 
effects of KAT7 protein loss if KAT7 enzymatic activity is required for the acetylation of histone 3 
lysine 14. Proliferation and differentiation assays also showed that G485A KAT7 mutant does not 
affect the proliferative potential of MOLM-13 cells (Figure 4.5B) and does not induce CD11b 
expression (Figure 4.5C). In contrast, the GFP control MOLM-13 cell lines phenocopies parental 




Figure 4.4 Genetic construct of G485A mutant KAT7 transgene. 
A) Expression of G485A KAT7 mutant under the expression of EF1a promoter. GFP is expressed under 
the same promoter and separated with the G485A transgene by a T2A peptide. KAT7 cDNA is resistant 
to gKAT7 (5) and gKAT7 (A10) modification by generating synonymous mutations in the DNA 
sequence at the gRNA targeting sites. B) Single nucleotide mutagenesis (highlighted in blue) to generate 
the glycine to alanine (G>A) substitution at amino acid position 485. C) Validation of G485A KAT7 by 







Figure 4.5 G485A mutant possesses catalytic activity and does not affect proliferation and 
differentiation of MOLM-13 
A and C) MOLM-13 cell lines were transduced with lentivirus expressing empty (-) or gKAT7(A10) (+) 
and cells were sorted by flow cytometry for BFP-positive population on day 3 post-transduction. A) 
Parental MOLM-13 with GFP-expression (endogenous KAT7) and transgenic MOLM-13 cells with 
either knock-in of wild-type KAT7 (Wild-type KAT7) or G485A mutant (G485A KAT7). Changes in 
H3K14 acetylation levels day 4 post-transduction using gKAT7 (A10) to knock-out endogenous KAT7 



















































































Sample Name Subset Name Count
d3Sorted_d7_20170703_wtKAT7_KAT7(A10)_009.fcs BFP+ GFP+ 9544 
d3Sorted_d7_20170703_wtKAT7_Empty_008.fcs BFP+ GFP+ 9707 







Sample Name Subset Name Count
d3Sorted_d7_20170703_mutKAT7_KAT7(A10)_011.fcs BFP+ GFP+ 9393 
d3Sorted_d7_20170703_mutKAT7_Empty_010.fcs BFP+ GFP+ 9091 






100 Sample Name Subset Name Count
d3Sorted_d7_20170703_GFP_KAT7(A10)_007.fcs BFP+ GFP+ 9833 
d3Sorted_d7_20170703_GFP_Empty_006.fcs BFP+ GFP+ 9909 









Sample Name Subset Name Count
d3Sorted_d7_20170703_wtKAT7_KAT7(A10)_009.fcs BFP+ GFP+ 9544 
d3Sorted_d7_20170703_wtKAT7_Empty_008.fcs BFP+ GFP+ 9707 







Sample Name Subset Name Count
d3Sorted_d7_20170703_mutKAT7_KAT7(A10)_011.fcs BFP+ GFP+ 9393 
d3Sorted_d7_20170703_mutKAT7_Empty_010.fcs BFP+ GFP+ 9091 






100 Sample Name Subset Name Count
d3Sorted_d7_20170703_GFP_KAT7(A10)_007.fcs BFP+ GFP+ 9833 






MOLM-13 G485A KAT7 MOLM-13 GFB
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endogenous KAT7 knock-out in the presence of G485A mutant (MOLM-13 G485A KAT7) compared to 
parental MOLM-13 cell line (MOLM-13 GFP). The relative percentage of BFP and GFP double-positive 
cells were assayed over time and all the time points were normalized to day 4. Mean ± S.D., n= 3. C) Left 
panel: CD11b staining of MOLM-13 cells expressing GFP, G485A KAT7 and no endogenous KAT7 
(orange) and in cells expressing GFP, endogenous KAT7 and G485A KAT7 (grey); right panel: CD11b 
staining of parental MOLM-13 cells expressing GFP and endogenous KAT7 (grey) and of cells with 
KAT7 knock-out (orange), assayed on day 7 post-transduction.  
 
4.5.2 E508Q catalytic dead mutant 
 
We went on to search for other catalytic mutants by looking into other residues to mutate in the 
MYST domain of KAT7. Information on catalytic dead mutants in human KAT7 protein is scarce, 
however, MYST domain appears to be evolutionarily conserved between human and Saccharomyces 
cerevisiae (Figure 4.6) and the enzymatic activity of Esa1 in budding yeast has been extensively 
studied. Figure 4.6 shows the sequence homology of the human KAT7 protein with the mouse KAT7 
and the budding yeast Esa1. The boxed area in Figure 4.6 emphasizes the region of the MYST domain 
where mutation(s) of the highlighted amino acid has been shown to disrupt the enzymatic activity 
(Adachi et al., 2002; Berndsen et al., 2007; Decker et al., 2008; Smith et al., 1998; Yan et al., 2002; Yuan 
et al., 2012). The amino acid highlighted in blue was the one we chose to mutate in our study as the 
glutamic acid (E) to glutamine (Q) substitution in Esa1 give rise to a charge-switch mutation, thereby 
inducing maximal disruption to the catalytic activity. This residue corresponds to the amino acid at 
position 508 (E508Q) of the human KAT7 protein and the nucleotide sequence that give rise to this 
mutation is depicted in Figure 4.7A. Figure 4.7A also illustrates the synonymous mutations (lower 
case nucleotides) that render the E508Q mutant KAT7 transgene unmodifiable by gKAT7(A10) and 
gKAT7(5). The selectable marker for the integration and expression of E508Q mutant transgene is 
identical to one described above for G485A mutant and also introduced to MOLM-13 cells via 
lentivirus transduction. Cloning of E508Q was confirmed by Sanger Sequencing at the plasmid level 
(Figure 4.7B).  
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Figure 4.6 Potential human KAT7 catalytic mutants based on studies in yeast Esa1 
Many residues in the MYST domain of human, mouse and yeast are evolutionary conserved (boxed 
region). Arrow and blue residue indicate the E508Q mutation used in this study. Residues highlighted in 
yellow indicate other amino acids important for the HAT catalytic function based on published 
biochemical studies in yeast Esa1 listed on Uniprot (Adachi et al., 2002; Berndsen et al., 2007; Decker et 




Figure 4.7 Genetic construct of E508Q mutant KAT7 transgene. 
A) Knock-in transgene construct of KAT7 cDNA harbouring the glutamic acid to glutamine (E>Q) 
substitution and GFP separated by T2A peptide. Nucleotide sequences that give rise to the E508Q 
mutations and gRNA7 (5 and A10)-resistant modifications are shown in lower case letters. B) 
Validation of the presence of E508Q mutation by Sanger sequencing after the cloning of E508Q KAT7 
cDNA into the plasmid backbone. Top panel shows the targeted mutations at amino acid position 508 
and the flanking nucleotides.  Bottom panel shows the nucleotide readout from Sanger sequencing.  
 
 
After generating the E508Q KAT7 mutant MOLM-13 cell line which expresses both E508Q KAT7 and 
the endogenous KAT7, we compared its growth (Figure 4.8A, grey line) with parental MOLM-13 
without the expression of GFP (yellow line), MOLM-13 with GFP expression (blue line) and MOLM-
13 expressing both wild-type KAT7 transgene and GFP (orange line). Compared to parental MOLM-
13 cells with no GFP, expression of GFP protein reduces the growth of MOLM-13 cells marginally 
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growth of MOLM-13 (Figure 4.8A). Simultaneous expression of GFP, E508Q KAT7 and endogenous 
KAT7 appears to reduce the growth of MOLM-13. 
 
Next, we knocked-out the endogenous KAT7 using gKAT7(A10) or gKAT7(5) to assess the effect of 
E508Q KAT7. We first evaluated if E508Q mutation gives rise to a catalytic dead KAT7, by western blot 
analysis. Whilst wild-type KAT7 rescues the knock-out phenotype, E508Q KAT7 cannot “write” 
H3K14ac and H4K12ac in MOLM-13 cells (Figure 4.8B), implying that this mutation abolishes the 
enzymatic activity of KAT7. Interesting, we see reduced levels of H3K14ac and H4K12ac in cells 
expressing both E508Q and endogenous KAT7, although catalytic active KAT7 is present. This suggests 
that E508Q mutant has a dominant negative effect, by competing with endogenous KAT7 for histone 
substrates. In particular, we see H4K12ac level is more strongly affected compared to H3K14ac (Figure 
4.8B). This dominant negative effect at a histone level did not induce short-term effects on the growth 
or proliferation of MOLM-13. 
 
MOLM-13 harbouring E508Q phenocopied the KAT7 knock-out cells both in terms of their 
proliferation defect (Figure 4.8C) and the increase in CD11b expression (Figure 4.8D), suggesting that 
the catalytic activity of KAT7 is crucial for leukemic maintenance. We further demonstrated that the 
introduction of gKAT7(5) and gKAT7(A10)-resistant wild-type KAT7 transgene rescued the 
proliferation and differentiation phenotype, implying that the results from experiments using gKAT7 
















































































































Sample Name Subset Name Count
d4sorted_CD11b-APC_MOLM13_Empty_001.fcs Q1: 530_30 (488)-A- , 450_50 (405)-A+ 8574 
d4sorted_CD11b-APC_MOLM13_KAT7 (A10)_002.fcs Q1: 530_30 (488)-A- , 450_50 (405)-A+ 6915 
53.2
















e Sample Name Subset Name Count
d4sorted_CD11b-APC_MOLM13_E508Q_Empty_003.fcs BFP+GFP+ 7552 






















Sample Name Subset Name Count
d4sorted_CD11b-APC_MOLM13_E508Q_Empty_003.fcs BFP+GFP+ 7552 
d4sorted_CD11b-APC_MOLM13_E508Q_KAT7 (A10)_004.fcs BFP+GFP+ 6723 







Sample Name Subset Name Count
d3Sorted_d7_20170703_wtKAT7_Empty_008.fcs BFP+ GFP+ 9707 
d3Sorted_d7_20170703_wtKAT7_KAT7(A10)_009.fcs BFP+ GFP+ 9544 







Sample Name Subset Name Count
d3Sorted_d7_20170703_mutKAT7_KAT7(A10)_011.fcs BFP+ GFP+ 9393 
d3Sorted_d7_20170703_mutKAT7_Empty_010.fcs BFP+ GFP+ 9091 






100 Sample Name Subset Name Count
d3Sorted_d7_20170703_GFP_KAT7(A10)_007.fcs BFP+ GFP+ 9833 


























Figure 4.8 E508Q catalytic dead mutant KAT7 affects the proliferation and differentiation of 
MOLM-13 
A) Proliferation of parental MOLM-13 (GFP negative) and (GFP positive), MOLM-13 expressing wild-
type KAT7 transgene (Wild-type KAT7) and MOLM-13 expressing E508Q mutant transgene (E508Q 
KAT7). B and D) MOLM-13 transduced with gKAT7 (A10) were sorted by flow cytometry on day 3 
post-transduction to enrich for pure knock-out population. B) Changes in histone lysine acetylation 
levels after the knock-out of endogenous KAT7 in parental MOLM-13 cell line (Endogenous KAT7) and 
in MOLM-13 cells expressing either wild-type KAT7 transgene (wild-type KAT7) or E508Q mutant 
transgene (E508Q KAT7). C) Proliferation of MOLM-13 cells with endogenous KAT7 knock-out (BFP-
positive) in the presence of E508Q mutant or wild-type KAT7 transgene (GFP-positive). Relative 
percentage of BFP and GFP double-positive cells were assayed overtime and all timepoints were 
normalized to day 4. Mean ± S.D., n= 3. D) CD11b staining of MOLM-13 cells expressing either E508Q 
or wild-type transgene (green) and in MOLM-13 with endogenous KAT7 and the respective KAT7 
transgene (grey), day 7 post-transduction.  
 
4.5.3 Dominant negative effect of E508Q KAT7 on histone acetylation and cell proliferation 
 
The dominant negative phenotype of E508Q prompted us to investigate further on the mutant’s effect 
on H3K14ac and H4K12ac. Particularly, we are interested in whether one histone acetylation plays a 
more important role than the other in terms of maintaining leukemogenesis. One approach is to 
identify which KAT7 complex, KAT7-BRPF or KAT7-JADE is more “essential”. We analysed the 
AML CRISPR-Cas9 screening dataset and gene expression profiles in the AML cell lines of all the 
members of KAT7 protein complex, including paralogues in the BRPF (BRPF1/2/3) family and JADE 
(JADE1/2/3) family (Figure 4.9). As mentioned in Chapter 1, KAT7-BRPF and KAT7-JADE has an 
affinity for specific lysine residues on H3 and H4 histone tails, respectively. Expect for JADE3, all 
members of the KAT7 complexes seems to be relatively highly expressed in the five AML cell lines 
(Figure 4.9). For MOLM-13 cell line, JADE2 and BRPF1 both showed similar levels of essentiality 
(log10 (P-dropout)) as KAT7 (Figure 4.9). This data suggests that KAT7-JADE2 and KAT7-BRPF1 
may be the predominant complexes in MOLM-13 that acetylates H4K12ac and H3K14ac, respectively. 
In MV4-11, BRPF1 and BRPF2 are more essential than JADE family (Figure 4.9), implying perhaps 
acetylation on H3 tail may be more important. JADE2 and BRPF3 are the strongest dropouts among 
the two families of proteins in OCI-AML2 (Figure 4.9), suggesting perhaps both H3K14ac and 
H4K12ac may be involved in the regulation of the pro-proliferation and anti-differentiation 
phenotypes. In HL-60 and OCI-AML3, the two cell lines in which KAT7 is not cell-essential, BRPF1 
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seems to be the most essential, although not as strongly depleted as in MOLM-13 and MV4-11 (Figure 
4.9).  
 
Figure 4.9 CRISPR-Cas9 depletion and gene expression of the members within the KAT7 protein 
complex 
Left panel: Depletion p-value of each gene in the corresponding cell line. The lower the log10(P-dropout), 
the more significant the gene is considered a drop-out. Right panel: Gene expression in log-transformed 
reads per kilobase millions (RPKM) of each gene in the corresponding cell line. log10 (P-dropout) values 
and transcriptomics data were obtained from the study performed Tzelepis et al.  
 
To approach this question from another angle, we looked into the E508Q KAT7 mutant in MOLM-13 
by sorting the bulk population into “low”, “mid” and “high” levels of mutant KAT7 expression via the 
levels of GFP signal. The aim is to explore the dominant negative effect of E508Q and its correlation 
with H3K14ac and H4K12ac levels as well as growth/proliferation. Notably, when sorting the MOLM-
13 E508Q cells, we noticed two distinct GFP populations, which together constitute the bulk of the 
total cell population. We gated these two populations for cell sorting and named them “low” (brown) 
and “mid2” (purple) (Figure 4.10A).  Additionally, we also sorted the population between “low” and 
“mid2” that we named population “mid1” (blue) as well as the populations at the extreme ends— 
“very low” (lime green) and “high” population (grey) (Figure 4.10A). The “very low”, “low”, “mid1”, 
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Mol Cell 21:51, 2006
HeLa cell extract
- ING4 pulldown contains JADE1/2/3, HBO1 and Eaf6. 
- ING4 pulldown acetylates H4-K5, K8 and K12 in nucleosome, but also can 
   acetylates K16 in free histone.
- HBO1 siRNA shows reuced Ac at H4-K5, K8 and K12, but not at K16.
- ING4 pulldown can acetylates H3, albeit at a lesser degree.
- HBO1 pulldown contains JADE1/2/3, ING4/5, and Eaf6.
- HBO1 pulldown acetylates H3 and H4 (stronger at H4).
- HBO1 pulldown doesn’t contain BRPF1.
- ING5 pulldown contans JADE1/2/3, BRPF1/2/3, HOB1, MOZ/MORF and Eaf6.
- ING5 pulldown can acetylate H4 (K5,8,12) and H3 (K14).
- ING5 pulldown also contain MCM2/4/6 (by western blot).
- HBO1 pulldown contains MCM2 (by western blot).
- ING4/5 are required for HBO1 to acetylate chromatin, but not free histone.
Blood 118:2443, 2011
K562 lysate
- BRD1 (BRPF2) pulldown contains HBO1, ING4, Eaf6 and other minors. 
- BRD1 pulldown acetylates H4 (K 5,8,12) strongly and H3 (K9, K14) to a lesser degree (free histone assay?).
- BRD1 overexpression, but not BRPF1, induce erythroid differentiation in K562. 
- HBO1 KO fetal liver > CD71+Ter119-/+ erythroblasts : H3K14 80-90% decrease, H3K9 moderate decrease. H4 not affected.
- MOZ KO  fetal liver > CD71+Ter119-/+ erythroblasts : H3 not affected
- Same Ac defect pattern in MEF and brain from HOB1 and MOZ KO.
- H3K9me3 and H3K27me3 not affected in erythroblasts and MEFs. 
- Kit+CD71- progenitors from12.5dpc fetal livers > HBO1 KO > erythroid differentiation 
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respectively. Unfortunately, not enough cells were collected from the “very low” and “high” 
populations for western blot analysis but were sufficient for proliferation assay. Wild-type KAT7 
MOLM-13 cells were also sorted by flow cytometry according to GFP expression, using the same 
gating as E508Q mutant.  
 
Both H3K14ac and H4K12ac levels were significantly reduced in MOLM-13 despite having catalytic 
active KAT7 present in the cells (Figure 4.10B). In the varying concentration of E508Q KAT7 within 
the cell, higher “dose” of E508Q KAT7 protein, is associated with further reduction of H3K14ac and 
H4K12ac (compared to bulk), even with the presence of endogenous KAT7 (Figure 4.10B). This is 
particularly pronounced for H4K12ac as levels of this histone mark appears to be abolished in the 
“mid1” and “mid2” populations, whilst still detectable in the “low” population (Figure 4.10B). 
Conversely, H3K14ac has detectable levels across the “low”, “mid1” and “mid2” populations, although 
H3K14ac levels in the “mid2” population were significantly diminished compared to the bulk E508Q 
population (Figure 4.10B). In summary, cells with “low” amounts of E508Q has detectable levels of 
H3K14ac and H4K12ac, while “mid1” and “mid2” levels of this mutant KAT7 has detectable levels of 
H3K14ac but not H4K12ac. This recapitulates the findings in Figure 4.8B, where H4K12ac is relatively 
more affected than H3K14ac. In the wild-type KAT7 MOLM-13 population, higher levels of wild-type 
KAT7 transgene is associated with higher levels of H4K12ac, as seen with the “low”, “mid1” and 
“mid2” populations (Figure 4.10B). Regrettably, the exposed films of histone acetylation and KAT7 
levels were not numerically quantified by densitometry for proper statistical analysis. 
 
The proliferation of the GFP-sorted MOLM-13 populations with varying levels of KAT7 transgene 
was assessed over a 6-day time course, starting with 30000 cells in each well of a 96-well plate. At day 
3, wild-type KAT7 populations appear to proliferate better than E508Q populations (Figure 4.10C). 
There is no apparent association between growth and the “dose” of mutant E508Q, among the sorted 
populations of E508Q KAT7 MOLM-13 (Figure 4.10C). MOLM-13 cells with wild-type transgene 
KAT7 has the highest cell number at day 3, further suggesting that having more KAT7 in the cell 
provide MOLM-13 with a growth advantage. Most populations except for E508Q “low”, reach at a 
comparable number of cells at day 6 (Figure 4.10C). Ideally, this assay should be conducted over a 
longer period, where the potentially varying growth rates between the different populations may 
become more pronounced. However, while maintaining the bulk E508Q MOLM-13 population over 
long term culture, we observed that these cells need to be repeatedly re-sorted to enrich for pure GFP-
positive cells, as GFP-negative cells prevail over time, probably due to the growth disadvantage of 
expressing the E508Q mutant. It was not necessary to re-sort of GFP positive cells in wild-type 
MOLM-13, further supporting that KAT7 provides a growth advantage to cells.   
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Collectively, these data reflect that the level of H4K12ac is relatively more affected than H3K14ac by 
the presence of the E508Q mutant KAT7 (Figure 4.8B and Figure 4.10B). However, MOLM-13 E508Q 
can still proliferate, albeit at a slower rate, in the absence of H4K12ac (Figure 4.10B-C), meanwhile, 
these proliferating cells retain detectable levels of H3K14ac. These findings suggest that H3K14ac is 
necessary to sustain the leukemic programme in MOLM-13 cells, although H4K12ac may also play a 
role. In addition, the dominant negative effect of E508Q does not appear to have drastic consequences 
on the short-term proliferation but is unfavourable for MOLM-13 cells in long-term cell culture.  
 
Figure 4.10 E508Q KAT7 mutant MOLM-13 populations with different levels of GFP expression 
A) Flow-cytometry gating used for sorting E508Q KAT7 MOLM-13 cells into populations of different 
levels of GFP expression—very low, low, middle 1 (mid1), middle 2 (mid2), high. B) Immunoblot of the 
unsorted bulk population and the sorted wild-type KAT7 (wtKAT7) and E508Q KAT7 MOLM-13 
populations with different levels of GFP/KAT7 transgene expression and their corresponding levels of 

































































population of E508Q KAT7 MOLM-13 cells, compared to the bulk. C) The proliferation of the wild-type 
KAT7 MOLM-13 and the E508Q KAT7 MOLM-13 cells with varying expression of GFP.  
 
4.6 KAT7 predominantly occupies the gene promoter region 
 
Having established that KAT7 is required for the global acetylation of H3K14 and H4K12, we next 
investigated the genomic location of KAT7 activity, using chromatin immunoprecipitation 
sequencing (ChIP-seq). We chose to sequence MOLM-13 and MV4-11 to represent cell lines in which 
KAT7 is essential and OCI-AML3 as the non-essential cell line. By examining the ChIP-seq data, we 
found a clear enrichment of KAT7 at promoters of protein-coding genes in MOLM-13, MV4-11 and 
OCI-AML3 cell lines (Figure 4.11A-B).  
 
Promoter regions (±2kb from TSSs), despite constituting a small fraction of the genome, contain 
63.3%, 40% and 48.5% of the KAT7 signals in MOLM-13, MV4-11 and OCI-AML3, respectively 
(Figure 4.11B). The total number of promoter peaks, by gene, in each cell line is indicated in Figure 
4.11C. Notably, the number of genes bound by KAT7 at the promoter in MOLM-13 is approximately 
half of the promoter peaks found in MV4-11 and OCI-AML3 (Figure 4.11C). This observation could 
be explained, in part, by the immunoblot of the chromatin-immunoprecipitation (ChIP) (Figure 
4.11D). In Figure 4.11D, the input of MOLM-13 showed two distinct KAT7 isoforms (~80 kDa and 
~70 kDa), whilst only one isoform (~80 kDa) predominates in MV4-11 and OCI-AML3. The 
polyclonal KAT7 antibody used could pulldown the larger KAT7 isoform in MV4-11 and OCI-AML3, 
but not in MOLM-13. Furthermore, the ChIP in MOLM-13 pulls down the short isoform exclusively, 
and at a lesser amount than the ChIP in MV4-11 and OCI-AML3.  
 
The immunoblot (Figure 4.11D) shows chromatin-immunoprecipitated IP (ChIP), whereby the KAT7 
protein has been cross-linked with the chromatin using formaldehyde before immunoprecipitating 
with the KAT7 polyclonal antibody. This may suggest that in MOLM-13, only the short isoform of 
KAT7 binds the chromatin, Alternatively, the large isoform may also bind but if it forms a different 
protein complex, where the epitope recognized by the KAT7 antibody may be shielded within the 
macro-complex, which can also explain the relatively less efficient IP in MOLM-13 compared to the 




The DNA element that has the next highest proportion of KAT7 occupancy is intergenic region 
and/or intron, depending on the cell line (Figure 4.11B). KAT7 has the lowest occupancy in the exon 
of protein-coding genes (Figure 4.11B). As KAT7 predominantly binds at gene promoter in all three 
AML cell lines, we subsequently focus on KAT7 promoter binding in the pathogenesis of AML at a 
chromatin level. Binding of histone acetyltransferases at the promoter and the subsequent acetylation 
of histones tails are typically associated with gene expression (Sheikh and Akhtar, 2018). Correlating 
KAT7 binding with gene expression, we found that the KAT7 occupancy at active promoters (purple) 
is significantly higher than inactive promoters (black) in MOLM-13 (Figure 4.11E-F), OCI-AML3 
(Figure 4.11G-H) and MV4-11 (Figure 4.11I-J), which is consistent with the activating effect of 
promoter acetylation. Moreover, the highly active genes (red) has the highest KAT7 binding, 





Figure 4.11 Genome-wide chromatin binding of KAT7 in MOLM-13, OCI-AML3 and MV4-11 
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A) KAT7 occupancy around 5kb windows at TSSs of protein-coding gene. B) Distribution of KAT7 
occupancy at promoters (TSS±2kb), exons (excluding promoter exons), introns and intergenic regions 
quantified by MACS2 peaks. C) The total number of promoter binding peaks (by gene) from KAT7 
ChIP-seq in each cell line. D) Immunoblot of KAT7 ChIP identical to the antibody and protocol used to 
generate KAT7 ChIP-seq. E, G and I) Average occupancy of KAT7 per gene per base of highly active 
genes (>10 FPKM), active genes (0-10 FPKM) and inactive genes (FPKM=0). F, H and J) Significant 
higher promoter (TSS±2kb) KAT7 in highly active genes than active genes and inactive genes by Mann-
Whitney-Wilcoxon test. Highly active vs active: MOLM-13 (p = 3.5 × 10-227); OCI-AML3 (p = 5.35 × 10-
273); MV4-11 (p = 9.3 × 10-100); highly active vs inactive: MOLM-13 (p = 5.0 × 10-324); OCI-AML3 (p = 
5.0 × 10-324); MV4-11 (p = 0). Gene expression dataset was obtained from the study performed Tzelepis 
et al. ChIP-seq bioinformatics analysis and the corresponding figures are generated in collaboration with 
Muxin Gu. 
 
4.7 Transcriptomics changes following KAT7 loss 
 
To identify the genes which are regulated by KAT7, we performed RNA sequencing (RNA-seq) in 
MOLM-13, OCI-AML3 and MV4-11 for KAT7 knock-out cells and empty as control. From the time 
course experiment presented earlier in this chapter, KAT7 protein was reduced as early as day 3 post- 
transduction and was depleted by day 4. We, therefore, extracted mRNA from cells on day 3 and day 5 
post-transduction to capture primary and secondary gene expression changes respectively.  
 
Figure 4.12 showed the number of up and downregulated genes for MOLM-13, OCI-AML3 and 
MV4-11. Expectedly, day 3 has a significantly fewer number of differentially expressed genes 
compared to day 5 in all cell lines. By day 3 of KAT7 knock-out, we observed 317 up-regulated and 
227 down-regulated genes in the MOLM-13 cell line. For MV4-11 and OCI-AML3, the transcriptomic 
response to KAT7 knock-out is slower and by day 5 reaches comparable numbers of differentially 
expressed genes as MOLM-13 day 3 (Figure 4.12). The relationship between KAT7 binding and gene 
expression changes in MOLM-13, MV4-11 and OCI-AML3, will be discussed further in the next 






Figure 4.12 Gene expression changes after KAT7 knock-out 
Number of differentially expressed genes in KAT7 knock-out versus empty control on day 3 and day 5 
post-transduction in MOLM-13, OCI-AML3 and MV4-11. BFP-positive cells were sorted by flow 
cytometry on day 3 post-transduction and RNA were harvested at the respective time points. RNA-seq 
bioinformatics analysis and the corresponding figures are generated in collaboration with Muxin Gu 




The catalytic activity of KAT7 is essential for the proliferation of MLL-fusion AML. Drastic reductions 
in H3K14ac and H4K12ac can be seen following the loss of KAT7 protein and in E508Q catalytic dead 
KAT7, however, it remains unclear if one modification or a combination of acetylation at both residues 
are responsible for the phenotype. Our findings hint that H3K14ac might be more critical in MOLM-
13, however, we cannot discount the additive effects of the lysine acetylation deposited by KAT7. 
Regrettably, we did not generate E508Q mutant in other AML cell lines therefore, unable to make 
broader conclusions on the dominant negative effects of the catalytic mutant of KAT7. Moreover, the 
extent to which non-histone protein acetylation by KAT7 in mediating transcription of target genes 
warrants further investigation as acetylation of nuclear and cytoplasmic protein such as transcription 
factors and tumour suppressors by other HATs have previously been reported (Roe et al., 2015; Sharma 
et al., 2000; Sheikh and Akhtar, 2018). Interestingly, both erythroblast and embryonic knock-
down/knock-out of KAT7 in mice showed depletion of H3K14ac but not H4K12ac (Kueh et al., 2011; 









































































































































































































































was not observed in our study (Mishima et al., 2011). Furthermore, H4K5ac and H3K9ac levels were 
found to increase after the knock-out of KAT7 in mouse embryos (Kueh et al., 2011). These 
observations further imply that the net change in acetylation upon KAT7 depletion is likely to be cell-
type and context-specific. In contrast to the findings of Sauer et al., we did not observe significant 
changes in H4K5ac levels, at a global level. 
 
Our attempt to generate H3K14ac ChIP-seq data has been unsuccessful, most likely due to the quality 
of the antibodies, as previously illustrated in Chapter 2. Possibly, H3K14ac levels may not be as 
abundant as other histone acetylation marks— which can also hinder the efficiency of ChIP experiments. 
Generating H3K14ac and H4K12ac ChIP-seq datasets from our cellular models will be pivotal in 
enhancing our understanding of whether these marks are important for the expression of KAT7-bound 
genes. Importantly, we confirmed that KAT7 promoter occupancy positively correlates with gene 
expression, typical of the effects of HATs and histone lysine acetylation (Sheikh and Akhtar, 2018).  
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Chapter 5: Mechanistic link between KAT7 and the pathogenesis of 




Genetic ablation of KAT7 had the most pronounced anti-leukemic effects in AML cell lines 
harbouring the translocations involving the mixed-lineage leukemia (MLL or KMT2A) gene based on 
the findings described in Chapter 3. Partial tandem duplication (PTD) mutations of the MLL gene 
have also been found in patients, although less commonly than translocations of MLL (Ballabio and 
Milne, 2012; Meyer et al., 2013, 2018; Zeisig and So, 2015). Despite the fact that only 5-10% of adult 
acute leukemias possess the MLL gene fusion (Chen and Armstrong, 2015; Meyer et al., 2013, 2018; 
Slany, 2016), MLL-fusion leukemia generally characterize a subtype of the disease associated with a 
poor prognosis (Ayton and Cleary, 2001; Krivtsov and Armstrong, 2007; Papaemmanuil et al., 2016; 
Saultz and Garzon, 2016). The wild-type MLL gene encodes a histone methyltransferase that catalyzes 
the methylation of histone 3 lysine 4 residues (H3K4) and is crucial for the regulation of embryonic 
development and hematopoiesis (Jude et al., 2007; Yagi et al., 1998; Yokoyama, 2015, 2017; Yu et al., 
1995). More than 70 fusion partners of MLL have been identified, however, the majority of the fusion 
partners are proteins involved in transcriptional elongation, namely AF9, AF4, AF6, AF10, ENL and 
ELL (Meyer et al., 2018; Slany, 2009, 2016; Zeisig and So, 2015). Interestingly, these fusion partners 
biochemically interact with one another and are part of the same protein complexes (Deshpande et al., 
2012; Zeisig and So, 2015). 
 
Target recognition and transcriptional activation of the MLL-fusion oncoprotein is hypothesized to be 
mediated through the MLL portion and the fusion partner portion, respectively (Yokoyama, 2015). 
MLL-fusion preferentially binds to non-methylated CpGs sites in the promoter-proximal regions via 
its CXXC domain of the N-terminal portion of the MLL retained in the fusion protein (Ayton and 
Cleary, 2001; Birke et al., 2002; Cierpicki et al., 2010; Yokoyama, 2017). In addition, target recognition 
of MLL-fusion protein is thought to depend on additional interactions of the N-terminal portion 
(MLL) with MENIN (Caslini et al., 2007; Grembecka et al., 2012; Kühn and Armstrong, 2015; 
Muntean and Hess, 2012; Yokoyama and Cleary, 2008; Yokoyama et al., 2005), LEDGF (Ashkar et al., 
2018; Liedtke and Cleary, 2009; Okuda et al., 2014; Yokoyama and Cleary, 2008) and PAFc (Milne et 
al., 2010; Muntean and Hess, 2012; Muntean et al., 2010; Yokoyama, 2015, 2017). The C-terminal 
portion of the fusion protein, consisting of the fusion partner, can subsequently interact and form 
multiprotein complexes with the super elongation complex (SEC), AF4 family/ ENL family/ p-TEFb 
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(AEP) complex and DotCom complex (Ballabio and Milne, 2012, 2014; Deshpande et al., 2012; Zeisig 
and So, 2015). 
 
p-TEFb (CDK9 and Cyclin T1/2) can be found in SEC, AEP and EAP complexes, whilst DOTCOM 
complex lacks p-TEFb but possesses DOT1L protein (Table 5.1). It is thus suggested that p-TEFb and 
DOT1L exist in a mutually exclusive manner with the MLL-fusion protein. However, some studies 
have reported the association of MLL fusion proteins with ENL associated protein (EAP) complex, 
which consists of both p-TEFb and DOT1L (Deshpande et al., 2012; Zeisig and So, 2015) (Table 5.1). 
The findings from these biochemical studies suggest that MLL-fusion does not act in isolation to 
regulate the leukemic transcriptional programme.  
 
 
Complex name AEP SEC DotCom EAP 
Components 
p-TEFb p-TEFb   p-TEFb 
AF4 AF4   AF4 
AF5Q31 AF5Q31   AF5Q31 
ENL ENL ENL ENL 
  AF9 AF9   
    DOT1L DOT1L 




Table 5.1 Multiprotein complexes associated with MLL-fusion proteins 
 
In Chapter 4, we established a positive correlation between KAT7 promoter binding and gene 
expression. In this chapter, we explored the molecular mechanism by which KAT7 regulate the 
expression of MLL-fusion target genes.  
 
5.2 Majority of the MLL-AF9 and MLL-AF4 spreading targets are bound by KAT7  
 
Analysis of ChIP-seq in MOLM-13, MV4-11 and OCI-AML3 revealed that KAT7 predominantly 
occupied gene promoter, compared to other DNA regulatory elements, as described in Chapter 4. 
MLL-fusion protein binding to non-methylated CpG promoter-proximal regions of target genes is a 
popular model of gene activation by MLL-fusion (Kerry et al., 2017; Marschalek, 2011; Okuda et al., 
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2014; Yokoyama, 2015, 2017). To find shared targets between KAT7 and MLL-fusion, we compared 
KAT7 promoter peaks with existing MLL-AF9 (from THP-1) and MLL-AF4 (from MV4-11) ChIP-
seq datasets (Kerry et al., 2017), specifically those defined as “spreading targets”. Genes in which MLL-
fusion bind to at the gene promoter and spread to the gene body are coined “spreading targets”, whilst 
genes that have promoter-restricted MLL-fusion binding patterns are termed “non-spreading targets” 
(Kerry et al., 2017). Furthermore, spreading targets are associated with higher gene expression 
compared to non-spreading targets and it is suggested that the expression of spreading MLL-fusion 
target genes are important for this subtype of leukemia (Kerry et al., 2017). The MLL-AF9 and MLL-
AF4 spreading gene lists were applied filters to remove duplicates and non-coding genes, giving rise to 
150 and 117 genes respectively. 35.5% (53 out of 150) of MLL-AF9 target genes are also bound by 
MLL-AF4, while 54.7% (53 out of 117) of MLL-AF4 spreading targets are bound by MLL-AF9 (Figure 
5.1). 
 
75.3% of MLL-AF9 spreading targets are bound by KAT7 at the promoter in MOLM-13 (Figure 5.2A). 
In the case of MV4-11, a striking 98.3% of MLL-AF4 spreading targets are bound by KAT7 at the 
promoter (Figure 5.2C). Majority of the MLL-AF9 and MLL-AF4 target genes are also bound by 
KAT7 in OCI-AML3, a cell line without MLL-fusion and this overlap is statistically significant (Figure 
5.2B, D). As KAT7 additionally binds to promoter regions that are not occupied by spreading MLL-
AF9 or MLL-AF4 and that OCI-AML3 (without MLL-fusion) has a large number of KAT7 peaks, 
together suggest that the genome-wide chromatin occupancy of KAT7 may not be dependent on 
MLL-fusion.  
Figure 5.1 Shared spreading targets of MLL-AF9 and MLL-AF4 













MLL-AF9 and MLL-AF4 ChIP-seq dataset from THP-1 and MV4-11 respectively (Kerry et al., 2017). 
Spreading defines the binding pattern of MLL-fusion at the gene body in addition to the promoter of the 
target genes. The number of unique, protein-coding targets for MLL-AF9 (n = 150) and MLL-AF4 (n = 
117). Notable MLL-fusion spreading targets that are shared between MLL-AF4 and MLL-AF9 are listed.  
 
 
Figure 5.2 Majority of MLL-AF9 and MLL-AF4 spreading targets are co-bound by KAT7 at the 
promoter 
Significant overlap between KAT7-bound and MLL-AF9 spreading targets in A) MOLM-13 (p = 3.9 × 
10-34) and B) OCI-AML3 (p = 4.8 × 10-15) and between KAT7-bound and MLL-AF4 spreading targets in 
C) MV4-11 (p = 1.4 × 10-22) and D) OCI-AML3 (p = 3.6 × 10-16) by Fisher’s Exact test. 
 
5.3 Top KAT7 bound genes are MLL-fusion targets in MOLM-13 and MV4-11 but 
not in OCI-AML3 
 
To investigate the relationship between KAT7 binding and MLL-fusion binding, we ranked KAT7 
occupied promoter from low-to-high in MOLM-13, MV4-11 and OCI-AML3. Strikingly, we observed 
that the top KAT7-bound genes in MOLM-13 are MLL-AF9 exclusive spreading targets or are shared 
targets between MLL-AF9 and MLL-AF4 (Figure 5.3A). Correspondingly, genes with the highest 
KAT7 promoter occupancy in MV4-11 are either MLL-AF4 exclusive spreading targets or targets co-
bound by MLL-AF9 and MLL-AF4 (Figure 5.3B). In contrast, genes with the highest KAT7 promoter 
occupancy in OCI-AML3 are neither MLL-AF9 or MLL-AF4 bound genes (Figure 5.3C-D). This may 
suggest that KAT7 recruitment to these specific promoter sites may be MLL-fusion dependent in the 





Figure 5.3 Ranked normalized KAT7 promoter occupancy signal 
KAT7 promoter occupancy was normalized for comparison of ChIP-seq signal between cell lines. Blue 
and green dots represent the MLL-AF9 (THP-1) and MLL-AF4 (MV4-11) spreading genes respectively, 
dataset derived from Kerry et al. Top KAT7-bound genes in A) MOLM-13 and B) MV4-11 are bound by 
MLL-AF9 (blue), MLL-AF4 (green) or shared targets of MLL-AF9 and MLL-AF4 (red). C-D) Top 
KAT7-bound genes in OCI-AML3 are not targets of MLL-AF9/MLL-AF4. Normalisation was based on 
the assumption that promoter occupancy of KAT7 is unchanged for the majority of protein-coding genes. 
Promoter occupancies (±1000bp of TSS) of all the 20291 protein-coding genes were calculated for each 
background-subtracted sample and normalised to the median value of promoter occupancies.  
 
5.4 Genes co-bound by MLL-AF9 and KAT7 at promoter are downregulated after 
KAT7 loss in MOLM-13 
 
We next investigated whether KAT7 regulates the transcription of MLL-AF9 targets by examining how 
gene expression changes in KAT7 knock-out cells compared to wild-type using RNA-seq. The up and 
down-regulation of gene expression may be directly affected by the KAT7 loss or due to indirect effects. 
To establish which genes are directly regulated by KAT7, we separated the genes that are occupied by 
















































































































their expression levels change following KAT7 knock-out. We found that KAT7-bound genes that 
demonstrate spreading MLL-AF9 patterns in MOLM-13 are almost exclusively associated with 
decreased transcript levels at both day 3 and day 5 (Figure 5.4A) in marked contrast to the same genes 
in the OCI-AML3 cell line (Figure 5.4B). In MOLM-13 day 3, 20 (of 150) MLL-AF9 spreading targets 
are significantly downregulated (Figure 5.4C) and these genes display significantly higher KAT7 
occupancy than upregulated (n=4) or non-differentially expressed (n=126) genes (Figure 5.4D). These 
findings are in keeping with down-regulation likely caused by the KAT7 loss at promoters, whereas the 
up-regulation is likely caused by indirect effects.  
 
Notably, no association between high KAT7 occupancy and down-regulation was observed in OCI-
AML3, a cell line which lacks an MLL-fusion oncoprotein (Figure 5.4E-F). Furthermore, in MOLM-13 
only genes that are bound by both KAT7 and demonstrate an MLL-AF9 “spreading” pattern are down-
regulated, whilst the ones bound only by KAT7 are not (Figure 5.4G). These data suggest that KAT7 
likely operates in conjunction with MLL-AF9 to activate leukemogenic genes at these specific loci. As 
expected, the OCI-AML3 cell line displays no significant difference in expression changes with respect 




Figure 5.4 Transcriptomics change after KAT7 knock-out and the chromatin occupancy of KAT7 in 
MOLM-13 and OCI-AML3 
A-B) Heat map showing promoter KAT7 occupancy (Z-transformed log10 values), log2 fold changes of 
expression between KAT7 knock-out and wild-type (WT) in day 3 and day 5, for the 150 MLL-AF9 
spreading genes. Data for heat maps were unscaled and ordered by hierarchical clustering of Euclidian 
distances. C) Scatter plot of promoter KAT7 occupancy against the change of expression in KAT7 knock-
out for MLL-AF9 targets and MEIS1. Significantly up- and down-regulated genes (adjusted p < 0.05 by 
DESeq2) are highlighted in blue and red respectively. D) Significantly higher promoter KAT7 in down-
regulated genes compared to up-regulated genes (p = 0.0027) and genes that are not differentially 
expressed (ND, p = 2.7 × 10-7) by one-tailed T-test. ND versus up-reg p = 0.96. E) Same as C for OCI-
AML3. F) Same as D for OCI-AML3 showing no significant difference. Down-reg versus up-reg p = 0.75, 
down-reg versus ND p = 0.59 and up-reg versus ND p = 0.08. G) Distribution of change of gene 
expression (log2 scale) for KAT7-bound (>10 normalized units) and unbound (zero occupancy) genes in 
MOLM-13. On the genomic scale (Gen) two-tailed T-test p = 0.51 (18,622 unbound versus 85 bound 
genes) and within MLL-AF9 targets p = 4.3 × 10-5 (123 unbound versus 27 bound genes). H) Same as G 
for OCI-AML3. Genomic p = 0.057 (14766 unbound, 3941 bound) and MLL-AF9 targets p = 0.54 (78 
unbound, 72 bound). 
A B C D
E F G H
 104 
5.5 Loss of KAT7 results in general gene expression changes in MV4-11 that is not 
associated with MLL-AF4 spreading targets 
 
Binding of KAT7 does not show an obvious correlation with the gene-expression change of MLL-AF4 
spreading targets in MV4-11 on day 3 and day 5 after KAT7 knock-out (Figure 5.5A). Unexpectedly, 
the changes in gene expression on day 3 and day 5 appears to be contrasting (Figure 5.5A). Majority of 
the targets co-bound by spreading MLL-AF4 and KAT7 are not differentially expressed between 
KAT7 knock-out and empty control on day 3 post-transduction in MV4-11 (Figure 5.5B). On day 3, 
only 9 (of 117) MLL-AF4 targets are significantly downregulated, and the remaining (n=108) are not 
differentially expressed (Figure 5.5B-C). The targets co-bound by MLL-AF4 and KAT7 targets which 
are significantly downregulated on day 3 are NUDT5, JMJD1C, PTEN, FLT3, NUSAP1, RAB27A, 
MRPL33, ITGA4 and SATB1. Notably, there is no significant difference in KAT7 promoter occupancy 
between down-regulated and non-differential expressed MLL-AF4 spreading target genes (Figure 
5.5C), contrasting the trends observed in MOLM-13 (Figure 5.4C-D).  
 
When comparing MLL-AF4 targets in terms of those that are bound or unbound by KAT7 at the 
promoter, those that are occupied by KAT7 (n=60) are downregulated compared to loci that are 
unbound by KAT7 (n=57) on day 3 and the difference in gene expression between these two 
population of genes is statistically significant (Figure 5.5D). This is also the trend at a genome-wide 
level, excluding MLL-AF4 spreading targets (Figure 5.5D). These data suggest that the loss of KAT7 in 
MV4-11 results in the general downregulation of genes bound by KAT7 at the promoter and only a 
minor subset of MLL-AF4 spreading target genes are significantly downregulated despite the majority 
of the MLL-AF4 spreading genes are mutual targets of KAT7. 
 
Unexpectedly, although being co-bound by KAT7 and MLL-AF4, established MLL-fusion targets such 
as MEIS1 and PBX3 did not appear to be differentially expressed in KAT7 knock-out compared to 
empty control by RNA-seq on day 3 and day 5 post-transduction. Therefore, we analysed a set of well-
studied MLL-fusion targets, most of which are associated with spreading MLL-AF4 (PBX3, MEIS1, 
CDK6, BCL2, JMJD1C and SENP6) and some associated with non-spreading MLL-AF4 (HOXA9 and 
MYC). We also included a few genes of the HOXA cluster that are not bound by MLL-AF4 in MV4-11 
(HOXA5, HOXA6, HOXA10 and HOXA11) to investigate how they change in gene expression. We 
analysed the same RNA extracts that were submitted for RNA-seq by RT-qPCR to compare the output 
of two different methods that assess transcriptomics changes. Spreading MLL-AF4 targets PBX3, 
MEIS1, CDK6, BCL2, JMJD1C and SENP6 are strongly downregulated in KAT7 knock-out compared 
to wild-type by RT-qPCR on day 5 (Figure 5.5E). Only JMJD1C was significantly differentially 
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expressed in RNA-seq analyses. Genes not bound by MLL-AF4 in MV4-11 such as HOXA10 and 
HOXA11 also appears to be downregulated by RT-qPCR. The inconsistency between RNA-seq and 




Figure 5.5 Transcriptomics changes in MV4-11 after KAT7 knock-out and the chromatin occupancy 
of KAT7 
A) Heat map showing promoter KAT7 occupancy (Z-transformed log10 values), log2 fold changes of 
expression between KAT7 knock-out and wild type (WT) in day 3 and day 5, for the 117 MLL-AF4 
spreading genes. Data for heat maps were unscaled and ordered by hierarchical clustering of Euclidian 
distances. B) Scatter plot of promoter KAT7 occupancy against the change of expression in KAT7 knock-
out for MLL-AF4 targets. Significantly up- and down-regulated genes (adjusted p < 0.05 by DESeq2) are 
highlighted in blue and red respectively. C) No significant difference in KAT7 occupancy in down-


































































































































































tailed T-test. D) Distribution of change of gene expression (log2 scale) for KAT7-bound (>10 normalized 
units) and unbound (zero occupancy) genes in MV4-11. On the genomic (Gen) scale two-tailed T-test p 
= 2.7 × 10-42 (17619 unbound versus 1121 bound genes) and within MLL-AF4 targets p = 2.2 × 10-3 (57 
unbound versus 60 bound genes). E) Changes in gene expression of established MLL-fusion targets 
between KAT7 knock-out and empty control by RT-qPCR using the same RNA extract submitted for 
RNA-seq. 
 
5.6 Auxin-inducible degron (AID) system for rapid KAT7 protein degradation  
 
To study the acute effects of KAT7 depletion, we utilized the auxin-inducible degron (AID) system to 
rapidly eliminate KAT7 protein in cells (Nishimura et al., 2009). This system requires two components. 
Firstly, the protein of interest needs to be tagged with a mini-AID (mAID) peptide, a 68 amino acid 
fragment of the original AID (Natsume et al., 2016; Nishimura and Kanemaki, 2014). Secondly, the 
plant-specific F-box protein transport inhibitor response 1 (TIR1) gene, needs to be introduced as it is 
not expressed in mammalian system (Natsume et al., 2016; Nishimura and Kanemaki, 2014). Upon the 
treatment of plant hormone auxin, the protein of interest is poly-ubiquitylated by E3 ubiquitin ligase 
and rapidly degraded by proteasome within the cell (Natsume et al., 2016; Nishimura and Kanemaki, 
2014; Nishimura et al., 2009).  
 
Briefly, we generated stable KAT7-mAID expressing MOLM-13 and MV4-11 cells followed by knocked 
out endogenous KAT7 with gKAT7 (A10), such that the only KAT7 protein in cells is the tagged KAT7-
mAID, before introducing the OsTIR1 gene (TIR1 gene derived from Oryza sativa). The MOLM-13 
AID and MV4-11 AID cells were generated after successive rounds of fluorescent marker selection 
(Figure 5.6A). We first confirmed that the proliferation of both MOLM-13 AID and MV4-11 AID cells 
were similar to that of the parental (Figure 5.6B), indicating that the expression of mAID-tagged KAT7 
and ectopic expression of OsTIR1 was not detrimental to the cells.  
 
Then, using this system, we performed time-course experiments following treatment of indole-3-acetic 
acid (IAA), which is the most abundant hormone of the auxin class (Lavy and Estelle, 2016). A dramatic 
reduction of KAT7 protein levels is observed as early as 2 hours after treatment with IAA in both 
MOLM-13 AID (Figure 5.6C) and MV4-11 AID cells (Figure 5.6D). This was associated with the 
complete loss of H3K14ac over the same time course (Figure 5.6C-D). Notably, IAA needs to be 
replenished by 72 hours, as KAT7 levels in MV4-11 is restored following 3 consecutive days of IAA 
treatment (Figure 5.6D). Furthermore, the addition of IAA to parental MOLM-13 and MV4-11 cells do 
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not affect the levels of KAT7 protein or H3K14ac (Figure 5.6C-D), thus reflect that levels of endogenous 
proteins, particularly KAT7, without mAID-tagged is unaltered by the addition of this plant hormone.  
 
Two isoforms of KAT7 can be observed in the immunoblot of MOLM-13 AID and MV4-11 AID cells, 
(Figure 5.6C-D), potentially due to post-translational modifications on KAT7 protein that alter its 
molecular weight. Noticeably, parental MOLM-13 also has two distinct isoforms of KAT7, but this is 
not as distinct in the parental MV4-11. It is unknown if the different isoforms have different roles in 
the pathogenesis of AML. 
 
Figure 5.6 Auxin-inducible degron (AID) MOLM-13 and MV4-11 induces rapid KAT7 protein 
degradation and H3K14ac depletion 
A) Schematic illustrating the sequential rounds of transduction and selection to generate the AID 
MOLM-13 and MV4-11 cell lines. B) Cell proliferation of parental and AID MOLM-13 and MV4-11 
cells. C) Time-course experiment of indole-3-acetic acid (IAA) treatment and the corresponding levels of 



































KAT7 protein and H3K14ac in MOLM-13 AID cells (top panel) and parental MOLM-13 cells (bottom 
panel). D) Same as C for MV4-11. m, minutes; h, hours. 
 
5.7 Gene expression changes and the differentiation of IAA treated MOLM-13 AID 
and MV4-11 AID cells 
 
To address if KAT7 knock-out AID cells recapitulate gRNA-mediated KAT7 knock out cells, we 
assessed the differentiation phenotype and changes in gene expression of some of the classical MLL-
fusion targets such as PBX3, MEIS1, CDK6 and BCL2 (Dawson et al., 2011; Guenther et al., 2008; 
Kohlmann et al., 2005; Krivtsov et al., 2006; Liedtke and Cleary, 2009; Neff and Armstrong, 2013) 
following treatment of IAA in MOLM-13 AID and MV4-11 AID cells. These MLL-fusion target genes 
are all downregulated, albeit at different rates in the different cell lines (Figure 5.7A-B). For instance, 
SENP6, PBX3 and JMJD1C, which are bound by KAT7 in MOLM-13 and MV4-11 and are spreading 
target of both MLL-AF9 and MLL-AF4, is strongly reduced in MOLM-13 but to a lesser extent in MV4-
11 over a 48-hour time course. Furthermore, some genes such as MEIS1 and JMJD1C are significantly 
downregulated by 2 hours in MOLM-13. In general, the decrease in gene expression in MV4-11 AID 
cells is less pronounced compared to MOLM-13 AID cells over the same time course. Furthermore, 
myeloid differentiation (CD11b) is observed after 48 hours of IAA treatment in MOLM-13 AID, 
mirroring the phenotype seen CRISPR-Cas9 mediated KAT7 knock-out. A 41.1% increase in CD11b 
expression at 48 hours of IAA treated MOLM-13 AID compared to cells without IAA treatment (cells 
treated with water as control) (Figure 5.7C), corresponds to the differentiation phenotype on day 5 of 
gRNA-mediated KAT7 knock-out. This suggests that the auxin-inducible system leads to a more acute 
effect compared to the CRISPR-Cas9 system, therefore the former is a suitable system to assess primary 
changes immediately following the loss of KAT7 protein. No CD11b differentiation is observed in IAA 
treated MV4-11 AID cells compared to water-treated control (Figure 5.7D). This reinforces the lack of 
differentiation seen in the gKAT7-mediated knock-out MV4-11 cells in Chapter 3.6.3, strengthening 
the evidence that an increase in CD11b differentiation is not a consequent of KAT7 loss in this cell line. 
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Figure 5.7 Changes in gene expression and differentiation after IAA-induced KAT7 depletion in AID 
MOLM-13 and MV4-11 cells 
A-B) Treatment of IAA and the downregulation of well-known MLL-fusion targets over a 48-hour time 
course in A) MOLM-13 AID and B) MV4-11 AID cells. C) Increase in CD11b expression in IAA treated 
























































































treatment. D) Similar levels of CD11b expression in IAA treated and H2O treated MV4-11 AID cells at 
48 hours of IAA treatment.  
 
5.8 Loss of KAT7 and the occupancy of MLL-fusion proteins 
 
Given that the majority of MLL-AF4 and MLL-AF9 spreading targets are bound by KAT7, we sought 
to examine if KAT7 is needed for the recruitment of MLL-fusion to its target at the promoter region. 
Table 5.2 summarizes the genes of interest and whether its promoter region is bound by spreading 
(SP) or non-spreading (NSP) MLL-AF9 and MLL-AF4. The time point at which the genes are 
significantly downregulated in the KAT7 knock-out RNA-seq dataset for MOLM-13 and MV4-11 are 




Table 5.2 Selective established MLL-fusion targets and the binding profiles of KAT7, MLL-AF9, 
MLL-AF4 and the earliest time point of gene down-regulation following KAT7 knock-out. 
Selective KAT7 targets that are also well-known targets of MLL-fusions. A tick in the KAT7 column 
means there is binding of KAT7 at the promoter region of the gene in both MOLM-13 and MV4-11. 
MLL-AF9 and/or MLL-AF4 occupancy with spreading (SP) or non-spreading (NSP) patterns at the 
respective genes are indicated. The earliest timepoint (day post-transduction) at which significant gene 
expression changes are detected in the respective cell lines after KAT7 knock-out from RNA-seq analysis 
is indicated in the last two columns. All gene expression changes indicated in the table are associated 
with downregulation.  
 
Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) was performed in 
MOLM-13 AID and MV4-11 AID cells. The MLL N-terminal, AF9 C-terminal and AF4 C-terminal 
antibodies were used to probe for the chromatin occupancy of MLL-AF9 and MLL-AF4 binding in 
Gene KAT7 MLL-AF9 MLL-AF4 MOLM-13 (day) MV4-11 (day)
JMJD1C  SP SP 3 5
SENP6  SP SP 3
HOXA9  NSP NSP
HOXA10  NSP 3
PBX3  SP SP 3
MEIS1  SP 3
BCL2  NSP SP 5
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MOLM-13 and MV4-11. In addition to the promoter of the shared targets of MLL-AF9/MLL-AF4 and 
KAT7, we also assayed the KAT-bound introns and enhancer regions of these genes.  
 
5.8.1 MLL-AF9  
 
In MOLM-13, treatment with IAA for 24 hours leads to an insignificant increase in occupancy of 
MLL-N and AF9-C at the promoter of JMJD1C and SENP6 (Figure 5.8A and C). A marginal increase 
in binding of MLL-AF9 upon the loss of KAT7 is similarly observed for HOXA9 and HOXA10, 
although more replicates are needed to determine statistical significance (Figure 5.8A, C). For the 
promoter and intron binding at PBX3, a slight increase can be seen in the MLL-N portion but the 
contrary is observed for AF9-C terminal (Figure 5.8A, C). This inconsistency could reflect noise or the 
difference in occupancy of the wild-type MLL and wild-type AF9 at the PBX3 loci. Although MLL-
AF9 ChIP-seq data derived from THP-1 did not show binding at MEIS1 (Kerry et al., 2017; Prange et 
al., 2017), our ChIP-qPCR suggests that MLL-AF9 might bind to MEIS1 at both promoter and intron 
regions in MOLM-13. However, we cannot eliminate that the ChIP-qPCR signal is picking up the 
wild-type MLL and wild-type AF9 binding, therefore needs to be verified by performing MLL-C and 
AF9-N ChIP-qPCR. Moreover, the binding of MLL-N and AF9-C at BCL2 promoter and enhancer 
region is relatively weak and there are minimal changes in occupancy at these loci after the loss of 
KAT7 (Figure 5.8A, C).  
 
As a control, we performed AF9-C terminal ChIP-qPCR for the same targets in MV4-11 (Figure 
5.8D), and found low levels of AF9 occupancy at these loci, compared to MOLM-13. This is reflected 
by the low ChIP signal levels (percentage input) across all the loci and these are also similar to the 
binding signals detected at a negative, gene desert region (Figure 5.8D). Furthermore, the low 
percentage of input is unlikely to be attributed by poor antibody quality, as identical experimental set 
up using the same AF9 antibody in MOLM-13 yield approximately 100-times stronger signal (Figure 
5.8C, D). Assuming these loci are important for leukemogenesis in MV4-11, this finding could suggest 





After 24 hours of treatment with IAA, MLL-AF4 show similar trends of increase at all of the above-
mentioned MLL-fusion target loci in MV4-11, except for PBX3 intron (Figure 5.8B, F). Notably, 
signals of MLL-N and AF4-C at all of these loci (Figure 5.8B, F) are significantly stronger than AF9-C 
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in MV4-11 (Figure 5.8D). Repeats are needed to determine the statistical significance. Strikingly, we 
observed a statistically significant decrease in wild-type AF4 binding at these same target loci in 
MOLM-13 (Figure 5.8E). This suggests that KAT7 loss has an effect on the binding of AF4 in MOLM-
13, which could further imply that the MLL-AF9 macromolecule complex in MOLM-13 consists of 
AF4.  
 
Notably, ChIP-qPCR of MLL-N, AF9-C and AF4-C will detect signals from the wild-type 
counterparts as well as the MLL-fusion protein. Therefore, to distinguish between fusion vs wild-type, 
we need to assay MLL-C and AF9-N/AF4-N to account for the signals from the wild-type. If the slight 
increase in the recruitment of MLL-AF9 and MLL-AF4 observed at some loci following the loss of 
KAT7 is true, this could reflect some sort of compensation mechanism in order to restore the 
expression of these genes, at least in MOLM-13. However, the data thus far detects no significant 




Figure 5.8 MLL, AF9 and AF4 occupancy at KAT7-bound loci following KAT7 loss 
MOLM-13 and MV4-11 AID cells were treated with IAA for 24 hours. MLL-N terminal, AF9-C 
terminal and AF4-C terminal antibodies were used to probe for the binding of MLL-AF9 and MLL-AF4 
fusion protein at various loci of selective MLL-fusion targets in MOLM-13 and MV4-11, respectively. 
Loci are promoter region unless indicated otherwise. A, C and E) ChIP-qPCR in MOLM-13, Mean ± 
S.D., n = 3, two-tailed t-test (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). B, D and F) ChIP-qPCR in MV4-

























































































































5.9 Occupancy of BRD4 at MLL-fusion target loci is dependent on KAT7 in 
MOLM-13 but not in MV4-11 
                                                                                                                                                                                          
We subsequently investigated whether BRD4 occupancy at these target loci is affected by the loss of 
KAT7. This was motivated by several reasons. Firstly, BRD4 is a bromodomain protein, that is capable 
of “reading” histone acetylation marks, particularly lysine acetylation on H3 and H4 tails (Chiang, 
2009; Devaiah et al., 2016). Secondly, from the findings illustrated in Chapter 4, KAT7 is responsible 
for the global acetylation of H3K14ac and H4K12ac, which are putative marks “read” by BRD4 
(Chiang, 2009; Devaiah et al., 2016; Filippakopoulos and Knapp, 2012; Fiskus et al., 2014). Lastly, 
BRD4 interacts with and is a positive regulator of p-TEFb (a complex consisting of CDK9 and Cyclin 
T1/2), and p-TEFb is a member of various macromolecule complexes associated with MLL-fusion 
(Table 5.1) (Deshpande et al., 2012; Zeisig and So, 2015). Global BRD4 promoter occupancy is 
strongly correlated with the binding of KAT7 (Figure 5.9A). Similarly, at genetic loci co-bound by 
KAT7 and MLL-AF9 which are also downregulated in KAT7 knock-out show striking similarities in 
the binding profiles of these two proteins and BRD4 (Figure 5.9B).  
 
24 hours of IAA treatment in MOLM-13 AID cells leads to a significant decrease in BRD4 occupancy 
at promoters of JMJD1C, SENP6, PBX3, MEIS1 and BCL2, as well as introns of PBX3 and MEIS1 and 
the enhancer of BCL2 (Figure 5.10A). With the exception of the BCL2 promoter region, BRD4 
binding is also slightly reduced at these loci in MV4-11 AID cells following 24 hours of IAA treatment 
(Figure 5.10C). We further assayed how RNA polymerase 2 serine 5 phosphorylation (RNA-PolII 
pS5) levels, a modification associated with transcription initiation and necessary for the transition to 
elongation (Ahn et al., 2004; Ferrari et al., 2014; Koch et al., 2008; Komarnitsky et al., 2000; Nojima et 
al., 2018; Soutourina, 2018), are affected upon loss of KAT7, and found striking decrease in all the 
target loci assessed— including promoter and introns in MOLM-13 (Figure 5.10B). However, in 
MV4-11, the changes in RNA-PollII pS5 levels at these loci are negligible (Figure 5.10D) and this may 
explain why these genes were not differentially expressed between KAT7 knock-out and control cells 
by RNA-seq experiments. Collectively, these findings suggest that BRD4 occupancy at these MLL-
fusion target loci are dependent on KAT7 in MOLM-13 but not in MV4-11, potentially reflecting a 
different mechanism between MLL-AF9 and MLL-AF4 pathogenesis.  
 
Most of the classical MLL-fusion targets assayed showed significant gene expression downregulation 
in MOLM-13 KAT7 knock-out relative to the empty control, but these genes are not differentially 
expressed in MV4-11 (Table 5.2). The weak changes in the occupancy of BRD4 and RNA-PolII pS5 in 
MV4-11 are consistent with the transcriptomic profiles of MV4-11. In particular, among the loci 
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assayed, only JMJD1C showed a significantly reduced expression in knock-out compared to the wild-
type counterpart. It is likely that JMJD1C, along with the other selected MLL-fusion target genes are 
not the effectors responsible for maintaining the proliferation of MV4-11. The expression of the MLL-
AF4 spreading targets that are significantly downregulated upon KAT7 knock-out (NUDT5, PTEN, 
FLT3, NUSAP1, RAB27A, MRPL33, ITGA4 and SATB1), which were not assayed in this study, may 
depend on KAT7-mediated BRD4 binding for its expression and warrants further investigation. 
Alternatively, KAT7 in MV4-11 may have roles that are unrelated to BRD4 recruitment, such as the 
recruitment of other proteins via a different mechanism. Furthermore, KAT7 may be regulating 
transcription elongation rather than transcription initiation in MV4-11 and assaying RNA-PolII pS2 
can elucidate this possibility.  
 
 
Figure 5.9 Co-localization of MLL-AF9, KAT7 and BRD4 at the promoter 
Previously published BRD4 ChIP-seq in MV4-11 cell line (Gilan et al., 2016) and MLL-AF9 ChIP-seq in 



































B) Co-localization of KAT7, MLL-AF9 and BRD4 at the promoter of MLL-AF9 target genes JMJD1C, 
SENP6 and PBX3. Notably, the co-localization of these three proteins can also be seen at an intron of 
PBX3.  
 
Figure 5.10 Occupancy of BRD4 and RNA Polymerase II Serine 5 phosphorylation at KAT7-bound 
loci following IAA treatment 
MOLM-13 and MV4-11 AID cells were treated with IAA for 24 hours. The binding of BRD4 and RNA 
polymerase 2 serine 5 phosphorylation (RNA-PolII pS5) at the loci of various MLL-fusion targets in IAA 
treated compared to H2O treated controls. Loci are promoter region unless indicated otherwise. A) 
BRD4 and B) RNA-PolII pS5 ChIP-qPCR in MOLM-13, Mean ± S.D., n = 3, two-tailed t-test (NS, P > 
0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). C) BRD4 and D) RNA-PolII pS5 ChIP-qPCR in MV4-11, 
n = 1. 
 
5.10 Loci-specific changes in KAT7-mediated histone lysine acetylation levels upon 
IAA treatment   
 
As KAT7 loss leads to a global decrease in histone acetylation levels such as H3K14ac, we wanted to 
investigate the local changes of various H3 and H4 lysine residues that are known targets of KAT7 at 
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24 hours after the addition of IAA, H3K14ac levels are significantly reduced at the promoter of 
JMJD1C, SENP6 and MEIS1 in MOLM-13 AID cells, (Figure 5.11A). Additionally, an intron of PBX3 
also showed a significant decrease in H3K14ac following the loss of KAT7 in MOLM-13 (Figure 
5.11A). Data of one experimental replicate in MV4-11 suggests that H3K14ac levels are also reduced 
at the promoters of JMJD1C, PBX3, MEIS1 and BCL2, as well as at introns of PBX3 and MEIS1 (Figure 
5.11D). A similar trend is seen at these loci for H4K5ac in MV4-11 (Figure 5.11E). In MOLM-13, only 
the promoter of JMJD1C and the intron of PBX3 showed a significant decrease in H4K5ac after KAT7 
loss (Figure 5.11B). H4K8ac show a pattern of decrease at these loci in IAA treated MOLM-13 AID 
compared to control, but these changes are not statistically significant (Figure 5.11C). H4K8ac showed 
no changes at the promoter region of JMJD1C and BCL2 in MV4-11 while an increase in this 
acetylation mark is observed at the intron of MEIS1 after IAA treatment (Figure 5.11F). Promoter 
regions of SENP6, PBX3 and MEIS1, as well as the intron for PBX3, are relatively decreased in IAA 
treated MV4-11 (Figure 5.11F). For MOLM-13, local changes in H3K14ac are consistent with the 
global depletion of this histone marks by immunoblot analysis. 
 
Although not all statistically significant, KAT7 modified acetylation marks H4K5ac and H4K8ac are 
generally reduced at most loci assayed after the loss of KAT7 in both MOLM-13 and MV4-11. More 
repeats are required for MV4-11 ChIP-qPCR experiments to determine statistical significance.  
Notably, H4K5ac and H4K8ac signals are stronger compared to H3K14ac in both cell lines, which 
may be attributed to the quality of the H3K14ac antibody in recognizing the target or that the global 
levels of H4K5ac and H4K8ac are naturally more abundant than H3K14ac. It would be interesting to 
assay other KAT7-mediated histone lysine acetylation targets H3K23ac and H4K12ac to determine 
how all these histone marks change in response to KAT7 degradation in terms of genome-wide and 




Figure 5.11 Changes in H3K14ac, H4K5ac and H4K8ac levels at KAT7-bound loci following 
depletion of KAT7 protein 
MOLM-13 and MV4-11 AID cells were treated with IAA for 24 hours. Loci-specific changes in KAT7-
mediated histone acetylation targets following the depletion of KAT7 protein. Loci are promoter region 
unless indicated otherwise. A) H3K14ac, B) H4K5ac and C) H4K8ac ChIP-qPCR in MOLM-13. Mean ± 
S.D., n = 3, two-tailed t-test (NS, P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). D) H3K14ac, E) 



































































































































5.11 Working model for KAT7 mechanism of action in regulating the expression of 
MLL-AF9 target genes  
 
KAT7 recruits BRD4 to the promoter of MLL-AF9 targets, presumably through the acetylation of 
lysine residues on histone H3 and H4 tails. This is associated with the promoter occupancy of AF4 
protein. Binding of BRD4 and other MLL-fusion associated proteins such as AF4 drives the 
transcription of target genes (Figure 5.12A). In the absence of KAT7, acetylation on H3 and H4 tails 
are significantly reduced thereby result in the displacement of MLL-fusion associated proteins such as 
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5.12 MOLM-13 E508Q sensitizes cells to IBET-151 treatment  
 
The data thus far provides strong evidence that KAT7 affects the binding of BRD4 at the promoter 
regions, as well as selective introns and enhancer, of many MLL-AF9 target genes. Therapeutically, it 
is interesting to investigate if the loss of KAT7 catalytic activity could sensitize AML cells to treatment 
with BET inhibitors such as IBET-151. We utilized the E508Q catalytic dead MOLM-13 cell line (with 
the presence of endogenous KAT7), in which the mutant would mimic the effects of potential KAT7 
inhibitor. The viability of MOLM-13 E508Q mutant is significantly reduced, compared to GFP 
control, following 4 days of IBET-151 treatment (Figure 5.13). This is continuedly observed at 5 days 
of IBET-151 treatment. This enhanced sensitive in E508Q MOLM-13 cell lines compared to the 
control MOLM-13 cell suggests that BRD4 inhibitor-induced effect on viability is dependent on KAT7 
activity, further strengthening the proposed model that KAT7 acts upstream of BRD4. This finding 
may encourage the combination treatment of BRD4 inhibitor with novel KAT7 inhibitor for MLL-
fusion positive AML.   
 
 
Figure 5.13 E508Q KAT7 mutant sensitizes MOLM-13 to IBET-151 treatment. 
MOLM-13 E508Q mutant cells and MOLM-13 GFP cells were treated with 300 nM of IBET-151 for 3, 4 
and 5 days and the viability were assayed at each time-point. Mean ± S.D., n = 3, two-tailed t-test and 































Together, our finding suggests that KAT7 functions downstream of the MLL-fusion proteins where it 
is involved in the recruitment of MLL-AF9 associated accessory proteins such as BRD4 and AF4 to 
multiple target loci, presumably via the regulation of histone acetylation such as H3K14ac. The AID 
system mimics a KAT7 degrader as oppose to an enzymatic inhibitor of KAT7, therefore, the potential 
physical association of KAT7 at the promoter to facilitate the binding or recruitment of BRD4 cannot 
be eliminated. However, we have shown in Chapter 4 that the catalytic activity of KAT7 is essential for 
maintaining leukemogenesis in MOLM-13, which strongly implies that the catalytic function of KAT7 
is responsible. Currently, it is not possible to distinguish whether histone or non-histone acetylation is 
functionally important. This is partly due to the lack of study on potential non-histone target of KAT7. 
Therefore, it would be valuable to perform a comprehensive analysis of the acetylated proteome 
(acetylome) before and after the loss of KAT7 protein to examine the possible protein lysine acetylation 
functions of KAT7. Furthermore, it would be interesting to investigate whether KAT7 forms protein 
complexes with MLL-AF9 and/or BRD4 at the promoter of target genes. Intriguingly, KAT7 was found 
to be co-purified with seven distinct MLL-fusion— MLL-AF9, MLL-AF4, MLL-ENL, MLL-AF1p, MLL-
CBP, MLL-EEN and MLL-GAS7 (Skucha et al., 2018). 
 
Our study strengthens previous observations that histone acetylation at the promoter of 
transcriptionally active genes facilitates the binding of BRD4 and the subsequent phosphorylation of 
RNA PolII (Dawson et al., 2011; Roe et al., 2015; Sheikh and Akhtar, 2018; Zhang et al., 2012). Data on 
the occupancy of total RNA PolII and RNA PolII serine 2 phosphorylation following KAT7 loss will 
elucidate further if KAT7 is involved in pre-initiation complex (PIC) binding and transcription 
elongation respectively. Importantly, our findings suggest that the reduction in the promoter binding 
of BRD4 following KAT7 loss is not associated with the change in occupancy of MLL-AF9 at the 
promoter and that the binding of MLL-AF9 without BRD4 is insufficient for maintaining the expression 
of its target genes, especially those highly bound by KAT7. 
 
Interestingly, an intron region of PBX3 is not only co-bound by KAT7, BRD4 and MLL-AF9, but the 
BRD4 binding at this locus is also significantly reduced in MOLM-13 following the depletion of KAT7 
protein. Also, BRD4 is known to occupy enhancer regions (Dawson et al., 2014; Lovén et al., 2013) and 
whether KAT7 plays a role in this aspect can be investigated. The extent of KAT7 in regulating 
transcription via other DNA elements such as introns and enhancers warrants further investigation, in 
particular, the functional role of HAT occupancy, and the corresponding histone acetylation marks at 
introns is not well-characterized. Studies have suggested HATs and HDACS are co-enriched at 
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promoter and introns of transcriptionally active genes (Wang et al., 2009b; Yan Matthew S. and 
Marsden Philip A., 2015). H3K14ac, among other histone acetylation marks, have the majority of peaks 
at intron and distal intergenic regions, more than those found at gene promoters (Karmodiya et al., 
2012; Yan Matthew S. and Marsden Philip A., 2015). KAT7 may additionally control gene expression 
via the binding at introns. In support of this notion, a recent study on endothelial cell (EC) gene 
regulation reported that the expression of VEGFR-2 and other EC-related genes is dependent on KAT7-
mediated H3K14ac/pan-H4 acetylation in the intragenic region (Yan et al., 2018).   
 
Despite the binding of KAT7 at a wide range of loci across the genome, only a subset of genes is 
downregulated upon KAT7 knock-out. This suggests that histone acetylation-mediated transcription 
regulation can be compensated for by other HATs at the majority of KAT7-bound loci. The dynamic 
occupancy of specific HATs and HDACs at a given genomic region likely governs the extent of BRD4 
recruitment. BRD4 is a global regulator of transcription and is essential in a wide range of cells (Roe 
and Vakoc, 2016), however, KAT7 does not appear to be broadly essential at least among AML cell lines, 
suggesting that the mechanisms by which BRD4 is recruited to target loci can be context-specific. In the 




















Chapter 6: Discussion and future work 
 
Despite advances in understanding its genomics and molecular pathogenesis, AML remains fatal for 
the majority of the patients (Ferrara and Schiffer, 2013) and mainstream therapies have not changed 
significantly for several decades (Evans et al., 1961). Amongst different AML subtypes, cases driven by 
the MLL-fusion genes continue to represent a poor prognosis category (Krivtsov and Armstrong, 
2007; Papaemmanuil et al., 2016; Saultz and Garzon, 2016) and while there are recent developments in 
the field (Albrecht et al., 2016; Berthon et al., 2016; Daigle et al., 2011; Dawson et al., 2011; Gallipoli et 
al., 2015; Grembecka et al., 2012; Klaus et al., 2014; Zuber et al., 2011) clinical progress is still lacking, 
emphasising the need for new therapies.  
 
Here, we demonstrate that KAT7 represent a putative novel therapeutic target for MLL-fusion AML 
and give insights into its function in the maintenance of these leukemias, mainly in MLL-AF9 positive 
AML model. KAT7 is required for the recruitment of BRD4 and accessory proteins associated with 
transcription elongation complex such as AF4 to the promoter of MLL-AF9 target genes. Following 
reports of KAT7 as an AML-specific vulnerability from genome-wide CRISPR-Cas9 screening studies 
(Tzelepis et al., 2016; Wang et al., 2017), we are the first to decipher the underlying molecular 
mechanism of essentiality. Although no mutations in KAT7 have been found in AML cases, our 
findings accentuate KAT7 as a vulnerability that could be therapeutically exploited in AML. 
 
We are the first to elucidate a mechanistic link between KAT7 and BRD4. BRD4 is thought to be 
recruited to the promoter and enhancer regions genome-wide by lineage-specific transcription factors 
(Roe and Vakoc, 2016; Roe et al., 2015). Through the catalytic function of HATs such as p300 and CBP, 
HATs facilitate the recruitment of BRD4 by acetylation of both histone proteins and transcription 
factors (Roe and Vakoc, 2016; Roe et al., 2015). Interestingly, a study by Roe et al. investigated the 
essentiality of 17 mammalian HATs, KAT7 among one of them, in RN2 cells (murine AML with MLL-
AF9 and NRASG12D mutations). Although KAT7 was essential for the proliferation of RN2 cells, its 
transcriptomics profile following shRNA-mediated knock-down is inversely correlated with the 
transcriptomics of BRD4 knock-down cells, suggesting that KAT7 perform regulatory function in 
opposition to BRD4 (Roe et al., 2015). Instead, the gene expression of CBP and p300 knock-down 
resembles that of BRD4 knock-down. Inhibition of CBP/p300 catalytic activity or knock-down of p300 
resulted in a similar reduction of BRD4 binding at the genome-wide promoter and enhancer regions. 
Although we did not compare the global changes in gene expression upon KAT7 loss and BRD4 loss in 
our human AML models, given that BRD4 promoter occupancy at MLL-AF9 target loci is dependent 
on KAT7, ablation of KAT7 and BRD4 would predictively lead to similar mRNA changes. Conversely, 
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Roe et al., did not investigate whether loss of KAT7 resulted in reduced BRD4 occupancy in RN2 cell 
lines. The potential discrepancy of findings between our studies and the study by Roe et al. may be 
attributed to the difference between human and mice hematopoietic system. The presence of other 
oncogenic mutations in each of the models may also contribute to the identification of different effector 
HATs.  
 
Pharmacological inhibition of BET proteins, including BRD4, is an effective pre-clinical treatment for 
MLL-fusion leukemia (Chaidos et al., 2015; Dawson et al., 2011). Our studies provide evidence that loss 
of KAT7 protein results in the reduction of BRD4 occupancy at the promoter region of many canonical 
MLL-AF9 target loci. When using the AID protein-degradation system to study the molecular 
mechanism, we cannot eliminate the possibility that physical interaction of KAT7 is involved in the 
recruitment of BRD4 to these target loci. Given that potent and specific small molecules inhibiting the 
catalytic activity of KAT7 is not currently available, it is challenging to directly address this possibility 
due to the scalability of the existing experiment set up. However, we have shown through catalytic dead 
E508Q mutant KAT7 that the acetyltransferase activity of KAT7 is essential for leukemic maintenance 
in the MLL-AF9 context. It would be interesting to see if KAT7 physically associates with BRD4 and/or 
MLL-AF9 by co-immunoprecipitation experiments. Notably, our experiments conducted in this study 
does not distinguish between histone acetylation or protein acetylation. It would be interesting to 
ascertain if KAT7 also acetylates hematopoietic transcription factors, as with function identified for 
CBP/p300 (Roe et al., 2015). We cannot firmly conclude that BRD4 occupancy is mediated by KAT7-
dependent acetylation, but the evidence collectively strongly suggests this is the case.  
 
 
Yet to be addressed is how KAT7 genome-wide binding is regulated in the context of AML, particularly 
whether KAT7 is recruited by hematopoietic transcription factors important in MLL-fusion 
leukemogenesis. Although we did not find MLL-AF9 or MLL-AF4 occupancy to be significantly 
affected at various shared target loci after KAT7 protein degradation, we did observe a marginal increase 
in MLL-N and AF9-C and AF4-C occupancy. Furthermore, top KAT7 bound promoters are also 
spreading targets of MLL-AF9/MLL-AF4, suggesting that MLL-fusion may be selectively regulating 
KAT7 occupancy at these shared target loci. If MLL-fusion protein is involved in the recruitment of 
KAT7 to its target genes, a hypothetical theory could be the existence of a compensatory mechanism in 
which MLL-fusion chromatin binding increases in response to KAT7 loss in an attempt to “restore” the 
default levels of KAT7 occupancy at the target loci. A possible way to investigate whether MLL-fusion 
regulates KAT7 binding is to inhibit the chromatin binding of MLL-fusion via small molecules that 
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target the MENIN-MLL-fusion interactions or knock-down of MLL-AF9 by siRNA (Grembecka et al., 
2012; Shi et al., 2012) followed by KAT7 ChIP-Seq or ChIP-qPCR.  
 
It is possible that the chromatin binding of KAT7 and MLL-fusion is independent of one another, but 
the colocalization may depend on the same factors such as the presence of H3K36me3 and/or H3K4me3. 
As described in Chapter 1, depending on the proteins in which KAT7 associates with, the resulting 
protein complex may preferentially localize at H3K36me3 or H3K4me3. H3K36me3 can be recognized 
by the PWWP domain of LEDGF, a protein important for MLL-fusion target recognition (Eidahl et al., 
2013; Okuda et al., 2014; Yokoyama, 2015, 2017; Zhu et al., 2016), whilst H3K4me3 is a mark “written” 
by wild-type MLL protein and the wild-type MLL is essential for MLL-AF9 pathogenesis (Krivtsov and 
Armstrong, 2007; Milne et al., 2010; Rao and Dou, 2015; Thiel et al., 2010; Wang et al., 2009a).  
 
Various phenotypes reflected differences in response to KAT7 loss between MLL-AF9 and MLL-AF4 
models, notably in terms of the ability to induce differentiation and the changes in occupancy of BRD4. 
MLL-fusion can association with distinct biochemical complexes that comprise of different protein 
components (Ballabio and Milne, 2012, 2014; Deshpande et al., 2012; Zeisig and So, 2015), as mentioned 
in Chapter 5. Our findings suggest that KAT7 is not involved in BRD4 recruitment in MV4-11 driven 
by the MLL-AF4 oncogene. Furthermore, KAT7 is an essential gene in OCI-AML2 (possessing MLL-
AF6) and the genetic ablation of KAT7 induces differentiation and apoptosis in this cell line. The 
molecular mechanism by which KAT7 regulates the gene expression of MLL-AF6 transform cells 
remains elusive. In contrast to MLL-AF4 and MLL-AF9 oncoprotein, MLL-AF6 fusion protein 
homodimerizes and recruits DOT1L complex through an alternative mechanism that does not involve 
interaction with any transcriptional component (Ballabio and Milne, 2012, 2014; Deshpande et al., 2013; 
Liedtke et al., 2010; Manara et al., 2014; Yokoyama, 2015; Yokoyama et al., 2010). Regardless of the 
mechanisms of transformation by the respective MLL-fusion proteins, KAT7 is a shared vulnerability 
among our AML models with this oncogene. Therefore, the mechanisms of action of KAT7 in MLL-
fusion other than MLL-AF9 remains an interesting and important avenue for further studies. It is also 
important to replicate the mechanistic study in another MLL-AF9 model such as THP-1 or Nomo-1 to 
ensure that this is a general mechanism common to MLL-AF9 leukemogenesis.  
 
KAT7 does not appear to be involved in the haematopoiesis of human primary CD34+ progenitor and 
stem cells (HPSCs) or T-cells (Ting et al., 2018), which suggests that targeting KAT7 may not have 
detrimental effects on the development of normal blood cells. Critically lacking in this study are data 
on the effects of KAT7 loss on primary human AML cells, particularly of the MLL-fusion subtype. The 
function of KAT7 in other cell types also needs to be addressed comprehensively through appropriate 
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in vivo models. The presence of KAT7 inhibitor and/or KAT7 degrader will facilitate the efforts in 
addressing these questions. Encouragingly, the recent development of inhibitors targeting KAT6A/B 
has shown promising tumour growth inhibitory effects in vitro and in vivo (Baell et al., 2018), 
confirming direct targeting of MYST family of HATs as a valid therapeutic approach.  
 
Collectively, our findings revealed that KAT7 acts upstream of BRD4 to recruit MLL-fusion associated 
machineries to the promoter of MLL-AF9 target genes and may be an alternative therapeutic strategy 
for MLL-fusion leukemia. We anticipate that our work will motivate the development of potent small-
molecules that are highly specific against KAT7 and highlight KAT7 as a potential novel therapeutic 
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